

Friday, November 24, 2023

Volume 39 No. 11



NOTICE – Items in this issue will be listed online weekly and printed monthly.

NEW COMPANY DESCRIPTIONS

(For details on individual listings, see the News Section of this issue)

Masterworks 212 LLC
 Masterworks 247 LLC
 Masterworks 250 LLC
 Masterworks 253 LLC
 Masterworks 255 LLC
 Masterworks 266 LLC
 Masterworks 269 LLC
 Masterworks 270 LLC
 Masterworks 287 LLC
 Public Shrek Royalties LLC

NAME CHANGES

(For details on individual listings, see the News Section of this issue)

TD Holdings Inc (to BAIYU Holdings Inc)

ABEONA THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2023	2022
Total revenues	3,500,000	
Cost & expenses	26,092,000	29,945,000
Operating income	(22,592,000)	(28,599,000)
Interest income	781,000	
Other income (expense), net	(3,746,000)	
Net before taxes	(25,761,000)	
Net income	(25,761,000)	(29,086,000)
Balance for common		(32,868,000)
Earnings common share		
Primary	\$(1.48)	\$(5.67)
Fully Diluted	\$(1.48)	\$(5.67)
Common Shares:		
Full Diluted	17,464,026	5,800,822
Year-end	21,478,157	5,870,375

ACLARION INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2023	2022
Total revenues	61,607	37,924
Cost & expenses	3,811,246	4,657,032
Operating income	(3,749,640)	(4,619,108)
Interest expense	214,850	1,505,477
Other income (expense), net	318,463	602
Net before taxes	(3,646,027)	(6,123,983)
Net income	(3,646,027)	(6,123,983)
Balance for common	(3,646,027)	(6,539,506)
Earnings common share		
Primary	\$(0.44)	\$(1.17)
Fully Diluted	\$(0.44)	\$(1.17)
Common Shares:		
Full Diluted	8,255,606	5,522,950
Year-end	8,230,510	7,821,515

ADTHEORENT HOLDINGS CO INC

Earnings, 6 mos. to Jun 30(Consol. – \$):

	2023	2022
Total revenues	70,261,000	76,717,000
Cost & expenses	74,237,000	79,181,000
Operating income	(3,976,000)	(2,464,000)
Interest expense		156,000
Other income (expense), net	476,000	14,533,000
Gains or losses		1,939,000
Net before taxes	(2,457,000)	13,852,000
Income taxes	(5,316,000)	(1,635,000)
Net income	(2,859,000)	15,487,000
Earnings common share		
Primary	\$0.03	\$0.19

Fully Diluted	\$0.03	\$0.17
Common Shares:		
Full Diluted	92,407,260	93,263,518
Year-end	87,970,897	86,099,633

AETHLON MEDICAL INC

Earnings, 3 mos. to Jun 30(Consol. – \$):

	2023	2022
Cost & expenses	3,408,160	2,906,081
Operating income	(3,408,160)	(2,906,081)
Net before taxes	(3,282,179)	
Net income	(3,282,179)	(2,906,081)
Earnings common share		
Primary	\$(0.14)	\$(1.90)
Fully Diluted	\$(0.14)	\$(1.90)
Common Shares:		
Full Diluted	24,314,759	1,548,662
Year-end	24,835,321	1,599,372

Consolidated Balance Sheet Items, as of (\$):

	2023	2022
Assets:		
Cash & equivalents	12,897,734	
Current assets	13,307,957	
Net property & equip.	1,284,200	
Total assets	15,800,589	
Liabilities:		
Current liabilities	1,821,747	
Stockholders' equity	13,108,897	
Net current assets	11,486,210	

AILERON THERAPEUTICS INC

Dismissal of Accountant On Oct. 30, 2023, Co. dismissed PricewaterhouseCoopers LLP as its public accounting firm.

AILERON THERAPEUTICS INC

Merger Completed On Oct. 31, 2023, Co. acquired Lung Therapeutics, Inc., a Texas corporation ("Lung"), pursuant to the Agreement and Plan of Merger, dated October 31, 2023 (the "Merger Agreement"), by and among Co., AT Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Co. ("First Merger Sub"), AT Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Co. ("Second Merger Sub"), and Lung. Pursuant to the Merger Agreement, First Merger Sub merged with and into Lung, pursuant to which Lung was the surviving entity and became a wholly owned subsidiary of Co. (the "First Merger"). Immediately following the First Merger, Lung merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity (the "Second Merger," together with the First Merger, the "Merger"). As a result of the merger, Co. issued to the stockholders of Lung 344,566 shares of the common stock of Aileron, par value \$0.001 per share (the "Common Stock"), and 20,140 shares of newly designated Series X Preferred Stock. In addition, Co. assumed (i) all Lung stock options immediately outstanding prior to the First Merger, each becoming an option for Common Stock subject to adjustment pursuant to the terms of the Merger Agreement, and (ii) all warrants exercisable for Lung common stock immediately outstanding prior to the First Merger, each becoming a warrant to purchase Common Stock, subject to adjustment pursuant to the terms of the Merger Agreement. Immediately following the closing of the Merger, Co. had 4,885,733 shares of Common Stock issued and outstanding.

AILERON THERAPEUTICS INC

Official Changes On Oct. 30, 2023, the Board approved the appointment of Mr. Brian Windsor to President and Chief Operating Officer of Co. Also, on Oct. 30, 2023, Co. elected Mr. William C. Fairey and Mr. Alan A. Musso to the Board as directors. On Oct. 31, 2023, Mr. Jeffrey A. Bailey, Chairman of the Board, Mr. Jodie P. Morrison and Mr. William T. McKee resigned from the Board. Also, on Oct. 31, 2023, following Mr. Jeffrey A.

Bailey's resignation, Mr. Josef H. von Rickenbach will serve as the Chairman of the Board.

AKUMIN INC

Bankruptcy Proceedings On Oct. 22, 2023, Co. and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code, 11 U.S.C.101-1532 (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court"), thereby commencing chapter 11 cases for the Debtors (the "Chapter 11 Cases"). The Debtors are seeking approval of various "first day" motions from the Bankruptcy Court, which request customary relief intended to enable the Debtors to continue their ordinary course operations. The Debtors intend to implement the Restructuring during the Chapter 11 Cases. The Debtors cannot be certain that the Restructuring and the Prepackaged Plan would be approved by the Bankruptcy Court during the Chapter 11 Cases.

AKUMIN INC

Bankruptcy Proceedings On Oct. 22, 2023, Co. and certain of its affiliates (collectively, the "Debtors") filed with the Bankruptcy Court the Joint Prepackaged Chapter 11 Plan of Reorganization of Akumin Inc. and Its Debtor Affiliates (as amended, supplemented or otherwise modified from time to time, the "Prepackaged Plan") and the proposed Disclosure Statement for the Joint Prepackaged Chapter 11 Plan of Reorganization of Akumin Inc. and its Debtor Affiliates (as amended, supplemented, or otherwise modified from time to time, the "Disclosure Statement"). A hearing on confirmation of the Prepackaged Plan and final approval of the adequacy of the Disclosure Statement (the "Combined Hearing") would be held before the Bankruptcy Court on Nov. 29, 2023. On Oct. 23, 2023, the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") entered an interim order (the "Interim DIP Order") authorizing Co. to obtain junior secured postpetition financing from Stonepeak Magnet Holdings LP ("Stonepeak") on terms and conditions consistent with the Summary of Proposed Terms and Conditions for DIP Financing and use of Cash Collateral attached to the Interim DIP Order as Exhibit A (the "DIP Term Sheet"). Pursuant thereto, Co.'s debtor affiliates (together with Co., the "Debtors") unconditionally guaranteed, on a joint and several basis, Co.'s obligations in connection with such post-petition financing, consisting of a delayed draw term loan facility (the "DIP Facility") in an aggregate principal amount not to exceed \$75,000,000 (the "DIP Facility Commitment"), and the loans made under the DIP Facility (including through the payment of in-kind interest) (the "DIP Facility Loans"), subject to the terms and conditions set forth in the DIP Term Sheet and the Interim DIP Order. The DIP Facility Loans shall accrue interest at 8.00% per annum payable in kind. Unless otherwise provided in accordance with the terms of the Restructuring Support Agreement (as defined in the DIP Term Sheet), the DIP Term Loans shall convert to equity on the effective date of the Prepackaged Plan (as defined below) on the same terms as the new money investment to be provided by Stonepeak (the "New Money Investment") pursuant thereto and shall reduce the aggregate principal amount to be invested by Stonepeak as the New Money Investment on a dollar-for-dollar basis. On Oct. 24, 2023, a notice (the "Notice of Commencement") of Co. and certain of its affiliates (collectively, the "Debtors") chapter 11 cases (the "Chapter 11 Cases"), the Combined Hearing, applicable objection deadlines, and summaries of the Prepackaged Plan was served on certain notice parties by Co.'s claims agent, Epiq Corporate Restructuring LLC. On Oct. 26, 2023, Co. delivered to Stonepeak a Notice of Borrowing, dated Oct. 26, 2023, (the "Notice of Borrowing") pursuant to the terms of the DIP Term Sheet and the Interim DIP Order, requesting that Stonepeak provide funding under the DIP Facility in the aggregate principal amount of \$55,000,000 (the "Initial DIP Loan"). In connection with the Initial DIP Loan, Co. represented that it is in compliance with the DIP Conditions Precedent and the Conditions Precedent to All Credit Extensions (each as defined in the

DIP Term Sheet). Also, on Oct. 26, 2023, Co. used the proceeds from the Initial DIP Loan to pay in full all outstanding principal and interest owed under Co.'s revolving credit facility in the aggregate principal amount of \$55,000,000 (the "Revolving Credit Facility"), established pursuant to that certain Revolving Credit Agreement, dated as of Nov. 2, 2020, as amended by that certain Amendment No. 1, dated as of Feb. 8, 2021, Amendment No. 2, dated as of July 26, 2021, Amendment No. 3 & Waiver, dated as of Sept. 11, 2021, and Amendment No. 4 & Waiver, dated as of Oct. 22, 2021 (as has been and may be further amended, supplemented, or otherwise modified from time to time), by and among Co., as borrower, certain subsidiaries of Co. as guarantors, PNC Bank, National Association, as successor to BBVA USA, as administrative agent and collateral agent, and the lenders from time to time party thereto.

ALZAMEND NEURO INC

Annual Report

Consolidated Income Statement, Years Ended Apr. 30 (\$):

	2023	2022	2021 (revised)
Research & development	7,445,857	5,201,314	1,310,716
General & administrative	7,424,609	7,118,221	3,641,172
Total operating expenses	14,870,466	12,319,535	4,951,888
Income (loss) from operations	(14,870,466)	(12,319,535)	(4,951,888)
Gain on extinguishment of debt	...	4,000	62,418
Interest expense	7,701	46,524	142,421
Interest expense - related party	16,382
Interest income - related party	1,706
Total other income (expense), net	(7,701)	(42,524)	(94,679)
Income (loss) before income taxes
- federal	(14,878,167)	(12,362,059)	(5,046,567)
Net income (loss)	(14,878,167)	(12,362,059)	(5,046,567)
Weighted average shares outstanding			
- basic	6,501,268	5,939,685	4,843,338
Weighted average shares outstanding - diluted	6,501,268	5,939,685	4,843,338
Year end shares outstanding	6,462,675	6,365,453	4,495,302
Net earnings (loss) per share - basic	\$(2.25)	\$(2.10)	\$(1.05)
Net earnings (loss) per share - diluted	\$(2.25)	\$(2.10)	\$(1.05)
Number of full time employees	4	...	2
Number of part time employees	3	4	4
Number of common stockholders	119	133	...
Income from cont operations before income tax	(14,878,167)

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-15 stock split, October 31, 2023; ³ Shares increased due to the effect of issuance of common stock for restricted stock awards, warrants-related party, stock option exercise, initial public offering, debt and series A convertible stock; ⁴ As of July 15, 2021; ⁵ Approximately; ⁶ As of July 19, 2022

Consolidated Balance Sheet, Years Ended Apr. 30 (\$):

	2023	2022
Cash	5,140,859	14,063,811
Prepaid consulting fees	92,154	186,667
Prepaid insurance	...	155,880
Other prepaid expenses	2,800	7,176
Prepaid expenses & other current assets	447,589	349,723
Prepaid expenses - related party	247,334	...
Prepaid clinical trial

fees	352,635	...
Total current assets	5,835,782	14,413,534
Property, plant & equipment, net	79,843	102,909
Total Non-Current Assets	79,843	...
Total assets	5,915,625	14,516,443
Accounts payable & accrued liabilities	2,870,122	1,162,850
Related party payable	...	2,082
Total current liabilities	2,870,122	1,164,932
Total liabilities	2,870,122	1,164,932
Common stock	9,694	9,548
Additional paid-in capital	61,991,766	57,419,753
Note receivable for common stock - related party	(14,883,295)	(14,883,295)
Retained earnings (accumulated deficit)	(44,072,662)	(29,194,495)
Total stockholders' equity	3,045,503	13,351,511
Total Equity	3,045,503	...

Recent Dividends:

1. Alzamend Neuro Inc common.
No dividends paid.

Annual Dividends:

1. Alzamend Neuro Inc common.
No dividends paid.

ALZAMEND NEURO INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Baker Tilly US, LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheets of Alzamend Neuro, Inc. (the "Company") as of April 30, 2023 and 2022, the related statements of operations, stockholders' equity, and cash flows, for each of the two years in the period ended April 30, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of April 30, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended April 30, 2023, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company had cash of \$5.1 million and an accumulated deficit of \$44.1 million as of April 30, 2023. For the year ended April 30, 2023, the Company also incurred operating losses of \$14.9 million and had negative cash flows from operations of \$8.9 million. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

ALZAMEND NEURO INC

Earnings, 3 mos. to Jul 31(Consol. - \$):

	2023	2022
Cost & expenses	3,525,931	3,035,542
Operating income	(3,525,931)	(3,035,542)
Net before taxes	(3,527,766)	...
Net income	(3,527,766)	(3,037,074)
Earnings common share		
Primary	\$(0.60)	\$(0.45)
Fully Diluted	\$(0.60)	\$(0.45)
Common Shares:		
Full Diluted	6,562,675	6,498,786
Year-end	6,462,675	6,365,453

Consolidated Balance Sheet Items, as of (\$):

	2023
Assets:	
Cash & equivalents	1,695,416
Current assets	2,413,604
Net property & equip.	214,401
Total assets	2,628,005
Liabilities:	
Current liabilities	2,740,888
Stockholders' equity	(112,883)
Net current assets	(327,284)

AMERICA GREAT HEALTH

New Accountant On Oct. 11, 2023, Co. was informed that Gries & Associates, LLC ("Gries") had sold its business to Green-Growth CPAs ("GreenGrowth"). On Oct. 22, 2023, Co. engaged GreenGrowth as Co.'s new independent accountant to replace Gries.

AMERICAN BATTERY MATERIALS, INC.

New Accountant On Oct. 26, 2023, Co. dismissed Pinnacle Accountancy Group of Utah as its independent registered public accounting firm. Also on Oct. 26, 2023, Co. engaged Green-Growth CPAs as its new independent registered public accounting firm.

AMERICANN INC

Earnings, 9 mos. to Jun 30(Consol. - \$):

	2023	2022
Cost & expenses	1,460,316	1,973,138
Operating income	605,737	142,907
Net before taxes	53,442	...
Net income	53,442	(346,054)
Balance for common	53,442	...
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	24,391,961	24,333,911
Year-end	24,391,961	24,391,961

APOLLO MEDICAL HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	1,033,625,000	849,955,000
Net Sales	906,430,000	...
Cost & expenses	932,296,000	744,790,000
Operating income	88,483,000	91,685,000
Interest income	9,617,000	690,000
Interest expense	10,680,000	5,348,000
Other income (expense), net	1,494,000	(10,866,000)
Net before taxes	88,914,000	76,161,000
Income taxes	30,971,000	26,101,000
Net income	57,943,000	50,060,000
Earnings common share		
Primary	\$1.04	\$1.15
Fully Diluted	\$1.03	\$1.12
Common Shares:		
Full Diluted	46,881,567	45,993,001
Year-end	46,607,356	44,884,522

APPTTECH PAYMENTS CORP

Acquisition Completed On Oct. 26, 2023, Co. acquired all the membership interests of Alliance Partners, LLC ("Alliance Partners"), a software development company centered around the movement of money, nationally and globally, from Chris Leyva (the "Seller"), for \$500,000 to the Seller. Subsequent to the Closing Date, on or before Jan. 7, 2024, Co. shall pay \$750,000 to the Seller, and on or before Apr. 7, 2024, Co. shall pay \$750,000 to the Seller and Co. assumed the obligations and liabilities of Alliance Partners, subject to the satisfaction of certain customary closing conditions.

AQUABOUTY TECHNOLOGIES INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	1,186,276	...
Cost & expenses	14,111,983	12,706,932
Operating income	(12,925,707)	(10,674,345)
Interest expense	132,063	149,982
Other income (expense), net	62,956	176,559
Net before taxes	(12,994,814)	...
Net income	(12,994,814)	(10,647,768)
Earnings common share		
Primary	\$(3.60)	\$(3.00)
Fully Diluted	\$(3.60)	\$(3.00)
Common Shares:		
Full Diluted	3,562,839	3,551,828
Year-end	3,567,282	3,555,536

ARCA BIOPHARMA INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Cost & expenses	3,769,000	6,496,000
Operating income	(3,769,000)	(6,496,000)
Other income (expense), net	...	(2,000)
Net income	(2,826,000)	(6,419,000)
Earnings common share		
Primary	\$(0.20)	\$(0.45)
Fully Diluted	\$(0.20)	\$(0.45)

Common Shares:		
Full Diluted	14,410,143	14,410,143
Year-end	14,410,143	14,410,143

ARCA BIOPHARMA INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2023	2022
Cost & expenses	5,706,000	9,048,000
Operating income	(5,706,000)	(9,048,000)
Other income (expense), net		(5,000)
Net before taxes	(4,250,000)	
Net income	(4,250,000)	(8,752,000)

Earnings common share

Primary	\$(0.29)	\$(0.61)
Fully Diluted	\$(0.29)	\$(0.61)

Common Shares:

Full Diluted	14,410,143	14,410,143
Year-end	14,410,143	14,410,143

ARIDIS PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2023	2022
Total revenues	21,146	
Cost & expenses	14,609	24,451
Operating income	6,537	(22,573)
Other income (expense), net	(1,323)	(1,144)
Net before taxes	5,245	
Net income	5,245	(23,984)
Balance for common	5,245	(23,984)

Earnings common share

Primary	\$0.15	\$(1.35)
Fully Diluted	\$0.11	\$(1.35)

Common Shares:

Full Diluted	47,179	17,702
Year-end	44,574	17,702

ARTELO BIOSCIENCES INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2023	2022
Cost & expenses	6,690,000	6,811,000
Operating income	(6,690,000)	(6,811,000)
Interest income		2,000
Interest expense		5,000
Other income (expense), net	474,000	70,000
Net before taxes	(6,216,000)	
Net income	(6,216,000)	(6,744,000)
Balance for common	(6,216,000)	

Earnings common share

Primary	\$(2.15)	\$(2.38)
Fully Diluted	\$(2.15)	\$(2.38)

Common Shares:

Full Diluted	2,887,000	2,833,000
Year-end	3,162,354	2,855,688

ASCEND WELLNESS HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2023	2022
Total revenues	378,432	293,827
Net Sales	378,432	
Cost & expenses	382,615	297,674
Operating income	(4,183)	(12,908)
Other income (expense), net	25,211	(1,653)
Net before taxes	(7,391)	(36,092)
Income taxes	21,480	29,757
Net income	(28,871)	(65,849)

Earnings common share

Primary	\$(0.15)	\$(0.36)
Fully Diluted	\$(0.15)	\$(0.36)

Common Shares:

Full Diluted	196,616	181,833
Year-end	205,935	187,969

ASP ISOTOPES INC

Official Changes On Oct. 19, 2023, Co. announced the resignation of Mr. Sergey Vashnetsov from its Board of Directors, effective Oct. 23, 2023. On Oct. 23, 2023, Co.'s Board of Directors appointed Professor Michael Gorley, Ph.D. to its Board of Directors.

ATYR PHARMA INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2023	2022
Total revenues	353	
Cost & expenses	39,313	38,454
Operating income	(38,960)	(38,454)

Other income (expense), net	3,324	634
Net before taxes	(35,636)	
Net income	(35,636)	(37,820)

Earnings common share

Primary	\$(0.69)	\$(1.34)
Fully Diluted	\$(0.69)	\$(1.34)

Common Shares:

Full Diluted	51,701	28,185
Year-end	58,560	29,009

AUGMEDIX INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2023	2022
Total revenues	22,182,000	
Net Sales	32,175,000	
Cost & expenses	46,606,000	39,113,000
Operating income	(14,431,000)	(16,931,000)
Other income (expense), net	907,000	(685,000)
Gains or losses	(105,000)	
Net before taxes	(14,511,000)	
Income taxes	168,000	
Net income	(14,679,000)	(18,850,000)
Balance for common	(14,679,000)	

Earnings common share

Primary	\$(0.35)	\$(0.50)
Fully Diluted	\$(0.35)	\$(0.50)

Common Shares:

Full Diluted	42,236,063	37,412,238
Year-end	41,275,216	37,432,204

AVALO THERAPEUTICS INC

Interest Sale Completed On Oct. 27, 2023, Co. disposed of Co.'s rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) to AUG Therapeutics, LLC. Terms and conditions not disclosed.

AVINGER INC**Earnings, 6 mos. to Jun 30**(Consol. - \$000):

	2023	2022
Total revenues	3,929	4,020
Cost & expenses	11,916	12,475
Operating income	(7,987)	(8,455)
Interest expense	837	879
Other income (expense), net	4	(20)
Net before taxes	(8,820)	
Net income	(8,820)	(9,354)
Balance for common	(11,256)	(16,719)

Earnings common share

Primary	\$(19.50)	\$(47.40)
Fully Diluted	\$(19.50)	\$(47.40)

Common Shares:

Full Diluted	579	353
Year-end	623	405

AVINGER INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2023	2022
Total revenues	5,746	6,272
Cost & expenses	17,766	18,407
Operating income	(12,020)	(12,135)
Interest expense	1,292	1,286
Other income (expense), net	16	(20)
Net before taxes	(13,296)	
Net income	(13,296)	(13,441)
Balance for common	(13,296)	(21,933)

Earnings common share

Primary	\$(21.48)	\$(56.70)
Fully Diluted	\$(21.48)	\$(56.70)

Common Shares:

Full Diluted	619	387
Year-end	1,280	496

AVITA MEDICAL INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2023	2022
Total revenues	35,948,000	24,966,000
Net Sales	35,948,000	
Cost & expenses	66,330,000	46,563,000
Operating income	(30,382,000)	(21,597,000)
Other income (expense), net	2,141,000	307,000
Net before taxes	(28,262,000)	(21,300,000)
Income taxes	54,000	12,000
Net income	(28,316,000)	(21,312,000)

Earnings common share

Primary	\$(1.12)	\$(0.85)
---------	----------	----------

Fully Diluted	\$(1.12)	\$(0.85)
---------------	----------	----------

Common Shares:

Full Diluted	25,281,920	24,972,331
Year-end	25,550,694	25,030,902

AVITA MEDICAL INC

Official Changes On Mar. 23, 2023, Co. announced the appointment of Mr. Robert McNamara to its Board of Directors, effective Apr. 1, 2023.

AVITA MEDICAL INC

Official Changes On May 11, 2023, Co. announced the resignation of Ms. Erin Liberto as Co.'s Chief Commercial Officer.

AVITA MEDICAL INC

Official Changes On Jun. 15, 2023, Co. announced the appointment of Mr. David OToole as Co.'s Chief Financial Officer.

AYTU BIOPHARMA INC**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$):**

	2023	2022	2021
Product & service revenue, net	107,399,000	96,669,000	...
Product revenue, net	107,399,000	96,669,000	65,632,000
Cost of sales	40,767,000	44,386,000	36,432,000
Gross profit	66,632,000	52,283,000	29,200,000
Research & development expenses	4,095,000	12,662,000	5,623,000
Selling & marketing expenses	41,448,000	38,713,000	30,308,000
General & administrative expenses	28,630,000	31,167,000	25,500,000
Acquisition related costs	2,919,000
Restructuring costs	4,886,000
Impairment of goodwill	...	65,802,000	...
Impairment expense	5,705,000	9,656,000	12,825,000
Amortization of intangible assets	4,788,000	5,844,000	6,009,000
Gain from contingent consideration	969,000	1,655,000	...
Total operating expenses	83,697,000	162,189,000	88,070,000
Income (loss) from operations	(17,065,000)	(109,906,000)	(58,870,000)
Other income (expense), net	2,050,000
Other gain	...	1,605,000	...
Gain (loss) from contingent consideration	4,459,000
Gain (loss) on extinguishment of debt	...	169,000	(1,569,000)
Gain (loss) on derivative warrant liability	4,793,000
Other Expense/Income - Net	(4,779,000)	(757,000)	...
Total other income (expense)	14,000	1,017,000	840,000
Profit (loss) before income tax	(17,051,000)	(108,889,000)	(58,030,000)
Current state income taxes	46,000	7,000	16,000
Current- Federal	80,000
Total current tax expense	126,000	7,000	16,000
Deferred federal income taxes	...	(91,000)	200,000
Deferred state income taxes	...	(26,000)	43,000
Total deferred tax expense	(126,000)	(117,000)	243,000
Income tax expense (benefit)	...	(110,000)	259,000
Net income (loss)	(17,051,000)	(108,779,000)	(58,289,000)
Weighted average shares outstanding			

- basic	3,339,906	1,469,875	837,334
Weighted average shares outstanding			
- diluted	3,339,906	1,469,875	837,334
Year end shares outstanding	5,517,174	1,928,941	1,374,521
Net income (loss)			
per share - basic	\$(5.11)	\$(74.01)	\$(69.60)
Net income (loss)			
per share - diluted	\$(5.11)	\$(74.01)	\$(69.60)
Number of full time employees	150	...	175
Number of common stockholders	190	...	1,092

□ Restated to reflect latest presentation; □ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-20 stock split, January 6, 2022; □ Restated to reflect correction of accounting errors related to adjustment for warrants classification to derivative warrant liabilities at fair value and marked to market; □ Share increased due to the effect of stock-based compensation and issuance of common stock; □ As of September 10, 2021

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2023	2022 (revised)
Cash & cash equivalents	22,985,000	19,360,000
Accounts receivable, net	28,937,000	21,712,000
Raw materials	7,738,000	1,814,000
Work in process	2,956,000	1,838,000
Finished goods	1,301,000	7,197,000
Inventory, net	11,995,000	10,849,000
Prepaid expenses	8,047,000	7,375,000
Other current assets	868,000	633,000
Total current assets	72,832,000	59,929,000
Manufacturing equipment	2,433,000	2,487,000
Leasehold improvements	999,000	999,000
Office equipment, furniture & other fixed assets	1,125,000	1,128,000
Lab equipment	832,000	832,000
Asset under construction	107,000	...
Less accumulated depreciation & amortization	3,681,000	2,421,000
Property & equipment, net	1,815,000	3,025,000
Operating lease right-of-use asset	2,054,000	3,271,000
Intangible assets, net	58,970,000	70,632,000
Other non-current assets	792,000	766,000
Total non-current assets	63,631,000	77,694,000
Total assets	136,463,000	137,623,000
Accounts payable & other current liabilities	13,478,000	10,987,000
Accrued product-related fees	6,579,000	7,817,000
Accrued compensation	5,675,000	4,765,000
Accrued liabilities	46,799,000	44,187,000
Current portion of debt	1,563,000	3,813,000
Other current liabilities	7,090,000	5,359,000
Current portion of operating lease liabilities	1,258,000	1,227,000
Natesto payable	11,012,000	9,468,000
Current portion of debt	85,000	96,000
Capitalized Leases - Current Portion	85,000	96,000
Accrued liabilities - Balancing value	23,533,000	22,137,000
Other current liabilities		
- Balancing value	5,832,000	4,132,000
Total current liabilities	69,015,000	64,442,000
Long-term operating lease liability, net of current portion	832,000	2,090,000
Warrant derivative liability	6,403,000	1,796,000
Other non-current liabilities	6,975,000	12,798,000
Long-Term Debt including Capitalized Leases	14,713,000	14,279,000
Other long-term		

liabilities - Balancing value	6,143,000	10,708,000
Long-Term Debt including Capitalized Leases - Balancing value	14,713,000	14,279,000
Total liabilities	97,106,000	93,315,000
Common stock	1,000	...
Additional paid-in capital	343,485,000	331,386,000
Retained earnings (accumulated deficit)	(304,129,000)	(287,078,000)
Total stockholders' equity (deficit)	39,357,000	44,308,000
Total Equity	39,357,000	44,308,000

□ Restated to reflect latest presentation

Recent Dividends:

1. AYTU BioPharma Inc preferred.

No dividends paid.

2. AYTU BioPharma Inc common.

No dividends paid.

Annual Dividends:

1. AYTU BioPharma Inc preferred.

No dividends paid.

2. AYTU BioPharma Inc common.

No dividends paid.

AYTU BIOPHARMA INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Grant Thornton LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the financial statements We have audited the accompanying consolidated balance sheet of Aytu BioPharma, Inc. (a Delaware corporation) and subsidiaries (the "Company") as of June 30, 2023, the related consolidated statements of operations, stockholders' equity, and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. Going concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company's net loss was \$17.1 million and cash used in operating activities was \$5.1 million for the year ended June 30, 2023, and as of that date, the Company's accumulated deficit was \$304.1 million. These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

BAB INC

Earnings, 9 mos. to Aug 31 (Consol. - \$):

	2023	2022
Total revenues	2,546,644	2,445,029
Net Sales	870,543	...
Cost & expenses	2,104,525	1,992,046
Operating income	439,293	449,466
Interest income	20,613	282
Net before taxes	459,906	449,748
Income taxes	130,300	...
Net income	329,606	321,161
Balance for common	329,606	...
Earnings common share		
Primary	\$0.05	\$0.04
Fully Diluted	\$0.05	\$0.04
Common Shares:		
Full Diluted	7,263,508	7,263,508
Year-end	7,263,508	7,263,508

BAIYU HOLDINGS INC

New Name On Oct. 30, 2023, Co. changed its name from TD Holdings Inc. to BAIYU Holdings Inc.

BAIYU HOLDINGS INC

Stock Trading Symbol Stock symbol, BYU.

BAUDAX BIO INC

New Auditor On Oct. 19, 2023, Co. dismissed EisnerAmper LLP as its independent registered public accounting firm and engaged KPMG LLP as its new independent registered public accounting firm.

BEAM GLOBAL

Acquisition Completed On Oct. 20, 2023, Co. acquired all the equity stock of Amiga DOO Kraljevo ("Amiga") from the owners of Amiga (the "Sellers") in exchange for cash and common stock. With respect to the cash portion of the purchase price, Co. paid to the Sellers Euro4,550,000 at closing and would pay the Sellers Euro2,450,000 on or before Dec. 31, 2023. With respect to the equity portion of the purchase price, Co. issued to the Sellers 277,383 shares of its common stock and, on or before Dec. 31, 2023, would issue to the Sellers an additional 149,360 shares of its common stock.

BIOAFFINITY TECHNOLOGIES INC

Earnings, 6 mos. to Jun 30 (Consol. - \$):

	2023	2022
Total revenues	20,659	1,306
Cost & expenses	3,356,978	1,412,469
Operating income	(3,336,320)	(1,411,163)
Other income (expense), net	1,399,250	...
Net before taxes	(3,256,557)	(1,557,913)
Income taxes	16,406	2,159
Net income	(3,272,963)	(1,560,072)
Earnings common share		
Primary	\$(0.38)	\$(0.58)
Fully Diluted	\$(0.38)	\$(0.58)
Common Shares:		
Full Diluted	8,477,656	2,687,431
Year-end	8,555,365	2,694,458

BIOAFFINITY TECHNOLOGIES INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2023	2022
Total revenues	319,143	2,457
Cost & expenses	5,849,161	2,389,773
Deprec., depl. & amort.	100,805	...
Operating income	(5,630,823)	(2,387,316)
Other income (expense), net	(12,494)	(1,654,664)
Net before taxes	(5,545,147)	(6,477,071)
Income taxes	18,700	2,459
Net income	(5,563,847)	(6,479,530)
Earnings common share		
Primary	\$(0.65)	\$(2.03)
Fully Diluted	\$(0.65)	\$(2.03)
Common Shares:		
Full Diluted	8,551,154	3,194,765
Year-end	9,216,883	8,369,750

BIOFORCE NANOSCIENCES HOLDINGS INC

Earnings, 6 mos. to Jun 30 (Consol. - \$):

	2023	2022
Cost & expenses	243,936	248,192
Operating income	(243,936)	...
Net before taxes	(243,936)	...
Net income	(243,936)	(248,192)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	29,271,755	29,271,755
Year-end	29,271,755	29,271,755

BIOFORCE NANOSCIENCES HOLDINGS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2023	2022
Cost & expenses	357,543	370,779
Operating income	(357,543)	...
Net before taxes	(357,543)	...
Net income	(357,543)	(370,779)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	29,271,755	29,271,755
Year-end	29,271,755	29,271,755

BIOLIFE SOLUTIONS INC

Official Changes On Oct. 19, 2023, Co. announced the resignation of Mr. Michael Rice as Co.'s Chief Executive Officer and Chairman of the Board of Director. Also, on Oct. 19, 2023, Co. announced the appointment of Mr. Roderick de Greef as Co.'s President, Chief Executive Officer and Chairman of the Board of Director.

BIONIK LABORATORIES CORP

Annual Report

Consolidated Income Statement, Years Ended Mar. 31 (\$):

	2023	2022	[□] 2021 (revised)						
Selling, general & administrative expense	1,981,897	cost	204,447	168,691	Total stockholders' equity (deficit)	(1,640,588) 2,927,212	
Revenues, net	1,805,202	1,273,712	1,193,430	Less: accumulated depreciation - demonstration equipment	...	87,874	Total Equity	(1,640,588) ...	
Cost of revenues	815,325	320,454	269,632	Demonstration equipment, net	69,168	80,817	Recent Dividends:		
Gross profit	989,877	953,258	923,798	Manufacturing equipment, cost	130,563	88,742	1. Bionik Laboratories Corp common.	No dividends paid.	
Sales & marketing	...	1,920,749	1,025,404	Less: accumulated depreciation - manufacturing equipment	...	88,742	2. Bionik Laboratories Corp exchangeable common.	No dividends paid.	
Research & development	903,219	998,516	1,544,918	Manufacturing equipment, net	37,221	...	3. Bionik Laboratories Corp special voting preferred.	No dividends paid.	
General & administrative	2,929,800	2,806,584	4,508,748	Tools & parts, costs	11,422	11,422	Annual Dividends:		
Impairment of goodwill & intangible assets	...	5,200,608	7,182,053	Less: accumulated depreciation - tools & parts	...	11,422	1. Bionik Laboratories Corp common.	No dividends paid.	
Total operating expenses	5,814,916	10,926,457	14,261,123	Assets under capital lease	68,453	68,453	2. Bionik Laboratories Corp exchangeable common.	No dividends paid.	
Income (loss) from operations	(4,825,039)	(9,973,199)	(13,337,325)	Less: accumulated depreciation - assets under capital lease	36,795	68,453	3. Bionik Laboratories Corp special voting preferred.	No dividends paid.	
Interest expense, net	107,150	825,209	405,279	Furniture and fixtures- Other - Gross	36,795	...	BIONIK LABORATORIES CORP	Auditor's Report Auditor's Report	
Other income (expense), net	(13,835)	390,414	122,147	Leasehold Improvements - Gross	79,448	...	BIOSTAX CORP	New Name On Oct. 20, 2023, Co. changed its name from Immune Therapeutics Inc (FL) to Biostax Corp.	
Total other income (expense)	(120,985)	(434,795)	(283,132)	Leasehold Improvements - Net	75,034	...	BIOSTAX CORP	Stock Trading Symbol Stock symbol, BTAX.	
Income (loss) before provision for income taxes	(4,946,024)	Manufacturing equipment- Accumulated Depreciation & Impairment	93,342	...	BIOTRICITY INC	Annual Report	
Net income (loss)	(4,946,024)	(10,407,994)	(13,620,457)	Leasehold Improvements - Accumulated Depreciation & Impairment	4,414	...	Consolidated Income Statement, Years Ended Mar. 31 (\$):		
Weighted average shares outstanding - basic	6,903,664	5,844,006	5,128,421	Computers and electronics - Accumulated Depreciation & Impairment	309,587	...	2023	2022	[□] 2021 (revised)
Weighted average shares outstanding - diluted	6,903,664	5,844,006	5,128,421	Equipment	187,673	91,234	REVENUE	9,639,057	...
Year end shares outstanding	6,878,162	[□] 6,767,114	5,589,375	Goodwill	99,552	...	Revenue	9,639,057	7,650,269
Net earnings (loss) per share - basic	\$(0.72)	\$(1.78)	\$(2.66)	Technology & other assets	34,000	...	Cost of revenue	4,197,024	3,080,116
Net earnings (loss) per share - diluted	\$(0.72)	\$(1.78)	\$(2.66)	Right of Use Tangible Assets - Operating Lease - Net	254,650	...	Gross profit	5,442,033	4,570,153
Number of full time employees	12	[□] 12	[□] 13	Other assets	8,694	...	General & administrative expenses	17,621,865	19,845,939
Number of part time employees	...	[□] 4	[□] 5	Total assets	3,362,127	4,675,837	Research & development expenses	3,229,879	2,744,587
Number of common stockholders	315	[□] 318	[□] 316	Accounts payable	557,610	305,095	Total operating expenses	20,851,744	22,590,526
Foreign currency translation adjustments	1,719	(14,053)	...	Accrued personnel costs	...	115,992	Other income	(110,822)	15,120
				Accrued director fees	...	480,672	Loss upon convertible promissory notes conversion	...	1,155,642
				Accrued commissions	...	22,924	Other income - debt forgiveness	(71,119)	...
				Accrued professional fees	...	81,100	Accretion & amortization expense	743,459	9,286,023
				Accrued warranty costs	...	8,885	Change in fair value of derivative liabilities	(483,873)	(683,559)
				Accrued other	...	163,457	Interest expense	1,839,159	...
				Accrued liabilities	1,387,150	873,030	Net income (loss) before income taxes	(18,658,143)	(29,130,477)
				Deferred revenue, current portion	342,354	313,854	Net income (loss) before dividends	(18,658,143)	(29,130,477)
				Operating Lease Liabilities - Current	22,067	...	Less: preferred stock dividends	875,540	1,088,977
				Portion/Short-Term Total current liabilities	2,309,181	1,491,979	Net income (loss) attributed to common stockholders	(19,533,683)	(30,219,454)
				Deferred revenue, net of current portion	303,292	256,646	Weighted average shares outstanding - basic	[□] 8,659,640	7,574,953
				Convertible notes	2,155,794	...	Weighted average shares outstanding - diluted	[□] 8,659,640	7,574,953
				Operating Lease Liabilities - Long-Term	234,448	...	Year end shares outstanding	[□] 8,752,430	8,546,173
				Total liabilities	5,002,715	1,748,625	Net income (loss) per share - basic	[□] \$(2.26)	\$(3.99)
				Common stock	6,989	6,879	Net income (loss) per share - diluted	[□] \$(2.26)	\$(3.99)
				Additional paid in capital	98,670,953	98,294,558	Number of full time employees	55	44
				Retained earnings (accumulated deficit)	(100,348,345)	(95,402,321)	Number of part time employees	...	[□] 20
				Accumulated other comprehensive income	29,815	28,096	Total number of	...	[□] 20

[□] Reclassified to conform with 2022 presentation; [□] Shares increased due to the effect of share compensation expense, conversion of notes, shares issued in lieu of services and options exercised in conjunction with notes; [□] As of June 6, 2022; [□] As of June 18, 2021

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2023	2022
Cash & cash equivalents	427,383	1,991,377
Accounts receivable, net	453,084	274,844
Prepaid inventory	709,503	956,743
Prepaid insurance	...	77,553
Other prepaid expenses	68,094	93,066
Other prepaid expenses	85,006	...
Prepaid expenses and other current assets	862,603	1,127,362
Finished goods	829,907	1,083,718
Raw materials	204,581	107,302
Inventories	1,034,488	1,191,020
Total current assets	2,777,558	4,584,603
Computers & electronics, cost	315,837	315,837
Less: accumulated depreciation - computers & electronics	...	305,420
Furniture & fixtures, cost	...	36,795
Less: accumulated depreciation - furniture & fixtures	...	36,795
Demonstration equipment,		

employees.....	...	□64	□64
Number of common stockholders.....	210	□□199	□□132
Foreign currency translation adjustments.....	615,859	(134,470)	223,121

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-6 stock split, July 3, 2023; □ Approximately; □ As of July 13, 2022; □ As of June 18, 2021

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2023	2022
Cash.....	570,460	12,066,929
Accounts receivable, net.....	1,224,137	2,006,678
Finished Goods.....	1,150,271	...
Raw material.....	1,186,735	...
Inventory.....	2,337,006	842,924
Deposits & other receivables.....	588,599	406,280
Total current assets.....	4,720,202	15,322,811
Deposits & other receivables.....	85,000	...
Deposits.....	...	85,000
Long-term accounts receivable.....	96,344	...
Office equipment- Gross.....	16,839	...
Office equipment - Net.....	12,164	...
Leasehold Improvements - Gross.....	12,928	...
Leasehold improvement - Net.....	9,342	...
Property & equipment, cost.....	...	29,767
Leasehold Improvements - Accumulated Depreciation & Impairment.....	3,586	...
Less: accumulated depreciation.....	...	2,308
Office equipment-Under Capital Lease - Accumulated Depreciation & Impairment.....	4,675	...
Property & equipment.....	21,506	27,459
Operating lease right-of-use assets.....	1,587,492	1,242,700
Total assets.....	6,510,544	16,677,970
Trade & other payables.....	...	1,159,477
Accrued liabilities.....	1,607,353	1,436,270
Advances from investor.....	5,042,476	...
Accounts payable & accrued liabilities.....	3,435,123	2,595,747
Convertible promissory notes & short term loans.....	4,774,468	1,540,000
Operating lease obligations, current.....	335,608	210,320
Derivative liabilities.....	1,008,216	520,747
Total current liabilities.....	11,160,768	4,866,814
Federally guaranteed loans.....	870,800	870,800
Term loan.....	12,178,809	11,612,672
Derivative liabilities.....	759,065	352,402
Operating lease obligations, long-term.....	1,386,487	1,120,018
Total liabilities.....	26,355,929	18,822,706
Preferred stock.....	1	1
Series A preferred stock.....	6	7
Common stock.....	52,514	51,277
Shares to be issued.....	24,999	102,299
Additional paid-in-capital.....	92,800,717	91,507,478
Accumulated other comprehensive income (loss).....	(152,797)	(768,656)
Retained earnings (accumulated deficit).....	(112,570,825)	(93,037,142)
Total stockholders' equity (deficit).....	(19,845,385)	(2,144,736)
Total Equity.....	(19,845,385)	...

Recent Dividends:

- 1. Biotricity Inc exchangeable common.**
No dividends paid.

2. Biotricity Inc special voting preferred.

No dividends paid.

3. Biotricity Inc series A preferred.

No dividends paid.

4. Biotricity Inc common.

No dividends paid.

Annual Dividends:

1. Biotricity Inc exchangeable common.

No dividends paid.

2. Biotricity Inc special voting preferred.

No dividends paid.

3. Biotricity Inc series A preferred.

No dividends paid.

4. Biotricity Inc common.

No dividends paid.

BIOTRICITY INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, SRCO Professional Corporation, as it appeared in Co.'s 2023 10-K report: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Biotricity Inc. and its subsidiary (the Company) as of March 31, 2023 and 2022 and the related consolidated statements of operations and comprehensive loss, stockholders' deficiency, and cash flows for each of the years in the two-year period ended March 31, 2023 and related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as at March 31, 2023 and 2022 and the results of its operations and its cash flows for each of the years in the two-year period ended March 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Material Uncertainty Related to Going Concern The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has incurred recurring losses from operations, has negative cash flows from operating activities, working capital deficiency and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

BIOTRICITY INC

Earnings, 3 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues.....	3,020,765	2,056,052
Cost & expenses.....	5,337,251	6,533,102
Operating income.....	(2,316,486)	(4,776,252)
Other income (expense), net.....	(435,884)	(299,202)
Net before taxes.....	(3,412,882)	(4,776,252)
Net income.....	(3,412,882)	(4,776,252)
Balance for common.....	(3,601,579)	(5,024,389)

Earnings common share

Primary.....	\$(0.41)	\$(0.59)
Fully Diluted.....	\$(0.41)	\$(0.59)

Common Shares:

Full Diluted.....	8,752,430	8,573,491
Year-end.....	8,752,430	8,614,292

Consolidated Balance Sheet Items, as of (\$):

	2023	2022
Assets:		
Cash & equivalents.....	51,433	...
Inventories.....	2,215,560	...
Current assets.....	4,400,678	...
Net property & equip.....	20,017	...
Total assets.....	6,144,123	...
Liabilities:		
Current liabilities.....	15,097,543	...
Long-term debt.....	12,500,551	...
Stockholders' equity.....	(23,411,614)	...
Net current assets.....	(10,696,865)	...

BLUE WATER BIOTECH INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Cost & expenses.....	9,497,859	6,365,546
Operating income.....	(9,497,859)	(6,365,546)
Interest expense.....	213,996	...
Other income (expense), net.....	(59)	30,303
Net income.....	(9,711,914)	(6,335,243)
Balance for common.....	(9,711,914)	(6,431,602)

Earnings common share

Primary.....	\$(0.61)	\$(0.70)
--------------	----------	----------

Fully Diluted.....	\$(0.61)	\$(0.70)
--------------------	----------	----------

Common Shares:

Full Diluted.....	15,908,560	9,226,621
Year-end.....	16,413,058	12,229,399

BODY & MIND INC

Interest Sale Completed On Oct. 17, 2023, Co.'s wholly owned subsidiary, DEP Nevada, Inc. ("DEP") sold all the issued and outstanding interests and other ownership, equity, or profits interests in NMG OH 1, LLC ("NMG OH") to PharmaceuticalRX, LLC (the "Purchaser"). The Purchaser paid an initial total consideration of US\$8,225,000 (US\$7,975,000 on closing plus US\$250,000 deposit upon signing of the equity purchase agreement (the "EPA"), dated July 21, 2023) (the "Initial Purchase Price") in cash to DEP, which Initial Purchase Price is subject to a working capital adjustment and other customary adjustments pursuant to Section 2.3 of the EPA to be calculated within 365 days of the closing date (the "Final Purchase Price"). Based on the Accepted Adjustment Statement (as defined in the EPA), the parties shall determine if the Final Purchase Price shall be adjusted upwards or downwards. An amount equal to the Escrow Amount (as defined in the EPA) of US\$100,000 from the Final Purchase Price is being held in escrow and would be released to DEP on the fifth day of the twelfth month after the closing date unless there are any indemnification claims pending until such time as the claim is resolved. In addition, DEP shall receive a payment of US\$2,500,000 (each, a "Bonus Payment") for each additional dispensary license granted to NMG OH by the State of Ohio Board of Pharmacy or other regulatory body, in accordance with the terms of the EPA. Additional dispensary licenses that would receive the Bonus Payment shall specifically exclude an adult use license issued for the License (as defined in the EPA) and lease location at the time.

BRISTOL MYERS SQUIBB CO.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2023	2022
Total revenues.....	33,529,000	34,753,000
Cost & expenses.....	21,102,000	20,854,000
Operating income.....	5,698,000	4,290,000
Interest expense.....	850,000	938,000
Other income (expense), net.....	2,171,000	(66,000)
Gains or losses.....	(213,000)	211,000
Net before taxes.....	6,766,000	5,854,000
Income taxes.....	488,000	1,534,000
Net income.....	6,278,000	4,320,000

Earnings common share

Primary.....	\$3.01	\$2.01
Fully Diluted.....	\$2.99	\$2.00

Common Shares:

Full Diluted.....	2,093,000	2,154,000
Year-end.....	2,034,000	2,126,160

BRISTOL MYERS SQUIBB CO.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2023	2022
Total revenues.....	33,529,000	34,753,000
Cost & expenses.....	21,102,000	20,854,000
Operating income.....	5,698,000	4,290,000
Interest expense.....	850,000	938,000
Other income (expense), net.....	2,171,000	(66,000)
Gains or losses.....	(213,000)	211,000
Net before taxes.....	6,766,000	5,854,000
Income taxes.....	488,000	1,534,000
Net income.....	6,278,000	4,320,000

Earnings common share

Primary.....	\$3.01	\$2.01
Fully Diluted.....	\$2.99	\$2.00

Common Shares:

Full Diluted.....	2,093,000	2,154,000
Year-end.....	2,034,000	2,126,160

BULLFROG AI HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Cost & expenses.....	2,727,615	1,232,206
Operating income.....	(2,727,615)	(1,232,206)
Interest expense.....	71,122	110,509
Other income (expense), net.....	(7,208)	439
Net income.....	(2,805,945)	(1,342,276)

Earnings common share

Primary.....	\$(0.51)	\$(0.29)
Fully Diluted.....	\$(0.51)	\$(0.29)

Common Shares:

Full Diluted.....	5,451,138	4,627,761
Year-end.....	6,094,644	4,716,548

BULLFROG AI HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2023	2022
Total revenues	65,000	...
Net Sales	65,000	...
Cost & expenses	4,096,759	1,872,758
Operating income	(4,031,759)	(1,872,758)
Interest expense	76,880	234,668
Other income (expense), net	49,716	457
Net income	(4,058,923)	(2,106,969)
Earnings common share		
Primary	\$(0.72)	\$(0.08)
Fully Diluted	\$(0.72)	\$(0.08)
Common Shares:		
Full Diluted	5,667,997	27,586,200
Year-end	6,094,644	28,195,022

BUNKER HILL MINING CORP**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2023	2022
Cost & expenses	5,522,461	9,466,536
Operating income	(5,522,461)	(9,466,536)
Interest income	231,133	...
Interest expense	2,713,049	1,117,607
Other income (expense), net	(3,550,038)	19,979,362
Foreign currency	(3,479)	(221,324)
Net before taxes	(11,557,894)	...
Net income	(15,066,635)	9,173,895
Earnings common share		
Primary	\$(0.06)	\$0.05
Fully Diluted	\$(0.06)	\$0.04
Common Shares:		
Full Diluted	247,170,167	214,210,598
Year-end	265,810,755	217,640,683

BUTLER NATIONAL CORP.**Annual Report****Consolidated Income Statement, Years Ended Apr. 30 (\$):**

	2023	2022	2021
Revenues - management/professional services	37,141,000
Revenues - professional services	39,147,000	30,205,000	...
Revenues - aerospace products	34,326,000	31,275,000	...
Professional services	38,041,000
Total revenue	75,182,000	73,473,000	61,480,000
Cost of product sales	15,449,000
Cost of sales - management/professional services	25,854,000
Cost of sales - professional services	15,798,000	14,214,000	...
Cost of sales - aerospace products	22,434,000	23,293,000	...
Marketing & advertising expenses	5,246,000	5,236,000	3,752,000
Employee benefits	2,573,000	2,571,000	...
Depreciation & amortization	2,815,000	3,542,000	...
General, administrative & other expenses	19,979,000	8,488,000	8,208,000
Total costs & expenses	66,528,000	57,344,000	55,580,000
Operating income (loss)	8,654,000	16,129,000	5,900,000
Interest Expense on Financial Lease Liabilities	188,000
Interest expense - balancing values	2,555,000
Interest expense	2,743,000	2,689,000	3,138,000
Forgiveness of debt	2,001,000
Gain on sale of airplanes	69,000	75,000	...
Other income

(expense)	137,000	...	7,000
Gain on sale of building	410,000
Total other income (expense)	(2,127,000)	(613,000)	(3,131,000)
Income (loss) before income taxes	6,527,000	15,516,000	2,769,000
Provision (benefit) for income taxes	1,714,000	3,102,000	536,000
Deferred income tax expense (benefit)	297,000	174,000	(225,000)
Net income (loss)	4,516,000	12,240,000	2,458,000
Net loss (income) attributable to noncontrolling interest in BHCMC, LLC	...	(1,872,000)	(1,025,000)
Net income (loss) attributable to Butler National Corporation	4,516,000	10,368,000	1,433,000
Weighted average shares outstanding - basic	76,456,631	75,340,131	74,144,957
Weighted average shares outstanding - diluted	76,456,631	75,340,131	74,144,957
Year end shares outstanding	76,891,689	76,458,146	75,366,749
Earnings (loss) per share - basic	\$0.06	\$0.14	\$0.02
Earnings (loss) per share - diluted	\$0.06	\$0.14	\$0.02
Number of full time employees	104	107	113
Number of part time employees	3	5	5
Number of common stockholders	2,400	2,500	2,500

□ Approximately; □ As of July 8, 2022; □ As of July 9, 2021

Consolidated Balance Sheet, Years Ended Apr. 30 (\$):

	2023	2022
Cash	21,997,000	12,487,000
Accounts receivable, gross	3,998,000	3,841,000
Less: allowance for doubtful accounts	205,000	205,000
Accounts receivable, net	3,793,000	3,636,000
Raw materials	5,704,000	...
Parts & raw materials	...	4,722,000
Work in process	3,194,000	4,080,000
Finished goods	49,000	70,000
Total inventory, net of allowance	8,947,000	8,872,000
Contract asset	1,893,000	1,470,000
Prepaid expenses & other current assets	3,532,000	1,361,000
Total current assets	40,162,000	27,826,000
Lease right-to-use asset	...	3,240,000
Construction in progress	...	6,417,000
Land	4,751,000	4,751,000
Building & improvements	...	40,962,000
Building	47,867,000	...
Aircraft	8,515,000	8,719,000
Machinery & equipment	5,547,000	4,917,000
Office furniture & fixtures	13,881,000	11,826,000
Leasehold improvements	4,032,000	4,032,000
Building under capitalized leases	3,081,000	...
Property, plant & equipment, gross	84,593,000	84,864,000
Accumulated depreciation	25,526,000	23,290,000
Total property, plant & equipment	59,067,000	61,574,000
Supplemental type certificates	8,722,000	8,018,000
Other assets	1,401,000	1,621,000
Deferred tax asset, net	1,473,000	1,770,000
Total assets	113,906,000	100,809,000
Current maturities of

long-term debt	4,987,000	5,165,000
Current maturities of lease liability	...	106,000
Current maturities of finance lease liability	145,000	...
Accounts payable	5,320,000	2,773,000
Contract liability	6,031,000	820,000
Gaming facility mandated payment	1,730,000	1,630,000
Compensation & compensated absences	6,722,000	1,911,000
Income tax payable	228,000	1,049,000
Other current liabilities	214,000	211,000
Total current liabilities	25,377,000	13,665,000
Notes payable	...	48,965,000
Less: origination fees	...	(389,000)
Less: current maturities	...	5,165,000
Lease liability, net of current maturities	...	2,899,000
Finance lease liability, net of current maturities	3,330,000	...
Total long-term liabilities	41,748,000	46,310,000
Total liabilities	67,125,000	59,975,000
Common stock	808,000	803,000
Capital contributed in excess of par	13,647,000	12,160,000
Treasury stock at cost	2,138,000	2,077,000
Retained earnings (accumulated deficit)	34,464,000	29,948,000
Total Butler National Corporation's stockholders' equity	46,781,000	40,834,000
Total stockholders' equity	46,781,000	40,834,000

□ Net of accumulated amortization - supplemental type certificates: \$10,603,000; □ Net of accumulated amortization - supplemental type certificates: \$11,575,000; □ Net of accumulated amortization - other assets: \$12,290,000; □ Net of accumulated amortization - other assets: \$11,575,000

Recent Dividends:**1. Butler National Corp. common.**

No dividends paid.

Annual Dividends:**1. Butler National Corp. common.**

No dividends paid.

BUTLER NATIONAL CORP.**Earnings, 3 mos. to Jul 31**(Consol. – \$000):

	2023	2022
Total revenues	17,185	15,304
Cost & expenses	16,048	12,908
Deprec., depl. & amort.	...	771
Operating income	1,137	1,625
Interest income	47	...
Interest expense	...	723
Gains or losses	440	69
Net before taxes	985	971
Income taxes	266	...
Net income	719	431
Earnings common share		
Primary	\$0.01	\$0.01
Fully Diluted	\$0.01	\$0.01
Common Shares:		
Full Diluted	75,199	76,456
Year-end	68,728	76,782

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2023
Cash & equivalents	...	14,236
Inventories	...	9,047
Current assets	...	31,778
Net property & equip.	...	61,368
Total assets	...	105,000
Liabilities:		
Current liabilities	...	22,210
Long-term debt	...	40,574
Stockholders' equity	...	42,216
Net current assets	...	9,568

CARDIFF ONCOLOGY INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2023	2022
Cost & expenses	35,412,000	30,768,000
Operating income	(35,080,000)	(30,510,000)
Other income (expense), net	(85,000)	(338,000)
Net before taxes	(32,104,000)	(32,104,000)
Net income	(32,104,000)	(30,007,000)
Balance for common	(32,122,000)	(30,025,000)
Earnings common share		
Primary	\$(0.72)	\$(0.69)
Fully Diluted	\$(0.72)	\$(0.69)
Common Shares:		
Full Diluted	44,677,000	43,291,000
Year-end	44,677,000	43,335,000

CATALYST PHARMACEUTICALS INC

Official Changes On Oct. 19, 2023, Co. announced the appointment of Mr. Richard J. Daly as Co.'s Chief Executive Officer effective on Jan. 1, 2024.

CHARGE ENTERPRISES INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	341,135,000	344,019,000
Cost & expenses	356,832,000	362,101,000
Operating income	(18,099,000)	(19,394,000)
Other income (expense), net	1,932,000	(109,000)
Gains or losses	1,656,000	
Foreign currency	(169,000)	(87,000)
Net before taxes	(17,706,000)	(28,514,000)
Income taxes	352,000	(1,328,000)
Net income	(18,058,000)	(27,186,000)
Balance for common	(18,782,000)	(64,503,000)
Earnings common share		
Primary	\$(0.09)	\$(0.34)
Fully Diluted	\$(0.09)	\$(0.34)
Common Shares:		
Full Diluted	209,974,000	190,966,000
Year-end	212,899,281	206,082,652

CHINA HEALTH INDUSTRIES HOLDINGS, INC.

New Auditor On Oct. 23, 2023, Co.'s Board of Directors dismissed ARK Pro CPA & Co. as Co.'s independent registered public accounting firm and engaged Assenture PAC as Co.'s new independent registered public accounting firm.

CISO GLOBAL INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	29,251,675	20,557,355
Cost & expenses	92,754,693	35,848,717
Operating income	(63,503,018)	(15,291,362)
Interest expense	1,156,231	108,233
Other income (expense), net	53,219	29,968
Net before taxes	(64,606,030)	
Income taxes	(435,678)	
Net income	(64,170,352)	(15,369,627)
Earnings common share		
Primary	\$(0.42)	\$(0.11)
Fully Diluted	\$(0.42)	\$(0.11)
Common Shares:		
Full Diluted	151,406,985	134,738,684
Year-end	178,006,398	137,097,860

COYA THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Cost & expenses	6,140,761	5,138,484
Operating income	(6,154,441)	(5,146,550)
Other income (expense), net	322,604	30,268
Net income	(5,831,837)	(5,116,282)
Earnings common share		
Primary	\$(0.59)	\$(1.98)
Fully Diluted	\$(0.59)	\$(1.98)
Common Shares:		
Full Diluted	9,835,505	2,590,148
Year-end	9,947,915	2,590,197

COYA THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	9,697,983	7,787,900
Operating income	(9,718,504)	(7,808,421)
Other income (expense), net	464,693	(1,328,687)
Net income	(9,253,811)	(9,137,108)
Earnings common share		
Primary	\$(0.94)	\$(3.53)

	2023	2022
Fully Diluted	\$(0.94)	\$(3.53)
Common Shares:		
Full Diluted	9,873,387	2,590,148
Year-end	9,947,915	2,590,197

CREATIVE REALITIES INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	19,140,000	
Net Sales		21,680,000
Cost & expenses	18,354,000	21,489,000
Deprec., depl. & amort.	1,576,000	1,175,000
Operating income	(790,000)	(984,000)
Interest expense		1,199,000
Other income (expense), net	43,000	7,560,000
Gains or losses		(1,557,000)
Net before taxes	(2,337,000)	3,820,000
Income taxes	88,000	56,000
Net income	(2,425,000)	3,764,000
Earnings common share		
Primary	\$(0.33)	\$0.63
Fully Diluted	\$(0.33)	\$0.63
Common Shares:		
Full Diluted	7,379,000	6,060,000
Year-end	7,409,000	7,247,951

CRYO-CELL INTERNATIONAL INC

Earnings, 6 mos. to May 31(Consol. - \$):

	2023	2022
Total revenues	15,597,105	14,891,748
Cost & expenses	12,324,112	11,668,860
Operating income	2,711,069	2,664,796
Interest expense	936,183	582,619
Other income (expense), net	(220,640)	127
Gains or losses	6,696	(26,830)
Net before taxes	1,560,942	2,055,474
Income taxes	573,154	
Net income	987,788	1,466,766
Earnings common share		
Primary	\$0.12	\$0.17
Fully Diluted	\$0.12	\$0.17
Common Shares:		
Full Diluted	8,402,538	8,643,106
Year-end	8,287,169	8,399,490

CRYO-CELL INTERNATIONAL INC

Earnings, 9 mos. to Aug 31(Consol. - \$):

	2023	2022
Total revenues	23,466,980	22,572,707
Cost & expenses	18,751,666	18,113,605
Operating income	3,872,113	3,619,107
Interest expense	1,405,825	947,968
Other income (expense), net	62,193	63,758
Gains or losses	100,082	(38,457)
Net before taxes	2,628,563	2,696,440
Income taxes	960,214	
Net income	1,668,349	1,933,586
Earnings common share		
Primary	\$0.20	\$0.23
Fully Diluted	\$0.20	\$0.23
Common Shares:		
Full Diluted	8,374,939	8,475,661
Year-end	8,286,785	8,525,255

DALLASNEWS CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2023	2022
Total revenues	105,713	111,548
Cost & expenses	110,185	116,468
Operating income	(5,590)	(7,047)
Other income (expense), net	1,082	(48)
Net before taxes	(4,508)	(7,095)
Income taxes	397	550
Net income	(4,905)	(7,645)
Balance for common	(4,905)	(7,645)
Earnings common share		
Primary	\$(0.92)	\$(1.43)
Fully Diluted	\$(0.92)	\$(1.43)
Common Shares:		
Full Diluted	5,352	
Year-end	5,352	5,352

DENTAL PATIENT CARE AMERICA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2022	2021	2020
Cooperative revenues	1,427,372	1,319,657	1,269,047
ERC Processing Services, (Net of Reserves)	882,473
Other revenues	301,351	297,152	245,879
Total revenues	2,611,196	1,616,809	1,514,926
General & administrative expenses	2,359,368	1,629,004	1,503,349
Total costs & expenses	2,359,368	1,629,004	1,503,349
Income (loss) from operations	251,828	(12,195)	11,577
Interest income	143	21	72
Interest expense	4,529	1,513	2,769
Gain on Extinguishment of Debt	237,500
Other Non-Operational Expense	271,834	1,080	...
Net other expense	504,948	(412)	(2,697)
Income (loss) from continued operations	756,776	(12,607)	8,880
Net income (loss)	756,776	(12,607)	8,880
Weighted average shares outstanding - basic	25,225,867	25,214,000	22,200,000
Weighted average shares outstanding - diluted	25,225,867	25,214,000	22,200,000
Year end shares outstanding	24,105,699	24,105,699	24,105,699
Net income (loss) per common share - basic	\$0.03	\$(0.00)	\$0.00
Net income (loss) per common share - diluted	\$0.03	\$(0.00)	\$0.00

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2022	2021
Cash	1,116,354	213,717
Cash held in controlled accounts	29	29
Accounts receivable	325,118	700
Prepays & other assets	...	1,798
Total current assets	1,441,501	216,244
Furniture & equipment	106,441	104,811
Less: accumulated depreciation	100,444	97,860
Property & equipment, net	5,997	6,951
ROU Lease Assets	16,204	65,569
Other assets	500	500
Total assets	1,464,202	289,264
Accounts payable	117,022	6,030
Credit card payable	12,190	11,746
Accrued payroll liabilities	290,816	290,816
S/T Portion of lease liabilities	16,204	49,365
Unearned Revenue	588,315	...
Sales tax payable	6,957	1,681
Total current liabilities	1,031,504	359,638
Long term notes payable	...	237,500
L/T Portion of lease liabilities	...	16,204
Total long-term liabilities	...	253,704
Total liabilities	1,031,504	613,342
Common stock & Contributed Capital	1,314,791	1,314,791
Retained earnings (accumulated deficit)	(882,093)	(1,638,869)
Total stockholders' equity (deficit)	432,698	(324,078)

Recent Dividends:

1. Dental Patient Care America Inc common.
No dividends paid.

Annual Dividends:

1. Dental Patient Care America Inc common.
No dividends paid.

DERMATO THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	5,822,074	7,962,797
Operating income	(5,822,074)	(7,962,797)
Net before taxes	(5,660,717)	(7,941,311)
Net income	(5,660,717)	(7,941,311)
Balance for common	(5,660,717)	(7,941,311)
Earnings common share		
Primary	\$(2.46)	\$(12.00)
Fully Diluted	\$(2.46)	\$(12.00)
Common Shares:		
Full Diluted	2,301,360	663,892
Year-end	3,189,034	756,388

DERMTECH INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	7,457,000	7,951,000
Cost & expenses	71,634,000	67,976,000
Operating income	(64,177,000)	(60,025,000)
Other income (expense), net	(1,000)	122,000
Net before taxes	(62,633,000)	(59,688,000)
Net income	(62,633,000)	(59,688,000)
Earnings common share		
Primary	\$(2.01)	\$(2.00)
Fully Diluted	\$(2.01)	\$(2.00)
Common Shares:		
Full Diluted	31,177,886	29,904,972
Year-end	33,408,810	30,037,447

DERMTECH INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	11,372,000	11,524,000
Cost & expenses	95,359,000	100,810,000
Operating income	(83,987,000)	(89,286,000)
Other income (expense), net	4,000	126,000
Net before taxes	(81,797,000)	(88,460,000)
Net income	(81,797,000)	(88,460,000)
Earnings common share		
Primary	\$(2.55)	\$(2.95)
Fully Diluted	\$(2.55)	\$(2.95)
Common Shares:		
Full Diluted	32,073,448	29,969,435
Year-end	34,241,523	30,213,206

DESTINY MEDIA TECHNOLOGIES INC

Earnings, 9 mos. to May 31(Consol. - \$):

	2023	2022
Total revenues	2,987,786	
Cost & expenses	2,536,669	2,995,758
Operating income	341,604	(55,962)
Interest income	26,038	
Gains or losses		11,018
Net before taxes	367,642	(40,251)
Net income	364,042	(40,251)
Earnings common share		
Primary	\$0.04	\$
Fully Diluted	\$0.04	\$
Common Shares:		
Full Diluted	9,101,050	10,185,320
Year-end	10,116,576	10,122,261

DOMINARI HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	1,034,000	
Net Sales	1,034,000	
Cost & expenses	16,983,000	11,202,000
Operating income	(15,949,000)	(11,202,000)
Other income (expense), net	42,000	155,000
Gains or losses	(564,000)	(4,390,000)
Net before taxes	(15,966,000)	(14,851,000)
Net income	(15,966,000)	(14,851,000)
Balance for common	(15,966,000)	(18,960,000)
Earnings common share		
Primary	\$(3.09)	\$(3.59)

Fully Diluted	\$(3.09)	\$(3.59)
Common Shares:		
Full Diluted	5,159,501	5,283,182
Year-end	5,285,164	5,140,114

DROR ORTHO-DESIGN INC

New Auditor On Oct. 18, 2023, Co.'s Board of Directors (the "Board") dismissed Sadler, Gibb & Associates, LLC as Co.'s independent registered public accounting firm. On Oct. 24, 2023, the Board engaged Barzily And Co., CPA's as Co.'s new independent registered public accounting firm.

DYNARESOURCE INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	22,865,248	20,590,513
Cost & expenses	25,010,835	16,965,670
Deprec., depl. & amort.		1,625
Operating income	(2,145,587)	3,623,218
Interest expense	224,175	241,505
Other income (expense), net	563,584	2,164,320
Foreign currency	34,227	37,790
Net before taxes	(1,771,951)	5,583,823
Income taxes	(1,211,215)	
Net income	(560,736)	5,583,823
Balance for common	(677,886)	5,446,673
Earnings common share		
Primary	\$(0.03)	\$0.30
Fully Diluted	\$(0.03)	\$0.30
Common Shares:		
Full Diluted	22,246,654	19,027,470
Year-end	22,246,654	20,746,654

EARTH SCIENCE TECHNOLOGIES INC

Earnings, 3 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	219,934	
Cost & expenses	231,327	692,172
Operating income	(77,090)	(692,172)
Other income (expense), net		547,608
Net before taxes	(89,708)	(154,682)
Net income	(89,708)	(154,682)
Earnings common share		
Primary		
Fully Diluted		
Common Shares:		
Year-end	314,881,821	53,851,966

Consolidated Balance Sheet Items, as of (\$):

	2023	2022
Assets:		
Cash & equivalents	91,989	
Inventories	101,807	
Current assets	193,796	
Net property & equip.	120,399	
Total assets	2,752,719	
Liabilities:		
Current liabilities	962,509	
Long-term debt	204,408	
Stockholders' equity	1,489,059	
Net current assets	(768,713)	

EFFECTOR THERAPEUTICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Cost & expenses	17,391,000	16,440,000
Operating income	(17,391,000)	(14,429,000)
Interest expense	1,411,000	983,000
Other income (expense), net	(29,000)	11,478,000
Net before taxes	(18,378,000)	(3,846,000)
Net income	(18,378,000)	(3,846,000)
Balance for common	(18,378,000)	
Earnings common share		
Primary	\$(0.41)	\$(0.09)
Fully Diluted	\$(0.41)	\$(0.09)
Common Shares:		
Full Diluted	44,930,987	40,984,273
Year-end	61,465,616	41,152,790

ELECTRONIC SYSTEMS TECHNOLOGY, INC.

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	890,295	
Net Sales	890,295	889,035
Cost & expenses	932,732	913,877
Operating income	(42,437)	(24,842)
Interest income	9,183	1,085
Net before taxes	(33,254)	(23,757)
Net income	(33,254)	(23,757)

Earnings common share		
Primary	\$(0.01)	\$
Fully Diluted	\$(0.01)	\$
Common Shares:		
Full Diluted	4,946,502	4,946,502
Year-end	4,946,502	4,946,502

ELECTRONIC SYSTEMS TECHNOLOGY, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	1,233,016	
Net Sales	1,233,016	1,376,195
Cost & expenses	1,326,334	1,329,040
Operating income	(93,318)	47,155
Interest income	17,559	2,459
Net before taxes	(75,759)	49,614
Net income	(75,759)	49,614
Earnings common share		
Primary	\$(0.02)	\$0.01
Fully Diluted	\$(0.02)	\$0.01
Common Shares:		
Full Diluted	4,946,502	4,946,502
Year-end	4,946,502	4,946,502

ENCISION INC.

New Auditor On Oct. 17, 2023, Co. announced the resignation of Gries & Associates, LLC as its independent registered public accounting firm. On Oct. 18, 2023, Co. engaged GreenGrowth CPAs Inc. as its new independent registered public accounting firm.

ENDRA LIFE SCIENCES INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	9,062,955	9,844,178
Operating income	(9,062,955)	(9,844,178)
Other income (expense), net	462,241	(45,318)
Net before taxes	(8,600,714)	(9,889,496)
Income contin. oper.	(8,600,714)	(9,889,496)
Net income	(8,600,714)	(9,889,496)
Balance for common	(8,600,714)	(9,889,496)
Earnings common share		
Primary	\$(1.53)	\$(3.60)
Fully Diluted	\$(1.53)	\$(3.60)
Common Shares:		
Full Diluted	5,630,888	2,800,811
Year-end	8,411,777	3,158,723

ENVIROTECH VEHICLES INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	2,656,079	1,595,810
Net Sales	2,656,079	1,595,810
Cost & expenses	6,215,454	5,708,149
Operating income	(3,559,375)	(4,112,339)
Other income (expense), net	(8,664)	(8,861)
Net before taxes	(3,521,937)	(4,113,444)
Net income	(3,521,937)	(4,113,444)
Earnings common share		
Primary	\$(0.23)	\$(0.27)
Fully Diluted	\$(0.23)	\$(0.27)
Common Shares:		
Full Diluted	15,021,088	14,961,938
Year-end	15,021,088	15,000,673

ENVIROTECH VEHICLES INC

Official Changes On Apr. 17, 2023, Co.'s Board of Directors appointed Mr. Douglas M. Campoli as Co.'s Chief Financial Officer.

EOM PHARMACEUTICAL HOLDINGS INC**Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2022	2021	2020
Salaries and Benefits	504,220	449,567	...
Research & development	1,225,592	1,301,437	...
Marketing and Advertising	53,312	554,025	...
General & administrative	1,102,185	308,434	535,767
Total operating expenses	2,885,309	2,613,463	535,767
Loss from			

operations	(2,885,309)	(2,613,463)	
Interest income	
Interest expense	
(net)	...	65,707	...
Interest income (expense), net (Not Revenues)	(45,595)
Change in Fair value of Derivative Liability	254,000
Other Income	30,000
Income (losses) before provision for income taxes	(535,360)
Total other income (expense)	238,405	(65,707)	407
Net income (loss)	(2,646,904)	(2,679,170)	(535,360)
Weighted average shares outstanding - basic	113,270,751	45,431,844	4,195,213
Weighted average shares outstanding - diluted	113,270,751	45,431,844	4,195,213
Year end shares outstanding	113,270,751	113,270,751	4,195,213
Net earnings (loss) per share - basic	\$(0.02)	\$(0.06)	\$(0.13)
Net earnings (loss) per share - diluted	\$(0.02)	\$(0.06)	\$(0.13)

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2022	2021	
Cash	613,244	1,486,566	
Prepaid expenses	155,559	179,730	
Total current assets	768,803	1,666,296	
Total assets	768,803	1,666,296	
Research and development services	526,706	195,456	
General and administrative services	192,281	78,977	
Marketing and consulting	73,559	178,029	
Accrued interest	27,691	12,884	
Accounts payable and other accrued liabilities	820,237	465,346	
Convertible Note, Net of Debt Premium - Related Party	2,847,230	...	
Total current liabilities	3,667,467	465,346	
Convertible Note, Net of Debt Discount - Related Party	...	1,372,466	
Mandatory Convertible Notes, Net of Debt Discount	619,937	...	
Derivative Liability	670,000	...	
Total Long Term Liabilities	1,289,937	1,372,466	
Total liabilities	4,957,404	1,837,812	
Common stock	11,327	11,327	
Additional paid in capital	5,048,970	3,949,319	
Retained earnings (accumulated deficit)	(9,248,898)	(4,132,162)	
Total shareholders' equity (deficit)	(4,188,601)	(171,516)	

Recent Dividends:

- 1. EOM Pharmaceutical Holdings Inc preferred.**
No dividends paid.
- 2. EOM Pharmaceutical Holdings Inc common.**
No dividends paid.

Annual Dividends:

- 1. EOM Pharmaceutical Holdings Inc preferred.**
No dividends paid.
- 2. EOM Pharmaceutical Holdings Inc common.**
No dividends paid.

ESCALON MEDICAL CORP**Annual Report**

Consolidated Income Statement, Years Ended Jun. 30 (\$):			
	2023	2022	2021
Product revenue	11,555,907	9,980,343	9,547,606

Licenses & service plans	624,314
Service plans	...	722,727	924,011
Revenues, net	12,180,221	10,703,070	10,471,617
Cost of goods sold	6,698,858	6,096,169	6,044,399
Marketing, general & administrative	4,184,051	4,085,982	3,570,433
Research & development	818,769	990,982	890,482
Total costs & expenses	11,701,678	11,173,133	10,505,314
Income (loss) from operations	478,543	(470,063)	(33,697)
Other income	...	506,305	2,530
Interest income	128	245	985
Interest expense	21,845	18,406	21,841
Total other income (expenses), net	(21,717)	488,144	(18,326)
Net income (loss) from continuing operations	456,826
Deferred state income taxes (benefit)	64,399
Change in valuation allowance	(95,065)
Income Taxes - Foreign - Deferred	30,666
Net income	456,826
Distribution for Preferred Shares	183,695
Net income (loss)	456,826	18,081	(52,023)
Preferred stock dividends	51,600
Undeclared dividends on preferred stocks	...	51,600	51,422
Net income (loss) applicable to common shareholders	221,531	(33,519)	(103,445)
Weighted average shares outstanding - basic	7,415,329	7,415,329	7,415,329
Weighted average shares outstanding - diluted	13,564,202	13,220,202	7,415,329
Year end shares outstanding	7,415,329	7,415,329	7,415,329
Net income (loss) per share - basic	\$0.03	\$0.00	\$(0.01)
Net income (loss) per share - diluted	\$0.03	\$0.00	\$(0.01)
Number of full time employees	38
Total number of employees	...	41	41
Number of common stockholders	1,267	1,267	1,267

¹ As of September 27, 2022; ² As of September 24, 2021

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2023	2022	
Cash & cash equivalents	889,674	593,869	
Restricted cash	256,293	256,165	
Accounts receivable, gross	1,807,599	1,778,099	
Allowance for doubtful accounts	153,878	236,349	
Accounts receivable, net	1,653,721	1,541,750	
Raw materials	882,093	1,010,471	
Work in process	85,575	138,182	
Finished goods	880,717	805,698	
Total inventories	...	1,954,351	
Allowance for obsolete inventory	260,396	350,396	
Inventory, net	1,587,989	1,603,955	
Other current assets	249,790	190,043	
Total current assets	4,637,467	4,185,782	
Equipment	777,785	771,097	
Furniture & fixtures	128,499	128,499	
Leasehold improvements	39,048	39,048	
Property & equipment, gross	945,332	938,644	

Less accumulated depreciation & amortization	885,984	
Less accumulated depreciation	...	911,268	...	
Property & equipment, net	...	34,064	52,660	
Right-of-use assets	...	503,647	788,257	
Licenses, net	...	69,986	82,750	
Other long term assets	...	62,787	62,788	
Total assets	5,307,951	5,172,237	...	
Line of credit	201,575	
Current portion of long-term debt	...	3,105	...	
Current portion of note payable	...	37,087	3,401	
Current portion of economic injury disaster (EIDL) loan	3,105	
Accounts payable	1,205,510	1,012,451	...	
Accrued compensation	...	445,651	...	
Customer deposits	...	212,555	...	
Warranty reserve	...	32,078	...	
Tax payable	...	100,380	...	
Other accruals	651,978	111,332	...	
Related party accrued interest	112,389	112,389	...	
Current portion of operating lease liabilities	329,638	304,737	...	
Deferred revenue	426,227	332,383	...	
Other short term liabilities	...	129,961	...	
Liabilities of discontinued operations	87,125	
Total current liabilities	2,853,059	3,001,998	...	
Note payable, net of current portion	159,511	3,888	...	
Operating lease liabilities, net of current portion	214,103	538,794	...	
Economic Injury Disaster loan	...	149,540	...	
EIDL loan	146,435	
Total long-term liabilities	520,049	692,222	...	
Total liabilities	3,373,108	3,694,220	...	
Series A convertible preferred stock	645,000	645,000	...	
Common stock	7,415	7,415	...	
Additional paid-in capital	69,702,043	69,702,043	...	
Retained earnings (accumulated deficit)	(68,419,615)	(68,876,441)	...	
Total shareholders' equity	1,934,843	1,478,017	...	
Total Equity	1,934,843	

Recent Dividends:

- 1. Escalon Medical Corp series A preferred.**
No dividends paid.
 - 2. Escalon Medical Corp common.**
No dividends paid.
- Annual Dividends:**
- 1. Escalon Medical Corp series A preferred.**
No dividends paid.
 - 2. Escalon Medical Corp common.**
No dividends paid.

ESCALON MEDICAL CORP Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2023 10-K Report: "Opinion on the Financial Statements We have audited the accompanying balance sheet of Escalon Medical Corp. (the "Company") and Subsidiaries as of June 30, 2023, the related consolidated statements of operations, stockholders' equity and cash flows for the year ended June 30, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2023, and the results of its operations and its cash flows for the year ended June 30, 2023, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph -

Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company's historical recurring losses from operations and negative cash flows from operating activities raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

EXELA TECHNOLOGIES INC

New Auditor On Oct. 24, 2023, Co. engaged EisnerAmper LLP as its new independent registered public accounting firm.

FG FINANCIAL GROUP, INC (NEW)

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2023	2022
Total revenues	8,713	(583)
Cost & expenses	8,757	7,400
Operating income		(9,301)
Net before taxes		(9,301)
Income contin. oper.		(9,301)
Net income	(1,573)	(9,301)
Balance for common	(2,464)	(10,195)
Earnings common share		
Primary	\$(0.26)	\$(1.55)
Fully Diluted	\$(0.26)	\$(1.55)
Common Shares:		
Full Diluted	9,564	6,589
Year-end	10,304	9,278

FRANKLIN WIRELESS CORP

New Auditor On Oct. 20, 2023, Co. dismissed Kreit & Chiu CPA LLP as its independent registered public accounting firm and engaged Simon & Edward, LLC as its new independent registered public accounting firm.

FREEDOM HOLDING CORP (NV)

Annual Report

Consolidated Income Statement, Years Ended Mar. 31 (\$):

	2023	2022	2021
		(revised)	(revised)
Fee & commission income	327,215,000	335,211,000	216,008,000
Net gain on trading securities	71,084,000	155,252,000	28,807,000
Interest income on trading securities	178,288,000	78,327,000	21,913,000
Interest income on margin lending	34,558,000	14,164,000	3,163,000
Interest income on loans issued	43,486,000	4,617,000	384,000
Interest income on available-for-sale securities	27,003,000	22,437,000	11,238,000
Interest income on cash and cash equivalents and restricted cash	9,836,000	1,658,000	1,630,000
Interest income from dividends	1,524,000	406,000	146,000
Interest income	294,695,000	121,609,000	38,474,000
Insurance underwriting income	115,371,000	72,981,000	62,951,000
Net gain (loss) on foreign exchange operations	52,154,000	3,791,000	557,000
Net gain (loss) on derivatives	(64,826,000)	946,000	86,000
Total revenue, net	795,693,000	689,790,000	346,883,000
Fee & commission expense	65,660,000	85,909,000	70,537,000
Interest expense on securities repurchase agreement obligations	158,595,000	58,229,000	10,915,000
Interest expense on customer liabilities	40,335,000	16,336,000	7,335,000
Interest expense on margin lending payable	6,635,000		
Interest expense on debt securities issued	3,085,000	1,822,000	4,034,000

Interest expense on loans received	290,000	539,000	151,000
Other interest expense	7,000	21,000	9,000
Interest expense	208,947,000	76,947,000	22,444,000
Insurance claims incurred, net of reinsurance	77,329,000	54,447,000	52,405,000
Payroll & bonuses	81,819,000	46,288,000	23,435,000
Professional services	17,006,000	12,682,000	4,430,000
Stock compensation expense	9,293,000	7,859,000	114,000
Advertising expense	14,059,000	11,916,000	6,971,000
General & administrative expense	59,971,000	23,533,000	11,118,000
Provision for impairment losses (recoveries)	29,119,000	2,502,000	1,590,000
Other expense (income), net	(3,448,000)	4,014,000	2,034,000
Total expense	559,755,000	326,097,000	195,078,000
Income (loss) before income taxes - United States	(26,383,000)	(8,012,000)	1,076,000
Income (loss) before income taxes - Foreign	262,321,000	371,705,000	150,729,000
Net income (loss) before income tax	235,938,000	363,693,000	151,805,000
Current federal income tax expense (benefit)	22,387,000	15,184,000	7,771,000
Current foreign income taxes	21,406,000	27,381,000	14,040,000
Current income tax expense (benefit)	43,793,000	42,565,000	21,811,000
Deferred federal income tax expense (benefit)	(2,606,000)	(2,191,000)	1,752,000
Deferred state income tax expense (benefit)	1,589,000	(1,804,000)	(256,000)
Deferred income tax expense (benefit)	(1,017,000)	(3,995,000)	1,496,000
Income tax expense (benefit)	42,776,000	38,570,000	23,307,000
Income (loss) from continuing operations	193,162,000	325,123,000	128,498,000
Income (loss) before income tax expense (benefit) of discontinued operations	68,160,000	(117,199,000)	28,518,000
Reclassification of loss from cumulative translation adjustment of discontinued operations	(25,415,000)		
Loss from divestiture of discontinued operations	(26,118,000)		
Income tax expense (benefit) of discontinued operations	(4,203,000)	13,004,000	(6,735,000)
Income (loss) from discontinued operations, net	12,424,000	(104,195,000)	21,783,000
Net income (loss)	205,586,000	220,928,000	150,281,000
Less: net income (loss) attributable to noncontrolling interest in subsidiary	(446,000)	6,566,000	(631,000)
Net income (loss) attributable to controlling interest	205,140,000	227,494,000	149,650,000

Weighted average shares outstanding - basic	58,629,580	59,378,207	583,884,450
Weighted average shares outstanding - diluted	59,504,811	59,378,207	58,442,921
Year end shares outstanding	59,659,191	59,542,212	58,443,212
Earnings (loss) from continuing operations per common share - basic	\$3.29	\$5.59	\$2.19
Earnings (loss) from discontinued operations per common share - basic	\$0.21	\$(1.75)	\$0.37
Earnings per common share - basic	\$3.50	\$3.84	\$2.56
Earnings (loss) from continuing operations per common share - diluted	\$3.24	\$5.59	\$2.19
Earnings (loss) from discontinued operations per common share - diluted	\$0.21	\$(1.75)	\$0.37
Earnings per common share - diluted	\$3.45	\$3.84	\$2.56
Number of full time employees	3,247		
Number of part time employees	442		
Total number of employees	3,689		
Number of common stockholders	429		
Foreign currency translation adjustments	5,195,000	(20,622,000)	2,787,000

□ Restated to reflect the discontinued operations; □ Including from related parties - Fee and commission income: \$199,235,000; □ Including from related parties - Fee and commission income: \$291,163,000; □ Including from related parties - Fee and commission income: \$184,725,000; □ Including from related parties - Interest income: \$23,191,000; □ Including from related parties - Interest income: \$10,191,000; □ Including from related parties - Interest income: \$2,250,000; □ Including from related parties - Fee and commission expense: \$2,988,000; □ Including from related parties - Fee and commission expense: \$16,307,000; □ Including from related parties - Interest income: \$20,291,000

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2023	2022
		(revised)
Cash & cash equivalents	581,417,000	225,464,000
Restricted cash	445,528,000	547,950,000
Trading securities	2,412,556,000	1,158,377,000
Available-for-sale securities, at fair value	239,053,000	161,364,000
Margin lending, brokerage & other receivables, net	376,329,000	147,659,000
Loans issued	826,258,000	92,446,000
Buildings, gross	19,569,000	7,770,000
Office equipment, gross	11,004,000	4,633,000
Processing & storage data centers, gross	10,793,000	3,729,000
Land, gross	9,106,000	1,564,000
Furniture, gross	6,633,000	2,759,000
Capital expenditures on lease improvement, gross	3,288,000	1,239,000
Vehicles, gross	1,516,000	643,000
Other fixed assets, gross	1,428,000	722,000
Less: total accumulated depreciation	9,320,000	5,236,000
Fixed assets, net	54,017,000	17,823,000
Intangible assets, net	17,615,000	5,163,000
Goodwill	14,192,000	5,898,000

Right-of-use assets	30,345,000	7,431,000
Insurance contract assets	13,785,000	5,712,000
Other assets, net	73,463,000	29,641,000
Assets held for sale	825,419,000	
Total assets	5,084,558,000	3,230,347,000
Securities repurchase agreement obligation	1,517,416,000	840,224,000
Customer liabilities	1,925,247,000	765,628,000
Margin lending & trade payables	122,900,000	45,083,000
Liabilities from insurance activity	182,502,000	122,087,000
Current income tax liability	4,547,000	14,556,000
Securities sold, not yet purchased - at fair value		13,865,000
Debt securities issued	60,025,000	34,390,000
Lease liability	30,320,000	7,504,000
Payable for acquisition	7,188,000	
Liability arising from continuing involvement	440,805,000	6,447,000
Other liabilities	22,872,000	21,477,000
Liabilities held for sale		812,478,000
Total liabilities	4,313,822,000	2,683,739,000
Common stock	59,000	59,000
Additional paid in capital	164,162,000	174,745,000
Retained earnings (accumulated deficit)	647,064,000	441,924,000
Accumulated other comprehensive income (loss)	(34,000,000)	(63,125,000)
Total shareholder's equity	777,285,000	553,603,000
Non-controlling interest	(6,549,000)	(6,995,000)
Total FRHC shareholders' equity	770,736,000	546,608,000

¹ Restated to reflect the discontinued operations; ² Including from related parties - Cash and cash equivalents: \$35,549,000; ³ Including from related parties - Cash and cash equivalents: \$22,787,000; ⁴ Including from related parties - Restricted cash: \$114,885,000; ⁵ Including from related parties - Restricted cash: \$222,651,000; ⁶ Including from related parties - Margin lending, brokerage and other receivables, net: \$294,985,000; ⁷ Including from related parties - Margin lending, brokerage and other receivables, net: \$107,649,000; ⁸ Including from related parties - Loans issued: \$121,177,000; ⁹ Including from related parties - Loans issued: \$35,293,000; ¹⁰ Including from related party - Other assets, net: \$16,089,000; ¹¹ Including from related parties - Customer liabilities: \$130,210,000; ¹² Including from related parties - Customer liabilities: \$325,904,000; ¹³ Including from related parties - Margin lending and trade payables: \$3,239,000; ¹⁴ Including from related parties - Margin lending and trade payables: \$38,889,000

Recent Dividends:**1. Freedom Holding Corp (NV) common.**

No dividends paid.

Annual Dividends:**1. Freedom Holding Corp (NV) common.**

No dividends paid.

FREEDOM HOLDING CORP (NV)**Earnings, 6 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	751,791,000	
Cost & expenses	532,527,000	
Operating income	219,264,000	
Net before taxes	219,264,000	
Income taxes	35,864,000	
Income contin. oper.	183,400,000	
Net income	183,400,000	
Balance for common	183,949,000	
Earnings common share		
Primary	\$3.13	\$
Fully Diluted	\$3.09	\$
Common Shares:		
Full Diluted	59,292,757	
Year-end	59,659,191	59,542,212

GE HEALTHCARE TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2023	2022
Total revenues	14,346,000	13,403,000
Cost & expenses	12,600,000	11,658,000
Operating income	1,746,000	1,745,000
Other income (expense), net	417,000	75,000
Net before taxes	1,752,000	1,794,000
Income taxes	550,000	412,000
Income contin. oper.	1,202,000	1,382,000
Net income	1,198,000	1,394,000
Balance for common	982,000	
Earnings common share		
Primary	\$2.16	\$
Fully Diluted	\$2.15	\$
Common Shares:		
Full Diluted	458,000	
Year-end	455,224	

GEN DIGITAL INC**Earnings, 6 mos. to (Consol. - \$000):**

	09/29/23	09/30/22
Total revenues	1,894,000	1,455,000
Cost & expenses	1,385,000	903,000
Operating income	387,000	502,000
Interest expense	343,000	79,000
Other income (expense), net	1,000	(5,000)
Gains or losses	4,000	
Foreign currency	2,000	1,000
Net before taxes	63,000	424,000
Income taxes	(275,000)	155,000
Net income	338,000	269,000
Earnings common share		
Primary	\$0.53	\$0.46
Fully Diluted	\$0.52	\$0.45
Common Shares:		
Full Diluted	644,000	599,000
Year-end	641,000	661,000

GEOVAX LABS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Cost & expenses	19,049,189	8,722,589
Operating income	(19,049,189)	(8,641,063)
Interest income	674,835	3,747
Net before taxes	(18,374,354)	
Net income	(18,374,354)	(8,637,316)
Balance for common	(18,374,354)	
Earnings common share		
Primary	\$(0.69)	\$(0.63)
Fully Diluted	\$(0.69)	\$(0.63)
Common Shares:		
Full Diluted	26,442,847	13,818,315
Year-end	26,695,287	26,334,953

GHST WORLD INC

New Accountant On Oct. 25, 2023, Co. approved the dismissal of Co.'s independent registered public accounting firm, Salberg & Company, P.A. On Oct. 26, 2023, Co. appointed Fruci & Associates II, PLLC as the new independent registered public accounting firm of Co.

GOLDEN MATRIX GROUP INC**Earnings, 6 mos. to Apr 30(Consol. - \$):**

	2023	2022
Total revenues	21,086,038	17,359,848
Cost & expenses	21,905,726	16,197,356
Operating income	(819,688)	1,162,492
Interest income	28,825	983
Interest expense	1,738	
Foreign currency	33,314	198,829
Net before taxes	(759,287)	1,362,304
Income taxes	217,987	247,184
Net income	(977,274)	1,115,120
Balance for common	(977,274)	
Earnings common share		
Primary	\$(0.03)	\$0.03
Fully Diluted	\$(0.03)	\$0.03
Common Shares:		
Full Diluted	34,689,260	35,735,450
Year-end	36,124,526	28,115,909

GOLDEN MATRIX GROUP INC**Earnings, 9 mos. to Jul 31(Consol. - \$):**

	2023	2022
Total revenues	32,393,064	26,461,389
Cost & expenses	34,104,851	24,569,585

Operating income	(1,711,787)	1,891,804
Interest income	43,957	1,776
Interest expense	9,362	
Foreign currency	33,361	227,324
Net before taxes	(1,643,831)	2,120,904
Income taxes	299,071	326,135
Net income	(1,942,902)	1,794,769
Balance for common	(1,942,902)	1,564,695
Earnings common share		
Primary	\$(0.06)	\$0.06
Fully Diluted	\$(0.06)	\$0.04
Common Shares:		
Full Diluted	35,174,601	35,876,734
Year-end	36,134,932	28,182,575

GULFPORT ENERGY CORP.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	1,302,594,000	348,620,000
Cost & expenses	371,493,000	380,888,000
Deprec., depl. & amort.	238,747,000	189,305,000
Operating income	692,354,000	221,573,000
Other income (expense), net	20,492,000	11,385,000
Net before taxes	670,444,000	253,867,000
Income taxes	(554,741,000)	
Net income	1,225,185,000	253,867,000
Balance for common	1,041,073,000	258,003,000
Earnings common share		
Primary	\$55.72	\$(12.58)
Fully Diluted	\$55.08	\$(12.58)
Common Shares:		
Full Diluted	18,937,000	20,514,000
Year-end	18,634,300	19,400,000

GUSHEN INC**Annual Report****Consolidated Income Statement, Years Ended (\$):**

	09/30/22	09/30/21	04/30/21
Training revenue	1,124,655		
Charge for use of brand	961,005		
Other revenue	6,054		
Online sales	315,688		
Revenue	2,407,402	1,928,456	
COST OF REVENUE	1,458,804		
Cost of revenue	1,458,804	1,203,532	
Gross profit	948,598	724,924	
Salary & welfare - selling expenses		1,333,847	
Advertising fees		224,116	
Conference fees		129,542	
Marketing fee		4,358,393	
Rent - selling expenses		1,076	
Other - selling expenses		2,985,959	
Selling expenses		9,032,933	
Selling expenses	3,365,426		
Salary & welfare - general & administrative expenses		904,625	
Depreciation & amortization		105,598	
Rent - general & administrative expenses		142,295	
Profession fee		443,076	
Other - general & administrative expenses		367,780	
General & administrative expenses	1,443,045	1,963,374	
Administrative expenses			28,705
Total operating expenses, net	4,808,471	10,996,307	28,705
Income (loss) from operations	(3,859,873)	(10,271,383)	(28,705)
Interest income	4,222	20,950	
Other income	9,160	18,083	
Other expenses	3,730,716	442,701	

Total other income (expense), net	(3,717,334)	(403,668)	...
Income (loss) before provision for income taxes	(7,577,207)	(10,675,051)	(28,705)
Income taxes	1,895,387	(760,013)	...
Net income (loss)	(9,472,594)	(9,915,038)	(28,705)
Less: Net loss attributable to non-controlling interests	41	884	...
Net income (loss) attributable to non-controlling interests	(9,472,553)	(9,914,154)	...
Weighted average shares outstanding - basic	410,618,750	410,618,750	29,018,750
Weighted average shares outstanding - diluted	410,618,750	410,618,750	29,018,750
Year end shares outstanding	410,618,750	410,618,750	29,018,750
Earnings (loss) per share - basic	\$(0.02)	\$(0.02)	\$0.00
Earnings (loss) per share - diluted	\$(0.02)	\$(0.02)	\$0.00
Number of beneficiary stockholders	60	60	...
Foreign currency translation adjustment	965,977
Employees - Full-Time/Full-Time Equivalents - Period End	59

Consolidated Balance Sheet, Years Ended Sept. 30 (\$):
2022 2021

Cash & cash equivalents	841,686	2,659,116
Other monetary funds	25,933	506
Prepaid marketing fee	...	193,443
Prepaid service fee	...	388,125
Prepaid rent	...	36,757
Prepayment	452,425	618,325
Amount due from third parties	...	140,996
Amount due from employees	...	38,107
Deposit & guarantee	...	30,388
Others - other receivables	...	19,961
Total other receivables	...	229,452
Less: Allowance for doubtful accounts	33,175	30,796
Other receivables	140,738	198,656
Due from related parties	23,297	51,276
Cell phone	...	414,561
Less: provision for inventory	...	3,315
Inventory	91	414,063
Receivables - Other - Gross	173,912	...
Other receivables - Balancing value	1	...
Total current assets	1,484,170	3,941,942
Prepaid marketing fee	...	733,665
Prepaid service fee	...	64,853
Other long-term assets	80,593	798,518
Office & computer equipment	280,163	511,239
Less: accumulated depreciation	329,196	293,874
Transportation equipment	74,544	...
Leasehold improvement	120,255	...
Property, plant & equipment, net	145,766	217,365
Intangible assets	56,793	73,183
Deferred tax asset	...	1,922,113
Right of use assets	285,311	...
Total non-current assets	568,463	3,011,179
Total assets	2,052,633	6,953,121
Amount due to agents	...	1,350,292

Amount due to other service providers	...	1,018,608
Accounts payable	2,258,779	2,368,900
Contract liability	...	170,430
Amount due to related parties	340,343	543
Payroll payable	766,978	843,237
Tax payable	5,502,085	5,918,303
Other payable	332,781	13,892
Amount due to related parties	506	...
Lease Liability - current	130,598	...
Estimated Liabilities	3,434,651	...
Total current liabilities	12,766,721	9,315,305
Lease Liability - non-current	154,713	...
Total liabilities	12,921,434	9,315,305
Preferred stock, par value \$ 0.000 ,000,000 shares authorized, 0,000,000 shares issued and outstanding as of 0, 2022 and 0,000,000 shares authorized	100	...
Preferred stock	...	100
Common stock	41,062	41,062
Additional paid in capital	40,498	40,498
Statutory reserve	1,545	1,545
Retained earnings (accumulated deficit)	(12,080,418)	(2,607,865)
Accumulated other comprehensive gain (loss)	1,129,337	163,360
Non-controlling interest	(925)	(884)
Total stockholders' equity (deficit)	(10,868,801)	(2,362,184)

As reported by the Company

Dividends:

No dividends paid.

GUSHEN INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, WWC, P.C., as it appeared in Co.'s 2022 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheets of Gushen, Inc (the Company) as of September 30, 2022 and 2021, and the related statements of income, comprehensive income, stockholders' equity, and cash flows for each of the years in the two-year period ended September, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two-year period ended September 30, 2022, in conformity with accounting principles generally accepted in the United States of America. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of September 30, 2022, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated October 4, 2023, expressed an adverse opinion. Substantial Doubt About the Company's Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 2 to the consolidated financial statements, the Company has working capital deficit and stockholders' deficit that raise doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter."

ICC HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	40,271,117	30,805,437
Cost & expenses	37,544,069	36,256,184
Operating income	2,727,048	(5,450,747)
Net before taxes	2,727,048	(5,450,747)
Income taxes	562,014	(1,161,840)
Net income	2,165,034	(4,288,907)

Earnings common share

Primary	\$0.74	\$(1.40)
Fully Diluted	\$0.73	\$(1.40)
Common Shares:		
Full Diluted	2,969,975	3,073,689
Year-end	3,137,228	3,289,558

IDEANOMICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	13,837,000	11,615,000
Cost & expenses	112,424,000	79,750,000
Operating income	(108,476,000)	(70,683,000)
Interest expense	2,265,000	1,067,000
Other income (expense), net	2,067,000	585,000
Gains or losses	10,777,000	...
Equity earnings	1,928,000	...
Net before taxes	(108,195,000)	(58,805,000)
Income taxes	(3,382,000)	(339,000)
Income discont. oper.	(18,168,000)	(7,970,000)
Net income	(122,981,000)	(68,364,000)
Balance for common	(119,814,000)	...
Earnings common share		
Primary	\$(14.84)	\$(16.65)
Fully Diluted	\$(14.84)	\$(16.65)
Common Shares:		
Full Diluted	8,071,870	3,980,619
Year-end	10,976,787	...

INNOVATION PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Jun. 30 (\$):

	2023	2022	2021
			(revised)
Revenues	...	18,000	...
Research & development - gross	46,000
Research & development expenses	1,462,000	4,814,000	7,016,000
General & administrative expenses	750,000	1,223,000	963,000
Officers' payroll & payroll tax expenses	459,000	428,000	499,000
Professional fees	245,000	452,000	537,000
Stock compensation expense	161,000
Officer's compensation expenses	482,000
Rent and utility expense	41,000
Depreciation and amortization expenses	373,000
Directors fees	150,000
Insurance expenses	287,000
Other General and administrative expenses	111,000
Total operating expenses	...	6,917,000	9,015,000
Equity in income (loss) from equity investment	(172,000)	(22,000)	...
Total other operating income & (loss)	(172,000)	22,000	...
Income (loss) from operations	(3,111,000)	(6,921,000)	(9,015,000)
Other income	...	172,000	...
Change in fair value of preferred stock	...	(177,000)	...
Interest expense - debt	28,000	68,000	155,000
Interest expense - preferred stock	29,000	47,000	4,702,000
Total other income (expenses)	...	(120,000)	(4,857,000)
Income (loss) before provision

for income taxes	(3,168,000)	(7,041,000)	(13,872,000)
Net income (loss)	(3,168,000)	(7,041,000)	(13,872,000)
Weighted average class A shares outstanding - basic	495,764,410
Weighted average class B shares outstanding - basic	10,003,189
Weighted average shares outstanding - basic	505,767,599	503,867,136	386,163,208
Weighted average class A shares outstanding - diluted	495,764,410
Weighted average class B shares outstanding - diluted	10,003,189
Weighted average shares outstanding - diluted	505,767,599	503,867,136	386,163,208
Year end shares outstanding	518,347,691	503,867,136	433,798,605
Net income (loss) per share - basic	\$(0.01)	\$(0.01)	\$(0.04)
Net income (loss) per share - diluted	\$(0.01)	\$(0.01)	\$(0.04)
Full Time Employees	4
Total number of employees	...	4	4
Number of common stockholders	66	...	68
Number of class A common stockholders	...	66	...
Number of class B common stockholders	...	1	...
Clinical studies and development research	584,000

□ Approximately; □ As of September 22, 2022

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2023	2022
Cash	1,518,000	3,807,000
Prepaid expenses & other current assets	116,000	145,000
Total current assets	1,634,000	3,952,000
Equity investment	3,806,000	3,978,000
Patent costs - net	1,999,000	2,312,000
Deferred offering costs	...	59,000
Security deposit	78,000	78,000
Total assets	7,517,000	10,379,000
Accounts payable	2,985,000	2,567,000
Accrued research & development consulting fees	49,000	80,000
Accrued rent - related parties	8,000	8,000
Accrued interest - related parties	16,000	4,000
Accrued salaries - related parties	1,543,000	1,492,000
Accrued payroll taxes - related parties	...	71,000
Accrued employee bonuses	71,000	...
Withholding tax - payroll	...	77,000
Operating lease - current liability	55,000	197,000
Accrued salaries & payroll taxes	76,000	...
Convertible note payable - related party	...	250,000
Accrued dividend - series B 5% convertible preferred stock	5,000	62,000
Loan payable	213,000	...
Total current liabilities	5,021,000	4,808,000
Series B 5% convertible preferred stock liability	457,000	786,000
Operating lease - long term liability	...	55,000

Total liabilities	5,478,000	5,649,000
Common stock - class A	51,000	49,000
Common stock - class B	1,000	2,000
Additional paid-in capital	129,566,000	129,090,000
Retained earnings (accumulated deficit)	(125,325,000)	(122,157,000)
Treasury stock	2,254,000	2,254,000
Total stockholders' equity (deficit)	2,039,000	4,730,000

□ Including related party payables of approximately - Accounts payable: \$1,511,000

Recent Dividends:

1. Innovation Pharmaceuticals Inc series B 5% convertible preferred.

No dividends paid.

2. Innovation Pharmaceuticals Inc class A common.

No dividends paid.

3. Innovation Pharmaceuticals Inc series B 5% convertible preferred.

No dividends paid.

4. Innovation Pharmaceuticals Inc class B common.

No dividends paid.

Annual Dividends:

1. Innovation Pharmaceuticals Inc series B 5% convertible preferred.

No dividends paid.

2. Innovation Pharmaceuticals Inc class A common.

No dividends paid.

3. Innovation Pharmaceuticals Inc series B 5% convertible preferred.

No dividends paid.

4. Innovation Pharmaceuticals Inc class B common.

No dividends paid.

INNOVATION PHARMACEUTICALS INC Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Pinnacle Accountancy Group of Utah, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Innovation Pharmaceuticals, Inc. (the Company) as of June 30, 2023 and 2022, and the related consolidated statements of operations, changes in stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern Considerations The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has negative working capital, has suffered losses and negative cash flow from operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

INNOVATION PHARMACEUTICALS INC

New Accountant On Oct. 29, 2023, Co. dismissed Pinnacle Accountancy Group of Utah (a d/b/a of Heaton & Company, PLLC) as Co.'s independent public accounting firm. Also on Oct. 29, 2023, Co. engaged GreenGrowth CPAs as Co.'s new independent public accounting firm.

INSPIRE VETERINARY PARTNERS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2022	2021
Service revenue	7,032,800	1,813,621
Product revenue	2,801,978	735,513
Total revenue	9,834,778	2,549,134
Cost of service revenue	5,308,104	1,284,407
Cost of product revenue	1,981,046	435,437
General and administrative expenses	5,467,642	1,792,046
Depreciation and amortization	596,124	84,465
Total operating expenses	13,352,916	3,596,355
Loss from operations	(3,518,138)	(1,047,221)
Interest income	1,021	161

Interest expense	1,425,260	194,811
Other expenses	(357)	14,861
Total other expense	(1,423,882)	(209,511)
Loss before income taxes	(4,942,020)	(1,256,732)
Current income tax benefit (expense) - federal	...	33,982
Current income tax benefit (expense) - state	(30,094)	40,348
Provision (benefit) for income taxes	(30,094)	74,330
Net loss	(4,911,926)	(1,331,062)
Weighted average outstanding class A & B common shares - basic	5,160,182	5,001,699
Weighted average outstanding class A & B common shares - diluted	5,160,182	5,001,699
Year end shares outstanding	5,270,457	5,145,456
Net loss per class A and B common shares - basic	\$(0.95)	\$(0.27)
Net loss per class A and B common shares - diluted	\$(0.95)	\$(0.27)
Total number of employees	...	30

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2022	2021
Cash and cash equivalents	444,253	2,058,418
Due from former owners	269,883	35,985
Inventory	582,019	41,000
Refundable income tax	192,139	192,139
Prepaid expenses and other current assets	253,795	65,864
Total current assets	1,742,089	2,393,406
Land	1,839,596	863,973
Computers and equipment	1,321,708	173,498
Furniture and fixtures	143,874	9,710
Automobile	69,083	21,050
Leasehold improvements	95,991	15,027
Buildings	4,162,088	997,711
Property & equipment, subtotal	7,632,340	2,080,969
Less - accumulated depreciation	309,290	45,903
Property and equipment, net	7,323,050	2,035,066
Right-of-use assets	746,973	...
Other intangibles, net	2,729,574	239,195
Goodwill	7,614,553	1,610,843
Other assets	29,456	51,254
Total assets	20,185,695	6,329,764
Accounts payable	1,018,931	44,891
Accrued expenses	690,740	460,414
Operating lease liabilities	91,152	...
Bridge note, net of discount	3,899,156	1,031,917
Notes payable, net of discount	1,549,861	466,124
Total current liabilities	7,249,840	2,003,346
Operating lease liabilities, non-current	666,179	...
Convertible debentures	3,688,805	2,068,809
FNBD Notes Payable	8,863,423	1,004,759
FSNB Notes Payable	6,531,377	2,623,834
Car loan	6,653	13,309
Total notes payable	15,401,453	3,641,902
Unamortized debt issuance costs	(135,240)	(49,078)
Notes payable, net of issuance cost	15,266,213	3,592,824
Less current portion	1,549,861	466,124
Notes payable - noncurrent	13,716,352	3,126,700
Total liabilities	25,321,176	7,198,855
Common stock - Class A	98	85
Common stock - Class B	430	430
Additional paid in capital	1,107,439	461,916
Accumulated deficit	(6,243,448)	(1,331,522)
Total stockholder's deficit	(5,135,481)	(869,091)

Recent Dividends:

- Inspire Veterinary Partners Inc class A common.**
No dividends paid.
- Inspire Veterinary Partners Inc class B common.**
No dividends paid.

Annual Dividends:

- Inspire Veterinary Partners Inc class A common.**
No dividends paid.
- Inspire Veterinary Partners Inc class B common.**
No dividends paid.

INSPIRE VETERINARY PARTNERS INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Kreit & Chiu CPA LLP, as it appeared in Co.'s 2022 Prospectus: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Inspire Veterinary Partners, Inc. (the "Company") as of December 31, 2022 and 2021, and the related consolidated statements of operations, changes in stockholders' deficit, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of Inspire Veterinary Partners, Inc. as of December 31, 2022 and 2021, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph U Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2 to the financial statements, the Company has incurred recurring losses and at December 31, 2022, had an accumulated deficit of \$6,243,448. For the year ending December 31, 2022, the Company sustained a net loss of \$4,911,926. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might become necessary should the Company be unable to continue as a going concern."

INSPIRE VETERINARY PARTNERS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Total revenues	8,771,941	3,731,278
Cost & expenses	10,107,337	4,563,578
Deprec., depl. & amort.	602,508	162,355
Operating income	(1,937,904)	(994,655)
Interest income	6	38
Interest expense	830,811	601,335
Other income (expense), net	1,966	(4,596)
Net before taxes	(2,766,743)	(1,600,548)
Income taxes		(30,094)
Net income	(2,766,743)	(1,570,454)
Earnings common share		
Primary	\$(0.52)	\$(0.31)
Fully Diluted	\$(0.52)	\$(0.31)
Common Shares:		
Full Diluted	5,270,457	5,145,456
Year-end	5,270,457	5,145,456

INSPIRE VETERINARY PARTNERS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	12,891,589	6,655,357
Cost & expenses	16,745,070	8,495,640
Deprec., depl. & amort.	915,824	325,563
Operating income	(4,769,305)	(2,165,846)
Interest income	18	1,019
Interest expense	1,745,415	842,866
Other income (expense), net	(4,136,043)	(180)
Net before taxes	(10,650,745)	(3,007,873)
Income taxes		(30,094)
Net income	(10,650,745)	(2,977,779)
Balance for common	(10,784,573)	(2,977,779)
Earnings common share		
Primary	\$(1.90)	\$(0.58)
Fully Diluted	\$(1.90)	\$(0.58)
Common Shares:		
Full Diluted	5,662,712	5,145,456
Year-end	8,496,577	5,145,456

INTENSITY THERAPEUTICS INC**Annual Report****Income Statement, Years Ended Dec. 31 (\$):**

	2022	2021
Research & development costs	5,132,312	5,856,499
General & administrative costs	2,499,712	2,157,223
Total operating expenses	7,632,024	8,013,722
Income (loss) from operations	(7,632,024)	(8,013,722)
Interest income	2,481	2,609
Other income	47,646	115,513
Net income (loss)	(7,581,897)	(7,895,600)
Weighted average shares outstanding - basic	3,410,103	3,410,103
Weighted average shares outstanding - diluted	3,410,103	3,410,103
Year end shares outstanding	3,410,103	3,410,103
Earnings (loss) per share - basic	\$(2.22)	\$(2.32)
Earnings (loss) per share - diluted	\$(2.22)	\$(2.32)
Total number of employees	16	...
Number of common stockholders	78	...

¹ Adjusted for 1-for-2 stock split, April 27, 2023; ² As of June 29, 2023

Balance Sheet, Years Ended Dec. 31 (\$):

	2022	2021
Cash & cash equivalents	1,311,877	4,539,229
Prepaid insurance	29,359	70,444
Tax credit receivable	15,903	51,262
Receivable with related party	46,401	...
Other current assets	46,796	69,282
Other current assets	138,459	190,988
Total current assets	1,450,336	4,730,217
Right-of-use asset, net	139,089	318,126
Other assets	167,738	167,738
Total assets	1,757,163	5,216,081
Accounts payable	603,176	172,508
Accrued expenses	1,723,400	1,349,003
Current lease liability	143,221	182,338
Convertible note & accrued interest	4,348,548	2,016,767
Total current liabilities	6,818,345	3,720,616
Related party deposit	36,000	36,000
Long-term lease liability	...	143,569
Total long-term liabilities	36,000	179,569
Total liabilities	6,854,345	3,900,185
Series A redeemable convertible preferred stock	10,000,000	10,000,000
Series B convertible preferred stocks	145	145
Series C convertible preferred stocks	180	180
Common stock	341	341
Additional paid in capital	23,555,160	22,386,341
Retained earnings (accumulated deficit)	(38,653,008)	(31,071,111)
Total stockholders' equity (deficiency)	(15,097,182)	(8,684,104)

Recent Dividends:

- Intensity Therapeutics Inc common.**
No dividends paid.

Annual Dividends:

- Intensity Therapeutics Inc common.**
No dividends paid.

INTENSITY THERAPEUTICS INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, EisnerAmper LLP, as it appeared in Co.'s 2022 Prospectus: "Opinion on the Financial Statements We have audited the

accompanying balance sheets of Intensity Therapeutics, Inc. (the "Company") as of December 31, 2022 and 2021, and the related statements of operations, changes in redeemable convertible preferred stock and stockholders' deficiency, and cash flows for each of the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note B to the financial statements, the Company has incurred losses from operations and negative cash flows that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note B. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

INTENSITY THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Cost & expenses	2,475,832	4,308,319
Operating income	(2,475,832)	(4,308,319)
Interest income	487	856
Interest expense	305,161	29,754
Other income (expense), net	(2,256,507)	40,528
Net income	(5,037,013)	(4,296,689)
Earnings common share		
Primary	\$(1.45)	\$(1.26)
Fully Diluted	\$(1.45)	\$(1.26)
Common Shares:		
Full Diluted	3,463,635	3,410,103
Year-end	13,099,377	3,410,103

INTENSITY THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Cost & expenses	4,966,346	6,076,169
Operating income	(4,966,346)	(6,076,169)
Interest income	148,026	1,844
Interest expense	305,161	44,877
Other income (expense), net	(2,243,277)	47,646
Net income	(7,366,758)	(6,071,556)
Balance for common	(8,690,293)	(6,071,556)
Earnings common share		
Primary	\$(1.26)	\$(1.78)
Fully Diluted	\$(1.26)	\$(1.78)
Common Shares:		
Full Diluted	6,899,984	3,410,103
Year-end	13,709,377	...

ISPECIMEN INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Total revenues	4,575,339	4,857,348
Cost & expenses	10,679,584	9,800,743
Operating income	(6,104,245)	(4,943,395)
Interest income	225,144	26,535
Other income (expense), net	(29,255)	6,630
Net before taxes	(5,915,426)	...
Net income	(5,915,426)	(4,990,551)
Earnings common share		
Primary	\$(0.66)	\$(0.57)
Fully Diluted	\$(0.66)	\$(0.57)
Common Shares:		
Full Diluted	9,011,644	8,793,723
Year-end	9,063,274	8,873,711

ISPECIMEN INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	7,353,090	7,440,760
Cost & expenses	15,651,415	15,485,214
Operating income	(8,298,325)	(8,044,454)
Interest income	292,506	87,347
Other income (expense), net	(9,173)	9,778
Net before taxes	(8,026,527)	...
Net income	(8,026,527)	(8,086,241)
Earnings common share		
Primary	\$(0.89)	\$(0.92)
Fully Diluted	\$(0.89)	\$(0.92)
Common Shares:		
Full Diluted	9,029,732	8,822,423
Year-end	9,074,044	8,887,571

ISPIRE TECHNOLOGY INC**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$):**

	2023	2022	2021
Revenue	115,605,536	88,095,418	63,414,783
Cost of revenue	94,529,769	74,789,378	52,998,928
Gross profit	21,075,767	13,306,040	10,415,855
Sales & marketing expenses	4,714,923	5,503,630	3,561,731
General & administrative expenses	20,929,978	8,791,081	3,210,722
Total operating expenses	25,644,901	14,294,711	6,772,453
Income (loss) from operations	(4,569,134)	(988,671)	3,643,402
Interest income	195,209	5,078	882
Exchange gain (loss), net	(324,225)	58,143	(87,921)
Other income (expense), net	(155,150)	122,394	67,266
Total other income (expenses), net	(284,166)	185,615	(19,773)
Income (loss) before income taxes	7,444,203	6,679,431	5,463,770
Income (loss) before income taxes - Hong Kong			
Income (loss) before income taxes - United States	(12,297,503)	(7,482,487)	(1,840,141)
Income (loss) before income taxes	(4,853,300)	(803,056)	3,623,629
Income tax expense - current	1,245,303	1,071,097	685,823
Net income (loss)	(6,098,603)	(1,874,153)	2,937,806
Weighted average shares outstanding - basic	50,725,814	50,000,000	50,000,000
Weighted average shares outstanding - diluted	50,725,814	50,000,000	50,000,000
Year end shares outstanding	54,222,420	50,000,000	50,000,000
Net income (loss) per share - basic	\$(0.12)	\$(0.04)	\$0.06
Net income (loss) per share - diluted	\$(0.12)	\$(0.04)	\$0.06
Total number of employees	69	56	
Number of common stockholders	18	10	

[¶] As of January 27, 2023; [□] As of April 3, 2023

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2023	2022
Cash & cash equivalents	40,300,573	74,480,651
Accounts receivable - gross		8,260,574
Accounts receivable	24,526,262	8,260,574
Inventories, net	7,472,108	14,580,557
Deposit paid	14,635	14,616
Prepaid inventories	3,209,413	
Prepayment	26,974	50,460
Other receivable	127,595	127,423
Prepaid expenses & other current assets	3,378,617	192,499
Due from related parties		1,934,855
Held-to-maturity investment	9,133,707	
Total current assets	84,811,267	99,449,136
Leasehold improvement	518,854	433
Office & other equipment	339,155	146,798
Property, plant & equipment, gross		147,231
Furniture & fixture	309,990	
Less: accumulated depreciation	79,868	33,206
Property, plant & equipment, net	1,088,131	114,025
Rental deposit	732,334	876,100
Right-of-use assets - operating leases	4,061,617	295,804
Total other assets	5,882,082	1,285,929

Total assets	90,693,349	100,735,065
Accounts payable	1,274,391	290,541
Accounts payable - related party	51,698,588	41,982,373
Contract liabilities	988,556	1,672,051
Dividends payable		3,362,639
Accrued salaries & related benefits	97,314	43,487
Other payables	148,197	81,226
Accrued expenses	35,850	34,583
Accrued liabilities & other payables	281,361	159,296
Due to related parties	710,910	40,672,768
Income tax payable	63,853	481,113
Lease liabilities	944,525	347,541
Total current liabilities	55,962,184	88,968,322
Operating lease liabilities - net of current portion	3,356,232	
Total liabilities	59,318,416	88,968,322
Common stock	5,422	5,000
Accumulated other comprehensive income (loss)	(163,768)	(184,664)
Additional paid-in capital	25,685,475	
Retained earnings (accumulated deficit)	5,847,804	11,946,407
Total stockholders' equity (deficit)	31,374,933	11,766,743

Recent Dividends:**1. Ispire Technology Inc common.**

No dividends paid.

Annual Dividends:**1. Ispire Technology Inc common.**

No dividends paid.

ISPIRE TECHNOLOGY INC**Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2023	2022
Total revenues	82,976,746	66,247,507
Cost & expenses	88,116,463	65,359,402
Operating income	(5,139,717)	888,105
Interest income	77,202	2,083
Other income (expense), net	(108,440)	49,382
Foreign currency	183,178	136,902
Net before taxes	(4,987,777)	1,076,472
Net income	(6,057,776)	288,124
Earnings common share		
Primary	\$(0.12)	\$0.01
Fully Diluted	\$(0.12)	\$0.01
Common Shares:		
Full Diluted	50,000,000	50,000,000
Year-end	50,000,000	

JASPER THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Cost & expenses	31,774,000	24,741,000
Operating income	(31,774,000)	(24,741,000)
Interest income	2,532,000	
Other income (expense), net	(754,000)	6,912,000
Gains or losses	(344,000)	5,218,000
Net before taxes	(30,340,000)	
Net income	(30,340,000)	(12,611,000)
Balance for common	(30,340,000)	
Earnings common share		
Primary	\$(0.31)	\$(0.35)
Fully Diluted	\$(0.31)	\$(0.35)
Common Shares:		
Full Diluted	98,605,265	36,353,509
Year-end	110,800,413	37,981,317

KINETA INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2023	2022
Total revenues	5,442	
Net Sales	5,000	
Cost & expenses	16,894	25,229
Operating income	(11,452)	(21,148)
Interest expense	65	219
Other income (expense), net	281	(200)
Gains or losses	(180)	

Net before taxes	(11,416)	
Net income	(11,416)	(21,589)
Balance for common	(11,445)	(21,589)
Earnings common share		
Primary	\$(1.09)	\$(14.00)
Fully Diluted	\$(1.09)	\$(14.00)
Common Shares:		
Full Diluted	10,505	1,545
Year-end	10,215	1,551

KOSS CORP**Earnings, 3 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	3,373,938	
Net Sales	3,373,938	3,354,529
Cost & expenses	3,842,527	25,838,901
Operating income	(468,589)	(22,484,372)
Other income (expense), net		33,000,000
Net before taxes	(255,730)	10,542,684
Income taxes	1,879	597,941
Net income	(257,609)	9,944,743
Earnings common share		
Primary	\$(0.03)	\$1.09
Fully Diluted	\$(0.03)	\$1.01
Common Shares:		
Full Diluted	9,234,795	9,849,043
Year-end	9,234,795	9,179,795

Consolidated Balance Sheet Items, as of (\$):

	2023
Assets:	
Cash & equivalents	19,167,932
Inventories	5,778,872
Current assets	26,924,347
Net property & equip.	1,221,007
Total assets	37,339,103
Liabilities:	
Current liabilities	1,311,792
Stockholders' equity	31,250,078
Net current assets	25,612,555

LADRX CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Cost & expenses	2,932,625	3,610,172
Operating income	(2,941,517)	(3,610,172)
Interest income	31,405	2,643
Other income (expense), net	1,372	351,163
Gains or losses	4,167,219	
Net income	1,258,479	(3,256,366)
Balance for common	1,189,670	(3,748,938)
Earnings common share		
Primary	\$2.59	\$(9.00)
Fully Diluted	\$2.59	\$(9.00)
Common Shares:		
Full Diluted	486,101	428,027
Year-end	495,092	450,374

LIFELOC TECHNOLOGIES INC.

New Accountant On Oct. 17, 2023, Co. dismissed Gries & Associates, LLC and engaged GreenGrowth CPAs as its new independent public accounting firm.

LIPELLA PHARMACEUTICALS INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Total revenues	224,724	33,149
Cost & expenses	2,884,356	1,550,959
Operating income	(2,659,632)	(1,517,810)
Interest income	63,969	1,134
Interest expense	10,848	3,254
Other income (expense), net		(45)
Net before taxes	(2,606,511)	(1,519,975)
Net income	(2,606,511)	(1,519,975)
Earnings common share		
Primary	\$(0.45)	\$(0.39)
Fully Diluted	\$(0.45)	\$(0.39)
Common Shares:		
Full Diluted	5,743,945	3,866,625
Year-end	5,743,945	3,866,625

LIPELLA PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	328,775	33,149
Cost & expenses	4,345,134	2,263,599
Operating income	(4,016,359)	(2,233,722)

Interest income	97,126	1,636
Interest expense	10,848	4,908
Other income (expense), net		(45)
Net before taxes	(3,930,081)	(2,233,767)
Net income	(3,930,081)	(2,233,767)
Earnings common share		
Primary	\$(0.68)	\$(0.57)
Fully Diluted	\$(0.68)	\$(0.57)
Common Shares:		
Full Diluted	5,747,242	3,947,233
Year-end	5,803,945	4,195,072

MANGOCEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	241,959	
Cost & expenses	5,093,342	346,612
Operating income	(4,851,383)	(346,612)
Net before taxes	(4,844,910)	(349,084)
Net income	(4,844,910)	(349,084)
Earnings common share		
Primary	\$(0.33)	\$(0.04)
Fully Diluted	\$(0.33)	\$(0.04)
Common Shares:		
Full Diluted	14,500,230	8,816,917
Year-end	16,714,500	10,250,000

MANGOCEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	487,119	
Cost & expenses	7,137,962	1,319,727
Operating income	(6,650,843)	(1,319,727)
Net before taxes	(6,644,370)	(1,324,400)
Net income	(6,644,370)	(1,324,400)
Earnings common share		
Primary	\$(0.45)	\$(0.13)
Fully Diluted	\$(0.45)	\$(0.13)
Common Shares:		
Full Diluted	14,923,461	9,913,388
Year-end	16,789,500	12,015,500

MARKETWISE INC

Official Changes On Oct. 17, 2023, Co. announced the appointment of Mr. F. Porter Stansberry as Co.'s Chairman of the Board and Chief Executive Officer. Also on Oct. 17, 2023, Co. announced the resignation of Ms. Amber Mason as Co.'s Chief Executive Officer and a Directors. On Oct. 18, 2023, Co. announced the resignations of Mr. Mark Gerhard and Mr. Riaan Hodgson from its Board of Directors.

MASTERWORKS 212 LLC

History: Incorporated in Delaware on Oct. 17, 2022.

Business Summary: Masterworks 212 facilitates an investment in a single work of art identified as (212) Zao Wou-Ki, 06.10.70, 1970 by conducting an offering of Co.'s class A shares pursuant to a Tier II offering under Regulation A+, acquiring the Artwork and maintaining the Artwork for future sale. Co. is engaged in the activities related to the offering and the acquisition, ownership, maintenance, promotion and the eventual sale of the Artwork.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiary

212 Segregated Portfolio of Masterworks Cayman, SPC (Cayman Islands)

Officers

Nigel S. Glenday, Chief Executive Officer; Chief Financial Officer; Principal Accounting Officer; Subsidiary Officer
Joshua B. Goldstein, Chief Executive Officer; Chief Financial Officer; Subsidiary Officer

Directors

Joshua B. Goldstein, Director
Nigel S. Glenday, Director
Eli D. Broverman, Director

Auditors: AGD Legal, S. C.

Legal Counsel: Anthony L.G., PLLC

Transfer Agent: Equity Stock Transfer, LLC

No. of Stockholders: Dec. 31, 2022, 480

Address: 225 Liberty Street 29th Floor, New York, NY 10281

Tel: 203 518-5172

Web: www.masterworks.com

Email: legal@masterworks.com

Income Statement, Years Ended Dec. 31 (\$):

	2022
Total operating expenses	125,560
Net income (loss)	(125,560)
Weighted average shares outstanding - diluted	60,414
Year end shares outstanding	61,278
Net earnings (loss) per share - basic	\$(2.00)
Number of common stockholders	480

From October 17, 2022 (inception)

Balance Sheet, Years Ended Dec. 31 (\$):

	2022
Cash & cash equivalents	100
Total current assets	100
Current assets Artwork	1,100,000
Total assets	1,100,100

Capital Stock: 1. Masterworks 212 LLC common; no par.
OUTSTANDING—Dec. 31, 2022, 61,278 shs; no par.

MASTERWORKS 247 LLC

History: Incorporated in Delaware on Jan. 24, 2023.

Business Summary: Masterworks 247 facilitates an investment in a single work of art identified as (247) Yayoi Kusama, Infinity Nets (ONSR), 2011 by conducting an offering of Co.'s class A shares pursuant to a Tier II offering under Regulation A+, acquiring the Artwork and maintaining the Artwork for future sale. Co. is engaged in the activities related to the offering and the acquisition, ownership, maintenance, promotion and the eventual sale of the Artwork.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiary

247 Segregated Portfolio of Masterworks Cayman, SPC (Cayman Islands)

Officers

Nigel S. Glenday, Chief Executive Officer; Chief Financial Officer; Principal Accounting Officer
Joshua B. Goldstein, General Counsel; Secretary

Directors

Joshua B. Goldstein, Director
Nigel S. Glenday, Director
Eli D. Broverman, Director

Auditors: AGD Legal, SC

Legal Counsel: Anthony L.G., PLLC

Transfer Agent: Equity Stock Transfer, LLC

No. of Stockholders: Sept. 13, 2023, 934

Address: 225 Liberty Street 29th Floor, New York, NY 10281

Tel: 203 518-5172

Web: www.masterworks.com

Email: legal@masterworks.com

Consolidated Income Statement, Years Ended Sept. 13 (\$):

	2023
Total operating expense	45,460
Net income (loss)	(45,460)
Weighted average shares outstanding - diluted	22,517
Year end shares outstanding	25,023
Net earnings (loss) per share - basic	\$(2.00)
Number of common stockholders	934

From January 24, 2023 (inception)

Consolidated Balance Sheet, Years Ended Sept. 13 (\$):

	2023
Cash & equivalents	100
Total current assets	100
Current assets Artwork	455,000
Total assets	455,100
Total stockholders equity (deficit)	3,053,000

Capital Stock: 1. Masterworks 247 LLC common; no par.
OUTSTANDING—Sept. 13, 2023, 25,023 shs; no par.

MASTERWORKS 250 LLC

History: Incorporated in Delaware on Jan. 24, 2023.

Business Summary: Masterworks 250 facilitates an investment in a single work of art identified as (250) Barbara Kruger, Untitled (Your fact is stranger than fiction), 1983 by conducting an offering of Co.'s class A shares pursuant to a Tier II offering under Regulation A+, acquiring the Artwork and maintaining the Artwork for future sale. Co. is engaged in the activities related to the offering and the acquisition, ownership, maintenance, promotion and the eventual sale of the Artwork.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiary

253 Segregated Portfolio of Masterworks Cayman, SPC (Cayman Islands)

Officers

Nigel S. Glenday, Chief Executive Officer; Chief Financial Officer; Principal Accounting Officer
Joshua B. Goldstein, General Counsel; Secretary

Directors

Joshua B. Goldstein, Director
Nigel S. Glenday, Director
Eli D. Broverman, Director

Auditors: AGD Legal, SC

Legal Counsel: Anthony L.G., PLLC

Transfer Agent: Equity Stock Transfer, LLC, New York, NY

No. of Stockholders: Sept. 13, 2023, 611

Address: 225 Liberty Street 29th Floor, New York, NY 10281

Tel: 203 518-5172

Web: www.masterworks.com

Email: legal@masterworks.com

Consolidated Income Statement, Years Ended Sept. 13 (\$):

	2023
Total operating expenses	107,600
Net income (loss)	(107,600)
Weighted average shares outstanding - diluted	52,183
Year end shares outstanding	53,380
Net earnings (loss) per share - basic	\$(2.00)
Number of common stockholders	611

Consolidated Balance Sheet, Years Ended Sept. 13 (\$):

	2023
Cash & equivalents	100
Subscriptions	228
Total current assets	328
Artwork	960,000
Accounts payable	228
Total assets	960,328
Total liabilities	228
Total stockholders' equity	1,138,000

Capital Stock: 1. Masterworks 250 LLC common; no par.
OUTSTANDING—Sept. 13, 2023, 53,380 shs; no par.

MASTERWORKS 253 LLC

History: Incorporated in Delaware on Jan. 24, 2023.

Business Summary: Masterworks 253 facilitates an investment in a single work of art identified as (253) Hernan Bas, Untitled (Fountain), 2013 by conducting an offering of Co.'s class A shares pursuant to a Tier II offering under Regulation A+, acquiring the Artwork and maintaining the Artwork for future sale. Co. is engaged in the activities related to the offering and the acquisition, ownership, maintenance, promotion and the eventual sale of the Artwork.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiary

253 Segregated Portfolio of Masterworks Cayman, SPC (Cayman Islands)

Officers

Nigel S. Glenday, Chief Executive Officer; Chief Financial Officer; Principal Accounting Officer
 Joshua B. Goldstein, General Counsel; Secretary

2023

Directors

Joshua B. Goldstein, Director
 Nigel S. Glenday, Director
 Eli D. Broverman, Director

Auditors: AGD Legal, SC

Legal Counsel: Anthony L.G., PLLC

Transfer Agent: Equity Stock Transfer, LLC

No. of Stockholders: Sept. 21, 2023, 659

Address: 225 Liberty Street 29th Floor, New York, NY 10281

Tel: 203 518-5172

Web: www.masterworks.com

Email: legal@masterworks.com

Consolidated Income Statement, Years Ended Sept. 21 (\$):
 2023

Total operating expense	56,840
Net income (loss)	(56,840)
Weighted average shares outstanding - diluted	27,475
Year end shares outstanding	28,092
Net earnings (loss) per share - basic	\$(2.00)
Number of common stockholders	659

From January 24, 2023 (inception)

Consolidated Balance Sheet, Years Ended Sept. 21 (\$):
 2023

Cash & equivalents	100
Total current assets	100
Current assets artwork	505,000
Total assets	505,100
Retained earnings (accumulated deficit)	921,000
Total stockholders equity (deficit)	921,000

Capital Stock: 1. Masterworks 253 LLC common; no par.
 OUTSTANDING—Sept. 21, 2023, 28,092 shs; no par.

MASTERWORKS 255 LLC

History: Incorporated in Delaware on Jan. 24, 2023.

Business Summary: Masterworks 255 facilitates an investment in a single work of art identified as (255) Yayoi Kusama, Pumpkin (XZA), 2003 by conducting an offering of Co.'s class A shares pursuant to a Tier II offering under Regulation A+, acquiring the Artwork and maintaining the Artwork for future sale. Co. is engaged in the activities related to the offering and the acquisition, ownership, maintenance, promotion and the eventual sale of the Artwork.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiary

255 Segregated Portfolio of Masterworks Cayman, SPC (Cayman Islands)

Officers

Nigel S. Glenday, Chief Executive Officer; Chief Financial Officer; Principal Accounting Officer
 Joshua B. Goldstein, General Counsel; Secretary

Directors

Joshua B. Goldstein, Director
 Nigel S. Glenday, Director
 Eli D. Broverman, Director

Auditors: AGD Legal, SC

Legal Counsel: Anthony L.G., PLLC

Transfer Agent: Equity Stock Transfer, LLC

No. of Stockholders: June 29, 2023, 374

Address: 225 Liberty Street 29th Floor, New York, NY 10281

Tel: 203 518-5172

Web: www.masterworks.com

Email: legal@masterworks.com

Consolidated Income Statement, Years Ended Jun. 29 (\$):

Total operating expense	56,840
Net income (loss)	(56,840)
Weighted average shares outstanding - diluted	27,475
Year end shares outstanding	28,092
Net earnings (loss) per share - basic	\$(2.00)
Number of common stockholders	659

Total operating expense	67,620
Net income (loss)	(67,620)
Weighted average shares outstanding - diluted	31,592
Year end shares outstanding	33,631
Net earnings (loss) per share - basic	\$(2.00)
Number of common stockholders	374

Consolidated Balance Sheet, Years Ended Jun. 29 (\$):
 2023

Cash & cash equivalents	100
Total current assets	100
Current assets Artwork	605,000
Total assets	605,100
Total stockholders equity (deficit)	644,000

Capital Stock: 1. Masterworks 255 LLC common; no par.
 OUTSTANDING—June 29, 2023, 33,631 shs; no par.

MASTERWORKS 266 LLC

History: Incorporated in Delaware on Mar. 27, 2023.

Business Summary: Masterworks 266 facilitates an investment in a single work of art identified as (266) Yayoi Kusama, Pumpkin, 1991 by conducting an offering of Co.'s class A shares pursuant to a Tier II offering under Regulation A+, acquiring the Artwork and maintaining the Artwork for future sale. Co. is engaged in the activities related to the offering and the acquisition, ownership, maintenance, promotion and the eventual sale of the Artwork.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiary

266 Segregated Portfolio of Masterworks Cayman, SPC (Cayman Islands)

Officers

Nigel S. Glenday, Chief Executive Officer; Chief Financial Officer; Principal Accounting Officer
 Joshua B. Goldstein, General Counsel; Secretary

Directors

Joshua B. Goldstein, Director
 Nigel S. Glenday, Director
 Eli D. Broverman, Director

Auditors: AGD Legal, SC

Legal Counsel: Anthony L.G., PLLC

Transfer Agent: Equity Stock Transfer, LLC

No. of Stockholders: July 13, 2023, 351

Address: 225 Liberty Street 29th Floor, New York, NY 10281

Tel: 203 518-5172

Web: www.masterworks.com

Email: legal@masterworks.com

Consolidated Income Statement, Years Ended Jul. 13 (\$):
 2023

Year end shares outstanding	2,000
Number of common stockholders	351

From March 27, 2023 (inception)

Consolidated Balance Sheet, Years Ended Jul. 13 (\$):
 2023

Cash & equivalents	2,519,160
Subscriptions	2,519,060
Total current assets	5,038,220
Total assets	5,038,220
Current liabilities	2,519,060
Total liabilities	2,519,060
Total stockholders equity (deficit)	636,000

Capital Stock: 1. Masterworks 266 LLC class B ordinary; no par.

OUTSTANDING—July 13, 2023, 1,000 shs; no par.

2. Masterworks 266 LLC class A ordinary; no par.

OUTSTANDING—July 13, 2023, 1,000 shs; no par.
 OFFERED—(56,900 shares) at \$20.00 a share on Apr. 25, 2023.
 IPO

MASTERWORKS 269 LLC

History: Incorporated in Delaware on Mar. 27, 2023.

Business Summary: Masterworks 269 facilitates an investment in a single work of art identified as (269) Cecily Brown, Where They Are Now, 2013 by conducting an offering of Co.'s class A shares pursuant to a Tier II offering under Regulation A+, acquiring the Artwork and maintaining the Artwork for future sale. Co. is engaged in the activities related to the offering and the acquisition, ownership, maintenance, promotion and the eventual sale of the Artwork.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiary

269 Segregated Portfolio of Masterworks Cayman, SPC (Cayman Islands)

Officers

Nigel S. Glenday, Chief Executive Officer; Chief Financial Officer; Principal Accounting Officer
 Joshua B. Goldstein, General Counsel; Secretary

Directors

Joshua B. Goldstein, Director
 Nigel S. Glenday, Director
 Eli D. Broverman, Director

Auditors: AGD Legal, SC

Legal Counsel: Anthony L.G., PLLC

Transfer Agent: Equity Stock Transfer, LLC

No. of Stockholders: Oct. 19, 2023, 1,104

Address: 225 Liberty Street 29th Floor, New York, NY 10281

Tel: 203 518-5172

Web: www.masterworks.com

Email: legal@masterworks.com

Consolidated Income Statement, Years Ended Oct. 19 (\$):
 2023

Total operating expense	39,607
Net income (loss)	(39,607)
Weighted average shares outstanding - diluted	18,675
Year end shares outstanding	18,675
Net earnings (loss) per share - basic	\$(2.00)
Number of common stockholders	1,104

From March 27, 2023 (inception)

Consolidated Balance Sheet, Years Ended Oct. 19 (\$):
 2023

Cash & equivalents	28,100
Current assets settling subscriptions	28,000
Total current assets	56,100
Current assets artwork	361,393
Total assets	417,493
Current liabilities	55,500
Total liabilities	55,500
Retained earnings (accumulated deficit)	3,087,000
Total stockholders equity (deficit)	3,087,000

Capital Stock: 1. Masterworks 269 LLC common; no par.
 OUTSTANDING—Oct. 19, 2023, 18,675 shs; no par.

MASTERWORKS 270 LLC

History: Incorporated in Delaware on Mar. 27, 2023.

Business Summary: Masterworks 270 facilitates an investment in a single work of art identified as (270) Yayoi Kusama, A-PUMPKIN (BAGN8), 2011 by conducting an offering of Co.'s class A shares pursuant to a Tier II offering under Regulation A+, acquiring the Artwork and maintaining the Artwork for future sale. Co. is engaged in the activities related to the offering and the acquisition, ownership, maintenance, promotion and the eventual sale of the Artwork.

Property: Co. maintains its principal executive offices in New York, NY.

Subsidiary

270 Segregated Portfolio of Masterworks Cayman, SPC (Cayman Islands)

Officers

Nigel S. Glenday, Chief Executive Officer; Chief Financial Officer; Principal Accounting Officer

Joshua B. Goldstein, General Counsel; Secretary

Directors

Joshua B. Goldstein, Director
Nigel S. Glenday, Director
Eli D. Broverman, Director

Auditors: AGD Legal, SC

Legal Counsel: Anthony L.G., PLLC

Transfer Agent: Equity Stock Transfer, LLC

No. of Stockholders: Sept. 21, 2023, 2,550

Address: 225 Liberty St. 29th Floor, New York, NY 10281

Tel: 203 518-5172

Web: www.masterworks.com

Email: legal@masterworks.com

Consolidated Income Statement, Years Ended Sept. 21 (\$):
2023

Total operating expense	94,600
Net income (loss)	(94,600)
Weighted average shares outstanding - diluted	46,343
Year end shares outstanding	46,373
Net earnings (loss) per share - basic	\$(2.00)
Number of common stockholders	2,550

Consolidated Balance Sheet, Years Ended Sept. 21 (\$):
2023

Cash & cash equivalents	7,346
Subscriptions	7,140
Total current assets	14,486
Current assets Artwork	850,000
Total assets	864,486
Accounts payable	106
Current liabilities	24,386
Total liabilities	24,492
Total stockholders equity (deficit)	7,876,000

Capital Stock: 1. Masterworks 270 LLC common; no par.
OUTSTANDING—Sept. 21, 2023, 46,373 shs; no par.

MASTERWORKS 287 LLC

History: Incorporated in Delaware on Apr. 14, 2023.

Business Summary: Masterworks 287 facilitates an investment in a single work of art identified as (287) Rashid Johnson, Bruise Painting "Nina's Blues", 2023 by conducting an offering of Co.'s class A shares pursuant to a Tier II offering under Regulation A+ acquiring the Artwork and maintaining the Artwork for future sale. Co. is engaged in the activities related to the offering and the acquisition, ownership, maintenance, promotion and the eventual sale of the Artwork.

Property: Co. maintains its principal executive office in New York, NY.

Subsidiary

287 Segregated Portfolio of Masterworks Cayman, SPC (Cayman Islands)

Officers

Nigel S. Glenday, Chief Executive Officer; Chief Financial Officer; Principal Accounting Officer
Joshua B. Goldstein, General Counsel; Secretary

Directors

Joshua B. Goldstein, Director
Nigel S. Glenday, Director
Eli D. Broverman, Director

Auditors: AGD Legal, SC

Legal Counsel: Anthony L.G., PLLC

Transfer Agent: Equity Stock Transfer, LLC

No. of Stockholders: Sept. 7, 2023, 601

Address: 225 Liberty St. 29th Floor, New York, NY 10281

Tel: 203 518-5172

Web: www.masterworks.com

Email: legal@masterworks.com

Consolidated Income Statement, Years Ended Sept. 7 (\$):
2023

Year end shares outstanding	1,000
Number of common stockholders	601

Consolidated Balance Sheet, Years Ended Sept. 7 (\$):
2023

Cash & cash equivalents	270,500
Subscription	270,400
Total current assets	540,900
Total assets	540,900
Total current liabilities	270,400
Total liabilities	270,400
Stockholders' equity	833,000

Capital Stock: 1. Masterworks 287 LLC common; no par.
OUTSTANDING—Sept. 7, 2023, 1,000 shs; no par.

META MATERIALS INC

Official Changes On Oct. 16, 2023, Co. announced the resignation of Mr. George Palikaras from its Board of Directors.

MIDWEST HOLDING INC

Earnings, 6 mos. to Jun 30 (Consol. - \$):

	2023	2022
Total revenues	67,517,000	2,461,000
Cost & expenses	52,677,000	(6,621,000)
Operating income	11,223,000	7,180,000
Net before taxes	11,223,000	7,180,000
Income taxes	5,876,000	2,597,000
Net income	5,347,000	4,583,000
Earnings common share		
Primary	\$(0.01)	\$2.53
Fully Diluted	\$(0.01)	\$2.52
Common Shares:		
Full Diluted	3,855,462	3,749,564
Year-end	3,744,645	3,737,564

MIRA PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2022	2021
General and administrative expenses	2,992,125	770,115
Related party travel costs	1,704,350	697,600
Research and development expenses	2,351,465	684,447
Total operating costs	7,047,940	2,152,162
Interest expense	10,250	24,374
Net loss	(7,058,190)	(2,176,536)
Year end shares outstanding	13,313,000	12,673,800
Number of full time employees	1	...
Number of part time employees	5	...

[□] Adjusted for 1-for-5 stock split, June 28, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2022	2021
Cash	350,978	2,809,552
Deferred offering costs	143,427	100,000
Total current assets	494,405	2,909,552
Operating lease, right of use assets	164,910	...
Related party operating lease, right of use assets	198,759	...
Advances to affiliates	...	445,612
Total assets	858,074	3,355,164
Trade accounts payable and accrued liabilities	811,738	228,406
Related party accounts payable	116,350	547,600
Related party line of credit	133,062	293,062
Related party accrued interest	34,987	24,738
Current portion of operating lease liabilities	75,143	...
Related party current portion of operating lease liabilities	198,759	...
Total current liabilities	1,370,039	1,093,806
Non-current operating		

lease liabilities	84,267	...
Total liabilities	1,454,306	1,093,806
Common Stock	6,657	6,337
Additional paid-in capital	8,699,830	4,499,550
Accumulated deficit	(9,302,719)	(2,244,529)
Total stockholders' (deficit) equity	(596,232)	2,261,358

Recent Dividends:

1. Mira Pharmaceuticals Inc common.

No dividends paid.

Annual Dividends:

1. Mira Pharmaceuticals Inc common.

No dividends paid.

MIRA PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2023	2022
Cost & expenses	5,469,692	5,700,227
Net income	(6,194,965)	(5,708,711)
Balance for common	(6,194,965)	(5,708,711)
Earnings common share		
Primary	\$(0.45)	\$(0.43)
Fully Diluted	\$(0.45)	\$(0.43)
Common Shares:		
Full Diluted	13,639,197	13,166,200
Year-end	14,780,885	13,256,000

MONOGRAM ORTHOPAEDICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2022	2021
Product revenue	...	628,246
Cost of goods sold	...	458,675
Gross profit	...	169,571
Research & development expenses	4,972,881	5,278,768
Marketing & advertising expenses	2,714,421	3,271,600
General & administrative expenses	2,925,845	1,896,839
Total operating expenses	10,613,147	10,447,207
Income (loss) from operations	(10,613,147)	(10,277,636)
Grant income	256,000	...
Change in fair value of warrant liability	(3,431,865)	(1,563,439)
Interest income & other, net	98,065	26,107
Total other income (expense)	[□] (3,333,800)	(1,537,332)
Net income (loss) before taxes	(13,690,947)	(11,814,968)
Net income (loss)	(13,690,947)	(11,814,968)
Weighted average shares outstanding - basic	9,673,870	9,673,870
Weighted average shares outstanding - diluted	9,673,870	9,673,870
Year end shares outstanding	9,673,870	9,673,870
Earnings (loss) per share - basic	\$(1.42)	\$(1.22)
Earnings (loss) per share - diluted	\$(1.42)	\$(1.22)
Number of full time employees	[□] 24	...

[□] As reported by the Company; [□] As of September 21, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2022	2021
Cash & cash equivalents	10,468,645	5,535,710
Inventory	4,550	...
Receivable from investment platform vendor	157,598	418,503
Advance paid to vendor for supply development contract	250,000	250,000
Other prepaid expenses	375,856	309,407
Prepaid expenses & other		

current assets	788,004	977,910
Total current assets	11,256,650	6,513,620
Computer equipment	98,391	63,740
Furniture	27,405	20,116
Engineering equipment	214,547	171,153
Medical equipment	184,379	184,379
Robot equipment	524,506	368,637
Software	537,839	537,839
Equipment, gross	1,587,067	1,345,864
Less: accumulated depreciation	504,625	327,939
Equipment, net of accumulated depreciation	1,082,442	1,017,925
Intangible assets, net	758,750	968,750
Operating lease right-of-use assets	592,221	215,071
Total assets	13,690,063	8,715,366
Accounts payable	663,170	449,032
Accrued expenses	748,460	464,477
Warrant liability	7,519,101	4,087,236
Operating lease liabilities, current	118,166	92,886
Total current liabilities	9,048,897	5,093,631
Operating lease liabilities, non-current	491,989	118,577
Total liabilities	9,540,886	5,212,208
Series A preferred Stock	4,898	4,898
Series B preferred Stock	3,196	1,743
Series C preferred Stock	438	...
Common stock	9,674	9,674
Additional paid-in capital	41,894,417	27,559,342
Retained earnings (accumulated deficit)	(37,763,447)	(24,072,500)
Total stockholders' equity (deficit)	4,149,176	3,503,158

[□] As reported by the Company

Recent Dividends:

1. Monogram Orthopaedics Inc common.

No dividends paid.

Annual Dividends:

1. Monogram Orthopaedics Inc common.

No dividends paid.

MONOGRAM ORTHOPAEDICS INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Fruci & Associates II, PLLC, as it appeared in Co.'s 2022 Prospectus: "Opinion on the Financial Statements We have audited the accompanying balance sheets of Monogram Orthopaedics, Inc. ("the Company") as of December 31, 2022 and 2021, and the related statements of operations, changes in stockholders' equity (deficit), and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has sustained recurring losses and has an accumulated deficit. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

MONOGRAM ORTHOPAEDICS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Cost & expenses	9,634,267	5,600,669
Operating income	(9,634,267)	(5,600,668)
Other income (expense), net	442,474	(793,591)
Net before taxes	(9,095,263)	(6,364,096)
Net income	(9,095,263)	(6,364,096)
Earnings common share		
Primary	\$(0.63)	\$(0.66)
Fully Diluted	\$(0.63)	\$(0.66)
Common Shares:		
Full Diluted	14,472,695	9,673,870

Year-end 29,253,251 9,673,870

MONOPAR THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	6,919,247	7,627,879
Operating income	(6,919,247)	(7,627,879)
Interest income	330,966	8,579
Net before taxes	(6,588,281)	...
Net income	(6,588,281)	(7,619,300)
Balance for common	(6,588,281)	...
Earnings common share		
Primary	\$(0.49)	\$(0.60)
Fully Diluted	\$(0.49)	\$(0.60)
Common Shares:		
Full Diluted	13,551,776	12,664,387
Year-end	14,198,438	12,855,735

NETWORK CN INC.

New Accountant On Oct. 3, 2023, Gries & Associates, LLC ("Gries") resigned as Co.'s independent registered public accounting firm in connection with Gries's merger on Sept. 26, 2023, with GreenGrowth CPAs ("GreenGrowth"). On Oct. 26, 2023, Co. appointed GreenGrowth as Co.'s independent registered public accounting firm.

NEXT MEATS HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Apr. 30 (\$):

	2023	2022	2021
SubTotal	1,398,133
Revenues	1,398,133	6,950,236	...
Cost of revenues	1,326,938	5,707,788	...
Gross profit (loss)	71,195	1,242,448	...
Share-based expense	5,880,579,874
Depreciation	38,947	54,023	...
General & administrative expenses	2,793,603	6,592,923	28,146
Total operating expenses	2,832,550	6,646,945	5,880,608,020
Income (loss) from operations	(2,761,355)	(5,404,498)	...
Interest expense	8,986	4,201	...
Other expense	8,275	9,588	...
Stock loss	39,876	303,181	...
Other income	132,013	16,036	...
Provision for bad debt	1,864,630
Loss on sale and disposal of fixed assets	(317,648)
Total other income (expense)	(2,107,402)	(300,935)	...
Net income (loss) before tax	(4,868,757)	(5,705,432)	...
Income tax expense	4,253	90,547	...
NET INCOME (LOSS)	(4,873,010)
FROM CONTINUING OPERATIONS	(4,873,010)
Gain from discontinued operations	40,982
Net income (loss)	(4,832,028)	(5,795,980)	(5,880,608,020)
Weighted average shares outstanding - basic	502,465,609	500,557,170	152,260,753
Weighted average shares outstanding - diluted	502,465,609	...	152,260,753
Year end shares outstanding	502,562,280	502,255,600	500,000,000
Net income (loss) per share - basic	\$(0.01)	\$(0.01)	\$(38.62)
Net income (loss) per share - diluted	\$(0.01)	...	\$(38.62)
Number of common stockholders	87	83	57
Total number of employees	2	24	...

[□] Non-consolidated; [□] April 30, 2021 and prior periods for Turnkey Solutions, Inc. prior to reorganization with Intermedia

Marketing Solutions, Inc. ; [□] As reported by the Company; [□] Shares increased due to the effect of shares issued for services rendered and reorganization; [□] Approximately; [□] As of September 29, 2022; [□] As of August 12, 2021

Consolidated Balance Sheet, Years Ended Apr. 30 (\$):

	2023	2022
Cash & cash equivalents	292,454	620,297
Accounts receivable	339,463	1,288,591
Advance payments & prepaid expenses	194,987	1,335,832
Inventories	134,646	598,044
Accounts receivable - related party	839	...
Accounts receivable - related party from discontinued operations	13	...
Total current assets	962,402	3,842,764
Equipment, net depreciation	120,531	168,241
Construction in progress	...	282,230
Land & improvements	...	1,093,028
Long term prepaid expenses	...	2,695
Deferred assets	...	739
Security deposits	141,750	151,403
Stock	...	187,500
Total non-current assets	262,281	1,885,836
Total assets	1,224,683	5,728,600
Accrued expenses & other payables	343,742	558,361
Due to related party	9,815	...
Income tax payable	...	23,841
Short term loans	23,494	...
Short term loans - related party	23,857	...
Advance receipts	416,075	...
Total current liabilities	816,983	582,201
Loans	231,894	271,613
Other long term liabilities	1,752	...
Loans - related party	127,588	...
Total liabilities	1,178,219	853,814
Common stock	502,562	502,256
Additional paid-in capital	12,747,075	5,893,031,815
Retained earnings (accumulated deficit)	(11,712,412)	(5,887,460,258)
Accumulated other comprehensive income (loss)	(1,492,940)	(1,199,027)
Accumulated other comprehensive income (loss) from discontinued operations	2,178	...
Total shareholders' equity	46,464	4,874,786

[□] As reported by the Company

Dividends:

No dividends paid.

NEXT MEATS HOLDINGS INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, BF Borgers CPA PC, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheets of Next Meats Holdings, Inc. as of April 30, 2023 and 2022, the related statements of operations, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of April 30, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States. Substantial Doubt about the Company's Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise

substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

NEXTRACKER INC**Earnings, 6 mos. to (Consol. - \$000):**

	09/29/23	09/30/22
Total revenues	1,052,900	870,372
Cost & expenses	884,928	801,131
Operating income	167,972	69,241
Net before taxes	158,154	67,993
Income taxes	13,100	16,776
Net income	145,054	51,217
Earnings common share		
Primary	\$1.10	\$0.99
Fully Diluted	\$0.99	\$0.99
Common Shares:		
Full Diluted	147,008	144,669
Year-end	144,669	144,669

NI HOLDINGS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2023	2022
Total revenues	178,532	141,930
Cost & expenses	155,282	166,507
Operating income	(15,917)	(56,444)
Net before taxes	(15,917)	(56,444)
Income taxes	(3,182)	(11,847)
Net income	(12,735)	(44,597)
Earnings common share		
Primary	\$(0.58)	\$(2.06)
Fully Diluted	\$(0.58)	\$(2.06)
Common Shares:		
Full Diluted	21,325	21,376
Year-end	20,886	21,210

NI HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2023	2022
Total revenues	271,281	231,105
Cost & expenses	227,541	251,336
Operating income	(15,789)	(69,687)
Net before taxes	(15,789)	(69,687)
Income taxes	(3,352)	(14,921)
Net income	(12,437)	(54,766)
Earnings common share		
Primary	\$(0.57)	\$(2.53)
Fully Diluted	\$(0.57)	\$(2.53)
Common Shares:		
Full Diluted	21,253	21,360
Year-end	20,576	21,148

NOCOPI TECHNOLOGIES INC MD

Official Changes On Aug. 7, 2023, Co. announced the resignation of Dr. Michael A. Feinstein as Co.'s Chief Executive Officer and from Co.'s Board of Directors, effective Aug. 18, 2023. On Aug. 8, 2023, Co. announced the appointment of Mr. Michael S. Liebowitz, Co.'s Board of Directors, as its Chief Executive Officer and Chairman of the Board, effective Aug. 18, 2023.

NOCOPI TECHNOLOGIES INC MD

Official Changes On Aug. 29, 2023, Co. announced the resignation of Mr. Marc Rash from Co.'s Board of Directors.

NORDICUS PARTNERS CORP**Annual Report****Consolidated Income Statement, Years Ended Mar. 31 (\$):**

	2023	2022	2021
			(revised)
General & administrative expenses	39,602
Selling, general & administrative expenses	102,286
Non-cash compensation	8,141,501
Operating expenses	196,500	309,000	326,000
Income (loss) from operations	(8,479,889)	(309,000)	(326,000)
Interest expense	382
Other income - transaction fee	8,055	22,000	...
Interest & other income (expenses)	7,673

Income (loss) from operations before provision for income taxes	(8,472,216)	(287,000)	(326,000)
Net income (loss)	(8,472,216)	(287,000)	(326,000)
Weighted average shares outstanding			
- basic	5,938,851	944,651	566,773
Weighted average shares outstanding			
- diluted	5,938,851	944,651	566,773
Year end shares outstanding	8,296,248	5,681,248	565,247
Net income (loss) per common share - basic	\$(1.43)	\$(0.30)	\$(0.58)
Net income (loss) per common share - diluted	\$(1.43)	\$(0.30)	\$(0.58)
Number of part time employees	...	1	1
Number of common stockholders	112	63	318
Foreign currency translation adjustments	665

Reclassified to conform with 2022 presentation; Adjusted for 1-for-50 stock split, March 11, 2022; Shares increased due to the effect of issuance of common stock for investor; Approximately: As of June 17, 2022; As of September 8, 2021

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2023	2022
Cash	7,149	246,000
Accounts receivable - other	44,481	...
Prepaid expenses & other current assets	770	4,000
Total current assets	52,400	250,000
Website	2,625	...
Total assets	55,025	250,000
Accounts payable & accrued expenses	12,127	43,000
Related party payable	13,886	12,000
Accounts payable and accrued expenses	1,354	...
Total current liabilities	27,367	55,000
Total liabilities	27,367	55,000
Common stock	8,296	6,000
Additional paid-in capital	42,246,688	33,944,000
Retained earnings (accumulated deficit)	(42,197,663)	(33,725,000)
Accumulated other comprehensive income (loss)	665	...
Treasury stock	30,328	30,000
Total stockholders' equity (deficit)	27,658	195,000
Total Equity	27,658	...

Recent Dividends:**1. Nordicus Partners Corp common.**

No dividends paid.

Annual Dividends:**1. Nordicus Partners Corp common.**

No dividends paid.

NORDICUS PARTNERS CORP**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Fruci & Associates II, PLLC, as it appeared in the 2023 10K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Nordicus Partners Corporation and Subsidiary ("the Company") as of March 31, 2023, and the related consolidated statements of operations, changes in stockholders' equity, and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2023, and the results of its operations and

its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has not generated revenue, incurred losses since inception, and has an accumulated deficit. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

NORDICUS PARTNERS CORP**Earnings, 3 mos. to Jun 30(Consol. - \$):**

	2023	2022
Cost & expenses	51,589	5,035,000
Operating income	(51,589)	(5,035,000)
Interest income	1,913	...
Other income (expense), net	9,380	...
Net before taxes	(40,296)	(5,035,000)
Net income	(40,296)	(5,035,000)
Earnings common share		
Primary	\$(0.89)	\$(0.89)
Fully Diluted	\$(0.89)	\$(0.89)
Common Shares:		
Full Diluted	8,570,973	5,681,248
Year-end	10,796,248	5,681,248

Consolidated Balance Sheet Items, as of (\$):

	2023
Assets:	
Cash & equivalents	32,040
Current assets	32,815
Total assets	1,785,454
Liabilities:	
Current liabilities	23,153
Stockholders' equity	1,762,301
Net current assets	9,662

NORFOLK SOUTHERN CORP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2023	2022
Total revenues	9,083,000	...
Cost & expenses	6,072,000	4,968,000
Operating income	2,043,000	3,628,000
Other income (expense), net	153,000	(21,000)
Net before taxes	1,669,000	3,092,000
Income taxes	369,000	612,000
Net income	1,300,000	2,480,000
Balance for common	1,300,000	...
Earnings common share		
Primary	\$5.71	\$10.49
Fully Diluted	\$5.70	\$10.45
Common Shares:		
Full Diluted	227,800	237,200
Year-end	226,136	231,514

NOVACCESS GLOBAL INC**Earnings, 9 mos. to Jun 30(Consol. - \$):**

	2023	2022
Cost & expenses	2,056,751	1,074,187
Operating income	(2,056,751)	(1,074,187)
Interest expense	857,742	1,152,731
Other income (expense), net	(42,788)	568,719
Net before taxes	(2,957,281)	...
Net income	(2,957,281)	(1,658,199)
Balance for common	(3,001,522)	(1,658,199)
Earnings common share		
Primary	\$(0.15)	\$(0.11)
Fully Diluted	\$(0.15)	\$(0.11)
Common Shares:		
Full Diluted	20,290,280	16,032,484
Year-end	21,535,457	18,534,090

OCUGEN INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Cost & expenses	56,908,000	60,718,000
Operating income	(56,908,000)	(60,718,000)
Other income (expense), net	3,323,000	1,306,000
Net before taxes	(53,585,000)	(59,412,000)
Net income	(53,585,000)	(59,412,000)
Balance for common	(53,585,000)	(59,412,000)
Earnings common share		
Primary	\$(0.22)	\$(0.28)

Fully Diluted	\$(0.22)	\$(0.28)
Common Shares:		
Full Diluted	240,222,667	212,755,746
Year-end	256,499,987	216,688,437

OPTIMIZERX CORP

Merger Completed On Oct. 24, 2023, a newly formed wholly owned subsidiary of Co. merged with and into Healthy Offers, Inc. (d/b/a Medix Health) ("Medix"), a healthcare consumer-focused omnichannel marketing and analytics company, with Medix continuing as the surviving corporation and became a wholly owned subsidiary of Co. As the result of the merger, Co. paid the Securityholders of Medix \$95,000,000, subject to certain customary post-acquisition purchase price adjustments.

ORBITAL INFRASTRUCTURE GROUP INC

Interest Sale Completed On Oct. 24, 2023, Ocelot Bidco LLC (the "FLP Buyer") acquired all the issued and outstanding membership interests of Front Line Power Construction, LLC ("FLP"), a Texas limited liability company and wholly owned subsidiary of Co. (the "FLP Purchase Agreement"), for aggregate consideration consisting of (i) the FLP Buyer's credit bid of approximately \$171,000,000 for certain prepetition obligations and approximately \$7,500,000 for the Front Line DIP Obligations (as defined in the FLP Purchase Agreement), (ii) \$2,000,000 cash and (iii) the release of certain guarantees in respect of the Prepetition Credit Agreement Claims and Prepetition Secured Promissory Note Obligations (in each case, as defined in the FLP Purchase Agreement). The FLP Buyer also agreed to waive and release all other claims against, and debts owing from, any of Co. and certain of its subsidiaries (collectively, the "Company Parties"), other than any obligations of Co. under the FLP Purchase Agreement that survive the closing of the transactions contemplated thereby pursuant to the terms of the FLP Purchase Agreement. Also, on Oct. 24, 2023, Streeterville Capital, LLC (the "GTS Buyer") acquired all the issued and outstanding shares of common stock of Gibson Technical Services, Inc. ("GTS"), a Georgia corporation and wholly owned subsidiary of Co. (the "GTS Purchase Agreement"), for aggregate consideration consisting of (i) the GTS Buyer's credit bid of approximately \$33,500,000 for certain secured prepetition obligations, (ii) the GTS Buyer's credit bid of \$6,500,000 for the DIP Obligations (as defined in the GTS Purchase Agreement) and (iii) \$1,700,000 in cash to be paid to Co.'s chapter 11 estate. The GTS Buyer also agreed to waive and release all other claims against, and debts owing from, any of Co. and certain of its subsidiaries (collectively, the "Company Parties"), other than Co.'s obligations arising under the GTS Purchase Agreement. As previously disclosed, the GTS Buyer and certain affiliates of Ocelot Bidco LLC (the "FLP Buyer") were parties to superpriority senior secured debtor-in-possession financing credit agreements to provide up to \$15,000,000 of incremental liquidity to Co.

OUTDOOR SPECIALTY PRODUCTS INC

New Auditor On Oct. 23, 2023, Co. dismissed Pinnacle Accountancy Group of Utah as its independent registered public accounting firm and engaged GreenGrowth CPAs as its new independent registered public accounting firm.

PAVMED INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	1,403,000	265,000
Net Sales	1,403,000	
Cost & expenses	52,299,000	65,410,000
Operating income	(56,083,000)	(66,423,000)
Interest income	408,000	
Interest expense	570,000	1,049,000
Other income (expense), net	(4,509,000)	(11,194,000)
Gains or losses	(4,772,000)	
Net before taxes	(61,855,000)	(78,666,000)
Net income	(61,855,000)	(78,666,000)
Balance for common	(50,365,000)	(68,732,000)
Earnings common share		
Primary	\$(0.48)	\$(0.78)
Fully Diluted	\$(0.48)	\$(0.78)
Common Shares:		
Full Diluted	104,516,464	87,724,124
Year-end	119,701,959	92,228,862

PERMIAN RESOURCES CORP

Merger Completed On Nov. 1, 2023, Co., Smits Merger Sub I Inc., a Delaware corporation and a direct wholly owned subsidiary of Co., Smits Merger Sub II LLC, a Delaware limited liability company and a direct wholly owned subsidiary of Co., and Permian Resources Operating, LLC, a Delaware limited liability company ("Permian OpCo") entered into an Agreement

and Plan of Merger (the "Merger Agreement") with Earthstone Energy, Inc., a Delaware corporation ("Earthstone") and Earthstone Energy Holdings, LLC, a Delaware limited liability company ("EEH"). Pursuant to the Merger Agreement, Earthstone and EEH became wholly owned subsidiaries of Co.

PERMIAN RESOURCES CORP

Official Changes On Nov. 1, 2023, Co. appointed Robert J. Anderson and Frost W. Cochran to its Board of Directors.

PFSWEB INC

Merger Completed On Oct. 23, 2023, GXO Logistics, Inc. ("Parent") wholly owned subsidiary, Peregrine MergerSub I, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly owned subsidiary of Parent. As the result of the merger, each issued and outstanding shares of the common stock, par value \$0.001 per share, of Co. Share was converted automatically into and thereafter represent only the right to receive \$7.50 in cash, without interest and subject to any applicable withholding taxes. In addition, (1) each stock option to purchase Shares that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested or exercisable, was automatically cancelled and converted into the right to receive an amount of cash from the Surviving Corporation equal to the product of (i) the total number of Shares then underlying such stock option multiplied by (ii) the excess, if any, of the same cash consideration, without interest and less any applicable withholding taxes, for their Shares as was payable in the Offer (the "Merger Consideration") over the exercise price per share of such stock option. If the exercise price of any such stock option was equal to or greater than the Merger Consideration, such stock option was cancelled for no consideration; (2) each deferred stock unit award in respect of Shares that was outstanding as of immediately prior to the Effective Time, whether or not vested, was automatically cancelled and converted into the right to receive an amount of cash from the Surviving Corporation equal to the product of (i) the total number of Shares then underlying such deferred stock unit award multiplied by (ii) the Merger Consideration; (3) each other stock-based award in respect of Shares (including each restricted stock unit award and each performance-based restricted stock unit award) that was outstanding as of immediately prior to the Effective Time was automatically cancelled and converted into the right to receive an amount of cash from the Surviving Corporation equal to the product of (i) the number of Shares determined to be earned underlying such other stock-based award multiplied by (ii) the Merger Consideration. The number of Shares underlying each other stock-based award that was subject to performance-based vesting conditions was determined by measuring the level of achievement of the applicable performance goals in accordance with the provisions of the applicable award agreements. The aggregate consideration payable by Merger Sub to acquire the shares of Common Stock in the Offer and the Merger was approximately \$170,800,000.

PFSWEB INC

Official Changes On Oct. 23, 2023, Co. announced the resignations of Mr. David I. Beatson, Mr. Robert Frankfurt, Ms. G. Mercedes De Luca, Ms. Monica Luechtefeld, Mr. Benjamin Rosenzweig and Mr. Michael C. Willoughby from its Board of Directors. Also, on Oct. 23, 2023, Co. announced the terminations of Mr. Michael J. Willoughby as Co.'s Chief Executive Officer and Thomas J. Madden as Chief Financial Officer. Also, on Oct. 23, 2023, Co. announced the appointment of Mr. Karlis P. Kirsis as Co.'s Vice President, Secretary and Board of Directors. Also, on Oct. 23, 2023, Co. announced the appointment of Mr. Zeeshan Naqvi as Co.'s President, Treasurer and Board of Directors.

PHARMACYTE BIOTECH INC

Earnings, 3 mos. to Jul 31(Consol. - \$):

	2023	2022
Cost & expenses	2,075,326	1,680,608
Operating income	(2,075,326)	(1,680,608)
Interest income	875,878	139,502
Other income (expense), net	(1,983,849)	(3,906)
Net income	(3,183,297)	(1,545,012)
Balance for common	(3,503,146)	
Earnings common share		
Primary	\$(0.28)	\$(0.07)
Fully Diluted	\$(0.28)	\$(0.07)
Common Shares:		
Full Diluted	12,601,891	20,829,315
Year-end	8,778,101	20,750,068

Consolidated Balance Sheet Items, as of (\$):

Assets:	2023
Cash & equivalents	74,662,527
Current assets	74,751,177
Total assets	79,880,485
Liabilities:	

Current liabilities	1,518,015
Stockholders' equity	42,730,395
Net current assets	73,233,162

PHUNWARE INC

Official Changes On Oct. 25, 2023, Co. announced the termination of Mr. Russell Buyse as Co.'s Chief Executive Officer. On Oct. 26, 2023, Co. announced the resignations of Mr. Russell Buyse and Ms. Kathy Tan Mayor from its Board of Directors. On Oct. 25, 2023, Co. announced the appointment of Mr. Michael Snavely, Co.'s Chief Revenue Officer as its Chief Executive Officer.

PLUS THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Total revenues	3,600,000	
Net Sales	3,600,000	
Cost & expenses	13,061,000	14,213,000
Operating income	(9,461,000)	(14,140,000)
Interest income	290,000	74,000
Interest expense	333,000	552,000
Other income (expense), net		1,000
Gains or losses	(2,000)	
Net before taxes	(9,506,000)	
Net income	(9,506,000)	(14,617,000)
Balance for common	(9,506,000)	
Earnings common share		
Primary	\$(3.54)	\$(9.15)
Fully Diluted	\$(3.54)	\$(9.15)
Common Shares:		
Full Diluted	2,688,232	1,585,946
Year-end	4,522,656	2,171,333

PODCASTONE INC**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	03/31/22	03/31/21	06/30/20
Revenue	32,348	19,675	4,165
Cost of sales	26,271	15,368	2,911
Sales & marketing	5,155	3,077	915
Product development	251	495	149
General & administrative	4,871	2,359	1,354
Amortization of intangible assets	502	448	
Total operating expenses	37,050	21,747	5,329
Income (loss) from operations	(4,702)	(2,072)	(1,164)
Interest expense, net	5	4	1
Forgiveness of Paycheck Protection Program loans	1,103		
Other income (expense)		(23)	
Total other income (expense), net	1,098	(27)	(1)
Income (loss) before income taxes			
- Domestic	(3,604)	(2,095)	(1,169)
Income (loss) before provision (benefit) for income taxes	(3,604)	(2,099)	(1,165)
Current state income taxes		(4)	4
Total current provision (benefit) for income taxes		(4)	4
Deferred U.S. Federal income taxes	(873)	(22)	(1,597)
Deferred state income taxes	(6)	(2)	(98)
Valuation allowance	879	24	1,695
Provision (benefit) for income taxes		(4)	4
Net income (loss)	(3,604)	(2,095)	(1,169)
Weighted average shares outstanding			
- basic	147,984	147,984	147,984
Weighted average			

shares outstanding			
- diluted	147,984	147,984	147,984
Year end shares outstanding	147,984	147,984	147,984
Net earnings (loss) per share - basic	\$(0.02)	\$(0.01)	\$(0.01)
Net earnings (loss) per share - diluted	\$(0.02)	\$(0.01)	\$(0.01)
Number of full time employees	44	44	...

□ Successor; □ 2022 and prior periods for Courtside Group, Inc.;
□ Predecessor

Consolidated Balance Sheet, Years Ended Mar. 31 (\$000):

	2022	2021
Cash & cash equivalents	1,103	3,374
Accounts receivable, gross	8,094	4,025
Less: allowance for doubtful accounts	99	37
Accounts receivable, net	7,995	3,988
Prepaid expense & other current assets	543	291
Total current assets	9,641	7,653
Computer, machinery, & software equipment	109	96
Furniture & fixtures	14	14
Leasehold improvements	24	24
Capitalized internally developed software	343	72
Total property & equipment	490	206
Less accumulated depreciation & amortization	243	111
Property & equipment, net	247	95
Goodwill	12,041	12,041
Intangible assets, net	831	1,334
Related party receivable	1,167	4,204
Total assets	23,927	25,327
Accounts payable	2,453	1,917
Accrued revenue share	3,391	2,270
Other accrued liabilities	1,554	977
Accounts payable & accrued liabilities	6,998	5,164
Notes payable	1,098
Related party payable	3,844	4,902
Total liabilities	10,842	11,164
Additional paid in capital	18,784	16,258
Retained earnings (accumulated deficit)	(5,699)	(2,095)
Total stockholders' equity	13,085	14,163

□ 2022 and prior periods for Courtside Group, Inc.; □ As reported by the Company

Recent Dividends:

1. PodcastOne Inc common.
No dividends paid.

Annual Dividends:

1. PodcastOne Inc common.
No dividends paid.

PODCASTONE INC

Auditor's Report Auditor's Report

22,527.403 The following is an excerpt from the Report of the Independent Auditors, Macias Gini & O'Connell LLP, as it appeared in Co.'s 2022 Prospectus: "Opinion on the Financial Statements We have audited the accompanying restated consolidated balance sheets of Courtside Group, Inc. (a subsidiary of LiveOne, Inc.) (the "Company") as of March 31, 2022 and 2021, the related restated consolidated statements of operations, stockholders' equity, and cash flows for the year ended March 31, 2022 and for the period from July 1, 2020 to March 31, 2021 (Successor) and the period from April 1, 2020 to June 30, 2020 (Predecessor), and the related notes (collectively referred to as the "restated consolidated financial statements"). In our opinion, the restated consolidated financial statements present fairly, in all material respects, the restated consolidated financial position of the Company as of

March 31, 2022 and 2021, and the restated consolidated results of its operations and its cash flows for the period from July 1, 2020 to March 31, 2021 (Successor) and for the period from April 1, 2020 to June 30, 2020 (Predecessor), in conformity with accounting principles generally accepted in the United States of America. Restatement As discussed in Note 3 to the restated consolidated financial statements, the 2022 and 2021 financial statements have been restated to correct an error. We have also audited the adjustments described in Note 3 that were applied to restate the 2022 and 2021 consolidated financial statements to correct errors. In our opinion, such adjustments are appropriate and have been properly applied. Our opinion is not modified in respect of this matter. Substantial Doubt About the Company's Ability to Continue as a Going Concern The accompanying restated consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the restated consolidated financial statements, the Company has suffered recurring losses from operations, negative cash flows from operations and has an accumulated deficit. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters also are described in Note 1. The restated consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

PODCASTONE INC

Earnings, 9 mos. to Dec 31 (Consol. - \$000):

	2022	2021
Total revenues	25,802	24,131
Cost & expenses	26,742	27,089
Operating income	(1,016)	(3,389)
Interest expense	3,043	4
Other income (expense), net	1,043	498
Net before taxes	(3,016)	(2,895)
Net income	(3,016)	(2,895)
Earnings common share		
Primary	\$(0.02)	\$(0.02)
Fully Diluted	\$(0.02)	\$(0.02)
Common Shares:		
Full Diluted	140,511	147,984
Year-end	20,000	147,984

PUBLIC SHREK ROYALTIES LLC

History: Incorporated in Delaware on Sep. 12, 2022.

Business Summary: Public Shrek Royalties facilitates an investment in 25% of the right, title and interest of composer Harry Gregson-Williams, along with a security interest, in the songwriter's life of rights share of all public performance royalties attributable to works related to the Shrek franchise by conducting an offering of its membership interests pursuant to a Tier II offering under Regulation A+ of the Securities Act of 1933, acquiring such royalty interest and holding such interest for future royalties. Co. is engaged in the activities related to the offering and the acquisition of, ownership of, earning from, promotion of and eventual sale of the royalty interest.

Property: Co. maintains its principal executive offices in New York, NY.

Officers

Keith Marshall, President; Secretary; Treasurer

Directors

Keith Marshall, Director

Auditors: Artesian CPA, LLC

Legal Counsel: CrowdCheck Law LLP

Transfer Agent: Otis Secure LLC

Address: 6 Harrison Street 5th Floor, New York, NY 10013

Tel: 201 479-4408

Web: www.public.com

Email: alts@public.com

Consolidated Income Statement, Years Ended Oct. 30 (\$):

	2023
Year end shares outstanding	88,970

□ From September 12, 2022 (inception)

Consolidated Balance Sheet, Years Ended Oct. 30 (\$):

	2023
Royalty interest	868,000
Total current assets	868,000

Total assets	868,000
Contributions, net	868,000
Total liabilities	868,000

Capital Stock: 1. Public Shrek Royalties LLC common; no par.

OUTSTANDING—Oct. 30, 2023, 88,970 shs; no par.

PURE BIOSCIENCE INC

Annual Report

Consolidated Income Statement, Years Ended Jul. 31 (\$):

	2023	2022	2021
Impairment of tangible assets	315,000
Net product sales	1,871,000	1,813,000	3,698,000
Royalty revenue	6,000	40,000	229,000
Total revenues	1,877,000	1,853,000	3,927,000
Cost of goods sold	906,000	853,000	1,852,000
Gross profit	971,000	1,000,000	2,075,000
Selling, general & administrative	4,302,000	4,106,000	4,047,000
Research & development	297,000	319,000	339,000
Impairment of intangibles	299,000	...
Total operating costs & expenses	4,914,000	4,724,000	4,386,000
Income (loss) from operations	(3,943,000)	(3,724,000)	(2,311,000)
Interest expense, net	6,000	4,000
Interest income (expense), net	(14,000)
Other income (expense), net	(4,000)	...	(4,000)
Gain on extinguishment of indebtedness, net	239,000	...
Total other income (expense)	(18,000)	233,000	(8,000)
Net income (loss) before income taxes	(3,961,000)
Net income (loss)	(3,961,000)	(3,491,000)	(2,319,000)
Weighted average shares outstanding			
- basic	111,404,418	88,835,424	87,174,312
Weighted average shares outstanding - diluted	111,404,418	88,835,424	87,174,312
Year end shares outstanding	111,856,473	111,356,473	87,223,141
Net income (loss) per share - basic	\$(0.04)	\$(0.04)	\$(0.03)
Net income (loss) per share - diluted	\$(0.04)	\$(0.04)	\$(0.03)
Number of full time employees	11	15	10
Number of part time employees	1	1	1
Number of common stockholders	219	219	214

□ Shares increased due to the effect of issuance of common stock in private placements to related parties and issuance of common stock for vested restricted stock units; □ As of October 28, 2022; □ As of October 28, 2021; □ Approximately

Consolidated Balance Sheet, Years Ended Jul. 31 (\$):

	2023	2022
Cash & cash equivalents	1,095,000	3,391,000
Accounts receivable, gross	201,000
Less allowance for doubtful accounts	0
Accounts receivable	285,000	201,000
Raw materials	11,000	19,000
Finished goods	77,000	160,000
Inventories, net	88,000	179,000
Restricted cash	75,000	75,000
Prepaid expenses	61,000	18,000
Total current assets	1,604,000	3,864,000
Computers & equipment	1,582,000

Construction in progress	78,000	
Website	1,615,000	
Property, plant & equipment, gross	1,615,000	1,660,000
Less: accumulated depreciation	1,394,000	1,040,000
Property, plant & equipment, net	221,000	620,000
Total assets	1,825,000	4,484,000
Accounts payable	422,000	488,000
Accrued liabilities	110,000	87,000
Total current liabilities	532,000	575,000
Total Non-current Liabilities	1,021,000	
Total liabilities	1,553,000	575,000
Common stock	1,119,000	1,114,000
Additional paid-in capital	132,398,000	132,079,000
Retained earnings (accumulated deficit)	(133,245,000)	(129,284,000)
Total stockholders' equity (deficit)	272,000	3,909,000
Rep Total Equity & Minority Interest	272,000	

Recent Dividends:**1. PURE Bioscience Inc common.**

No dividends paid.

Annual Dividends:**1. PURE Bioscience Inc common.**

No dividends paid.

PURE BIOSCIENCE INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Weinberg and Company, P.A., as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Pure Bioscience Inc. (the "Company") and Subsidiaries as of July 31, 2023 and 2022, and the related statements of operations, stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of July 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and negative cash flows from operating activities that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

QUALSTAR CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2022	2021	2020 (revised)
Net revenues	9,845	9,164	8,097
Cost of goods sold	6,850	5,997	5,790
Gross profit (loss)	2,995	3,167	2,307
Engineering expenses	336	451	501
Sales & marketing expenses		1,476	1,516
General & administrative expenses	1,215	809	1,551
General & administrative expenses	1,352		
Total operating expenses	2,903	2,736	3,568
Income (loss) from operations	92	431	(1,261)
Other income (expenses)	(32)	2	7
Income (loss) before income taxes	60	433	(1,254)

Current state provision (benefit) for income taxes	5	3	4
Current provision (benefit) for income taxes	5	3	4
Provision (benefit) for income taxes	5	3	4
Net income (loss)	55	430	(1,258)
Weighted average shares outstanding	1,829	1,934	1,926
Weighted average shares outstanding - diluted	1,829	1,934	1,926
Year end shares outstanding	1,627	1,884	1,950
Net income (loss) per share - basic	\$0.03	\$0.22	\$(0.65)
Net income (loss) per share - diluted	\$0.03	\$0.22	\$(0.65)
Number of common stockholders		23	24
Net sales	9,845		

¹ Adjusted for 1-for-1,000 stock split, Setember 27, 2022; ² Adjusted for 1,000-for-1 stock split, Setember 27, 2022; ³ As is; ⁴ Approximately; ⁵ As of March 28, 2022; ⁶ As of March 23, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2022	2021
Cash & cash equivalents	2,767	4,095
Restricted cash		100
Marketable securities, short-term	33	
Accounts receivable, net	1,643	1,354
Raw materials	145	164
Finished goods	2,891	2,218
Inventories, net	3,036	2,276
Prepaid expenses & other current assets	138	304
Total current assets	7,617	8,129
Machinery & equipment	382	382
Furniture & fixtures & computer equipment	258	258
Leasehold improvements	119	119
Property & equipment, gross	759	759
Less: accumulated depreciation & amortization	677	635
Property & equipment, net	82	124
Right-of-use asset	243	300
Deferred tax assets	30	30
Other assets	71	24
Total assets	8,043	8,607
Accounts payable	946	977
Accrued salaries, wages & payroll taxes	32	82
Accrued vacation		106
Accrued bonuses	108	
Accrued other payroll & related liabilities	140	
Accrued payroll & related liabilities		188
Deferred service revenue	687	622
Lease liabilities, short term	165	117
Accrued warranty		142
Accrued outside commissions		26
Total current liabilities	2,071	2,072
Lease liabilities, long term	95	204
Deferred service revenue, long-term	510	447
Other long-term liabilities	27	28
Total long-term liabilities	632	679
Total liabilities	2,703	2,751

Common stock	18,218	18,789
Retained earnings (accumulated deficit)	(12,878)	(12,933)
Total stockholders' equity (deficit)	5,340	5,856
Total Equity	5,340	

As reported by the Company

Recent Dividends:**1. Qualstar Corp common.**

No dividends paid.

Annual Dividends:**1. Qualstar Corp common.**

No dividends paid.

QUALSTAR CORP**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2023	2022
Total revenues	4,070,000	4,273,000
Net Sales	4,070,000	
Cost & expenses	4,398,000	4,556,000
Operating income	(328,000)	(283,000)
Interest income	4,000	
Other income (expense), net		(67,000)
Gains or losses	26,000	
Net before taxes	(290,000)	(350,000)
Net income	(290,000)	(350,000)
Earnings common share		
Primary	\$(0.18)	\$(0.19)
Fully Diluted	\$(0.18)	\$(0.19)

Common Shares:

Full Diluted	1,603,000	1,884,000
Year-end	1,578,035	1,884,033

QUALSTAR CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2023	2022
Total revenues	7,212,000	7,019,000
Net Sales	7,212,000	
Cost & expenses	7,382,000	7,154,000
Operating income	(170,000)	(135,000)
Interest income	24,000	
Other income (expense), net		(84,000)
Gains or losses	41,000	
Net before taxes	(129,000)	(219,000)
Net income	(129,000)	(219,000)

Earnings common share

Primary	\$(0.08)	\$(0.12)
Fully Diluted	\$(0.08)	\$(0.12)

Common Shares:

Full Diluted	1,594,000	1,875,000
Year-end	1,572,890	1,749,345

REGULUS THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2023	2022
Cost & expenses	22,809	21,307
Operating income	(22,809)	(21,307)
Net before taxes	(21,975)	(21,527)
Income taxes	1	1
Net income	(21,976)	(21,528)

Earnings common share

Primary	\$(1.19)	\$(1.46)
Fully Diluted	\$(1.19)	\$(1.46)

Common Shares:

Full Diluted	18,535	14,728
Year-end	20,223	16,840

RENOVARO BIOSCIENCES INC**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$):**

	2023	2022	2021 (revised)
General & administrative expenses	15,318,198	14,329,801	7,557,990
Research & development expenses	4,165,197	8,372,800	15,720,262
Indefinite life intangible assets impairment charge		93,253,000	
Amortization expense	6,175		

Depreciation and amortization	107,321
Depreciation & amortization	113,496	123,590	123,535
Total operating expense	38,556,891	116,079,191	23,401,787
Income (loss) from operations	(38,556,891)	(116,079,191)	(23,401,787)
Change in fair value of contingent consideration	...	2,896,627	(3,048,033)
Interest expense	580,344	372,844	379,608
Impairment of tangible assets	18,960,000
Gain (loss) on currency transactions	(1,019)	9	(32,634)
Interest & other income	...	122,041	13,179
Interest income and other income (expense)	(126,620)
Loss on extinguishment of contingent liability	(419,182)
Total other income (expense)	(1,127,165)	2,645,833	(3,447,096)
Income (loss) before income taxes	(39,684,056)	(113,433,358)	(26,848,883)
Income tax expense (benefit)	...	34	(125,276)
Net income (loss)	(39,684,056)	(113,433,392)	(26,723,607)
Net income (loss) attributable to common stockholders	(39,684,056)
Weighted average shares outstanding - basic	56,265,362	52,528,024	47,167,262
Weighted average shares outstanding - diluted	56,265,362	52,528,024	47,167,262
Year end shares outstanding	63,698,144	53,007,082	52,219,661
Net income (loss) per share - basic	\$(0.71)	\$(2.16)	\$(0.57)
Net income (loss) per share - diluted	\$(0.71)	\$(2.16)	\$(0.57)
Number of full time employees	12	...	11
Number of part time employees	...	22	...
Number of common stockholders	194	190	227
Foreign currency translation adjustments	554	(19,602)	30,582

□ Reclassified to conform with 2022 presentation; □ Approximately; □ As of February 27, 2023; □ As of September 28, 2021

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2023	2022
Cash	1,874,480	9,172,142
Prepaid expenses	690,925	...
Prepays & other assets	...	392,996
Total current assets	2,565,405	9,565,138
Lab equipment & instruments	576,298	546,524
Leasehold improvements	224,629	224,629
Furniture, fixtures & equipment	172,861	172,861
Property & equipment, gross	973,788	944,014
Less: accumulated depreciation	464,799	357,478
Property & equipment, net	508,989	586,536
Definite-life intangible assets, net	39,676	44,268
Indefinite life intangible assets	42,611,000	61,571,000
Goodwill	11,640,000	11,640,000

Deposits & other assets	21,741	68,635
Operating lease right-of-use assets	913,985	1,157,086
Total assets	58,300,796	84,632,663
Accounts payable - trade	...	1,401,867
Accounts payable - non-trade	5,296,823	...
Accrued expenses	723,173	1,031,462
Other current liabilities	184,733	220,685
Contingent consideration liability	...	2,343,318
Convertible notes payable	...	1,200,000
Current portion of operating lease liabilities	193,422	253,636
Notes payable, net	4,624,947	...
Total current liabilities	11,023,098	6,450,968
Notes payable, net	...	4,577,148
Operating lease liabilities, net of current maturities	775,587	985,699
Total non-current liabilities	775,587	5,562,847
Total liabilities	11,798,685	12,013,815
Common stock	6,371	5,302
Additional paid-in capital	290,554,875	276,989,179
Retained earnings (accumulated deficit)	(244,029,253)	(204,345,197)
Accumulated other comprehensive income (loss)	(29,882)	(30,436)
Total stockholder's equity (deficit)	46,502,111	72,618,848

Recent Dividends:

1. Renovaro Biosciences Inc common.
No dividends paid.

Annual Dividends:

1. Renovaro Biosciences Inc common.
No dividends paid.

RENOVARO BIOSCIENCES INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Sadler, Gibb & Associates, LLC, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Renovaro Biosciences, Inc. ("the Company") as of June 30, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows for each of the years in the two-year period ended June 30, 2023 and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of June 30, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended June 30, 2023, in conformity with accounting principles generally accepted in the United States of America. Explanatory Paragraph Regarding Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Notes 1 and 2 to the financial statements, the Company has incurred substantial recurring losses from operations and has a net capital deficiency which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Notes 1 and 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

REVIVA PHARMACEUTICALS HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	29,515,151	16,532,598
Operating income	(29,515,151)	(16,532,598)
Other income (expense), net	(321,192)	267,031
Net before taxes	(29,514,903)	(16,208,606)
Income taxes	21,531	12,414
Net income	(29,536,434)	(16,221,020)
Earnings common share		
Primary	\$(1.30)	\$(0.87)
Fully Diluted	\$(1.30)	\$(0.87)
Common Shares:		
Full Diluted	22,775,407	18,737,330
Year-end	20,650,266	20,442,871

SALARIUS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	11,924,243	25,363,260
Operating income	(11,924,243)	(25,363,260)
Interest income	263,346	...
Other income (expense), net	...	12,570
Net before taxes	(11,660,897)	(25,237,020)
Income contin. oper.	(11,660,897)	...
Net income	(11,660,897)	(25,237,020)
Balance for common	(11,660,897)	...
Earnings common share		
Primary	\$(3.84)	\$(12.13)
Fully Diluted	\$(3.84)	\$(12.13)
Common Shares:		
Full Diluted	3,037,547	2,081,023
Year-end	3,938,433	2,249,371

SAVMOBI TECHNOLOGY INC

Annual Report

Consolidated Income Statement, Years Ended May 31 (\$):

	2023	2022	2021
Net revenues	3,723,088
Revenues	3,723,088	...	10,000
Cost o revenues	4,132,481	...	3,000
Gross profit	(409,393)	...	7,000
General & administrative expenses	4,481,871	43,026	48,477
Selling and marketing expenses	456,023
Research and development expenses	396,849
Impairment reversal/loss	922,434
Tax and surcharges	(24,201)
Total operating expenses	6,281,378	43,026	48,477
Operating income/(loss)	(6,690,771)
Interest income	440
Other income (expense)	(92,968)
Total other income (expense)	(92,528)
Income (Loss) before provision for income taxes	(6,783,299)
Net income (loss)	(6,783,522)	(43,026)	(41,477)
Net income (loss) attributable to owners of the company	(6,395,388)
Non-controlling interest	388,134
Weighted average shares outstanding - basic	467,379,452	61,900,000	61,900,000
Weighted average shares outstanding - diluted	467,379,452	61,900,000	61,900,000
Year end shares outstanding	1,061,900,000	61,900,000	61,900,000
Net earnings (loss) per common share - basic	\$(0.01)	\$0.00	\$0.00
Net earnings (loss) per common share - diluted	\$(0.01)	\$0.00	\$0.00
Total number of employees	4
Number of common stockholders	15,032	21	...
Provision for income taxes	223
Owners of the Company	(6,395,388)

□ As of September 11, 2022

Consolidated Balance Sheet, Years Ended May 31 (\$):

	2023	2022
--	------	------

Cash & cash equivalents	483,705	...
Prepaid expenses	1,029,533	35
Accounts receivable	409,380	...
Restricted cash	10,273	...
Inventories	177,034	...
Advances to employees	125,508	...
Amount due from related parties	16,000	...
VAT	39	...
Other	157,164	...
Loan receivable	342,882	...
Deposit	366,478	...
Total current assets	3,117,996	35
At May 31,2023	962,271	...
At May 31,2023	4,437,065	...
At May 31,2023	123,212	...
At May 31,2023	972,730	...
At May 31,2023	3,039,646	...
At May 31,2023	902,974	...
At May 31,2023	579,952	...
At May 31,2023	1,363,248	...
At May 31,2023	106,927	...
Plant and equipment, net	6,581,823	...
Intangible assets, net	15,543	...
Right-of-use assets	277,184	...
Other non-current assets	2,884,090	...
Total non-current assets	9,758,640	...
Total assets	12,876,636	35
Accounts payable	775,293	...
Accounts payable & accrued liabilities	...	8,000
Amounts due to related parties	1,057,721	...
Other	520,883	...
Other current liabilities	...	1
Advances from customers	622,069	...
Operating lease liabilities, current	126,659	...
Taxes payable	18,737	...
Accrued payroll and welfare payables	338,657	...
Loans payable	344,585	...
Deposit	27,194	...
Advanced to employees	70,305	...
Total current liabilities	3,902,103	8,001
Long-term loan	32,740,623	...
Operating lease liabilities	121,555	...
Total non-current liabilities	32,862,178	...
Total Liabilities including Debt - Short-Term & Long-Term	36,764,281	...
Common stock	1,061,900	61,900
Additional paid in capital	8,474,336	190,734
Retained earnings (accumulated deficit)	(32,751,349)	(260,600)
Accumulated other comprehensive income	344,031	...
Total stockholders' equity (deficit)	(22,871,082)	(7,966)
Non-controlling interest	(1,016,563)	...
Total capital/total equity/total partners' capital	(23,887,645)	...

Recent Dividends:

1. SavMobi Technology Inc common.
No dividends paid.

Annual Dividends:

1. SavMobi Technology Inc common.
No dividends paid.

SAVMOBI TECHNOLOGY INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Pan-China Singapore PAC, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheets of SavMobi Technology Inc. (the Company) as of May 31, 2023 and 2022, and the related consolidated statement of operations and comprehensive income (loss), changes in equity, and cash flow for year ended May 31, 2023 and 2022, and the related notes (collectively referred to as the financial

statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of May 31, 2023 and 2022, and the result of its operations and its cash flow for the year then ended May 31, 2023 and 2022, in conformity with accounting principles generally accepted in the United States. Explanatory Paragraph Regarding Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company had incurred substantial losses during the year, and has a working capital deficit, which raises substantial doubt about its ability to continue as a going concern. Management's plan in regards to these matters are described in Note 3. These financial statements do not include any adjustments that might result from the outcome of this uncertainty."

SEMLER SCIENTIFIC INC

Official Changes On Oct. 19, 2023, Dr. Arthur "Abbie" Leibowitz stepped down from Co.'s Board of Directors.

SEQLL INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Total revenues	78,659	...
Net Sales	1,177	...
Cost & expenses	3,202,231	1,911,816
Operating income	(3,202,231)	(1,833,157)
Interest expense	39,654	56,372
Other income (expense), net	54,508	...
Gains or losses	123,405	(106,324)
Net before taxes	(3,118,480)	...
Net income	(3,118,480)	(1,932,869)
Earnings common share		
Primary	\$(9.20)	\$(6.40)
Fully Diluted	\$(9.20)	\$(6.40)
Common Shares:		
Full Diluted	334,729	297,159
Year-end	347,159	297,159

SHUTTLE PHARMACEUTICALS HOLDINGS INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2023	2022
Cost & expenses	3,010,411	992,022
Operating income	(3,010,411)	(992,022)
Interest income	35,955	...
Other income (expense), net	1,148,751	54,235
Gains or losses	1,744	...
Net before taxes	(1,279,114)	...
Net income	(3,159,468)	(1,279,114)
Balance for common	(3,159,468)	(1,330,650)
Earnings common share		
Primary	\$(0.23)	\$(0.14)
Fully Diluted	\$(0.23)	\$(0.14)
Common Shares:		
Full Diluted	13,950,355	9,312,583
Year-end	15,482,038	9,312,991

SHUTTLE PHARMACEUTICALS HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	4,609,558	1,813,490
Operating income	(4,609,558)	(1,813,490)
Interest income	56,720	...
Other income (expense), net	1,557,843	495,719
Gains or losses	1,744	...
Net before taxes	(4,952,223)	(2,277,539)
Net income	(4,952,223)	(2,277,539)
Balance for common	(4,952,223)	(2,348,548)
Earnings common share		
Primary	\$(0.34)	\$(0.23)
Fully Diluted	\$(0.34)	\$(0.23)
Common Shares:		
Full Diluted	14,554,878	9,723,510
Year-end	15,999,125	13,586,393

SKINVISIBLE INC

New Auditor On Oct. 17, 2023, Co. dismissed Gries & Associates, LLC as its independent registered public accounting firm and engaged GreenGrowth CPAs as its new independent registered public accounting firm.

SKYWARD SPECIALTY INSURANCE GROUP INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2023	2022
Total revenues	400,451	296,960
Cost & expenses	355,713	270,023
Operating income	44,738	26,937

Net before taxes	44,738	26,937
Income taxes	9,730	5,561
Net income	35,008	21,376
Balance for common	33,606	11,093
Earnings common share		
Primary	\$0.97	\$0.67
Fully Diluted	\$0.93	\$0.66
Common Shares:		
Full Diluted	37,504	32,600
Year-end	37,674	...

SMITH (A O) CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2023	2022
Total revenues	2,864,700	...
Net Sales	2,864,700	2,817,800
Cost & expenses	2,308,100	2,351,200
Operating income	556,600	466,600
Net before taxes	556,600	466,600
Income taxes	137,300	110,800
Net income	419,300	355,800
Earnings common share		
Primary	\$2.79	\$2.29
Fully Diluted	\$2.77	\$2.27
Common Shares:		
Full Diluted	151,548	156,663
Year-end	151,179	152,776

SMITH MICRO SOFTWARE INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2023	2022
Total revenues	32,269	37,108
Net Sales	32,269	...
Cost & expenses	39,755	56,119
Operating income	(12,358)	(23,777)
Other income (expense), net	(3,047)	3,445
Gains or losses	3,486	...
Net before taxes	(17,659)	(21,230)
Income taxes	25	77
Net income	(17,684)	(21,307)
Balance for common	(17,684)	...
Earnings common share		
Primary	\$(0.28)	\$(0.39)
Fully Diluted	\$(0.28)	\$(0.39)
Common Shares:		
Full Diluted	62,297	55,140
Year-end	70,385	56,261

SPECTAIRE HOLDINGS INC

New Name On Oct. 20, 2023, Co. changed its name from Perception Capital Corp II to Spectaire Holdings Inc.

SPECTAIRE HOLDINGS INC

Stock Trading Symbol Stock symbol, SPEC.

STAFFING 360 SOLUTIONS INC**Annual Report**

Consolidated Income Statement, Years Ended (\$):

	12/31/22	01/01/22	01/02/21
			(revised)
Net sales	244,917,000
Revenue	244,917,000	197,770,000	204,527,000
Cost of revenue, excluding depreciation & amortization stated below	202,148,000	163,903,000	169,714,000
Gross profit (loss)	42,769,000	33,867,000	34,813,000
Selling, general & administrative expenses	43,236,000	35,305,000	37,506,000
Impairment of goodwill	10,000,000	3,104,000	2,969,000
Depreciation & amortization expenses	2,990,000	2,758,000	3,118,000
Amortization of intangible	2,464,000
Depreciation	526,000
Total operating expenses	56,226,000	41,167,000	43,593,000
Income (loss) from operations	(13,457,000)	(7,300,000)	(8,780,000)
Interest expense	3,881,000	3,856,000	7,195,000
Amortization of debt discount &

deferred financing costs	359,000	559,000	per share - diluted	\$(8.04)	\$3.70	ⒶⒷ\$(158.40)
Re-measurement gain (loss) on intercompany note	260,000	(584,000)	Number of full time employees	265	Ⓐ200	Ⓐ200
Gain (loss) on business sale	124,000		Number of common stockholders	504	ⒶⒷ502	ⒶⒷ514
Interest expense - restructuring	604,000	41,000	Foreign currency translation adjustments	(2,381,000)	(61,000)	281,000
Paycheck protection program ("PPP") forgiveness gain	19,609,000		Ⓐ Adjusted for 1-or-6 stock split, July 1, 2021; Ⓑ Adjusted for 1-for-10 stock split, June 24, 2022; Ⓒ Shares increased due to issuance of shares to employees, directors and consultants, to related party from debt arrangement, for series A preferred conversion and for sales of shares; Ⓓ Approximately; Ⓔ As of June 24, 2022; Ⓕ As of April 15, 2021			
Other income (expense), net	726,000	(33,000)	Consolidated Balance Sheet, Years Ended (\$):			
Total other income (expenses), net	(3,759,000)	15,101,000			12/31/22	01/01/22
Income (loss) before provision for income taxes - domestic	(9,543,000)	14,413,000	Cash	1,992,000	4,558,000	
Income (loss) before provision for income taxes - foreign	(7,673,000)	(6,612,000)	Accounts receivables, gross	23,730,000	20,778,000	
Income (loss) before provision for income tax	(17,216,000)	7,801,000	Less: allowance for doubtful accounts	102,000	60,000	
Current state provision (benefit) for income taxes	349,000	84,000	Accounts receivable, net	23,628,000	20,718,000	
Total current provision (benefit) for income taxes	349,000	84,000	Prepaid expenses & other current assets	1,762,000	988,000	
Deferred federal provision (benefit) for income taxes	(29,000)	14,000	Total current assets	27,382,000	26,264,000	
Deferred state provision (benefit) for income taxes	(154,000)	66,000	Computer software	1,323,000	432,000	
Deferred foreign provision (benefit) for income taxes	(388,000)	(521,000)	Office equipment	667,000	587,000	
Total deferred provision (benefit) for income taxes	(571,000)	(441,000)	Computer equipment	...	702,000	
Provision (benefit) for income taxes	(222,000)	(357,000)	Furniture & fixtures	1,434,000	1,181,000	
Reported Comprehensive Income	(16,994,000)	...	Leasehold improvements	1,250,000	650,000	
Net income (loss)	(16,994,000)	8,158,000	Website	662,000	...	
Dividends - series A preferred stock - related party	...	125,000	Total property & equipment, gross	5,336,000	3,552,000	
Dividends - series E preferred stock - related party	319,000	2,472,000	Less: accumulated depreciation	4,105,000	2,687,000	
Dividends - series E-1 preferred stock - related party	192,000	756,000	Property & equipment, net	1,230,000	865,000	
Dividends - series G preferred stock - related party	166,000	...	Goodwill	19,891,000	23,828,000	
Dividends - series G-1 preferred stock - related party	118,000	...	Intangible assets, net	17,385,000	13,649,000	
Deemed dividend	1,798,000	4,690,000	Collateral associated with wokmans' compensation insurance	...	3,072,000	
Earnings allocated to participating securities	2,395,000	...	Other non-current assets	...	434,000	
Net income (loss) attributable to common stockholders	(16,994,000)	3,170,000	Right of use assets	9,070,000	5,578,000	
Weighted average shares outstanding - diluted	2,113,509	952,207	Total assets	81,659,000	73,690,000	
Weighted average shares outstanding - basic	2,113,509	1,062,541	Accounts payable	1,168,000	2,749,000	
Year end shares outstanding	2,629,199	1,758,835	Accrued payroll, taxes & bonuses	...	8,594,000	
Net income (loss) per share - basic	\$(8.04)	\$3.30	Other accrued expenses	3,520,000	1,189,000	
Net income (loss) per share - diluted	\$(158.40)	...	Accrued expenses - related party	218,000	216,000	

Recent Dividends:		
1. Staffing 360 Solutions Inc common.		
No dividends paid.		
2. Staffing 360 Solutions Inc series A preferred.		
No dividends paid.		
3. Staffing 360 Solutions Inc series E-1 preferred.		
No dividends paid.		
4. Staffing 360 Solutions Inc series E preferred.		
No dividends paid.		
5. Staffing 360 Solutions Inc series C preferred (stated value: \$1.00).		
No dividends paid.		
6. Staffing 360 Solutions Inc series B preferred (stated value: \$10.00).		
No dividends paid.		
7. Staffing 360 Solutions Inc series D preferred (stated value: \$10.00).		
No dividends paid.		
8. Staffing 360 Solutions Inc series A preferred (stated value: \$10.00).		
No dividends paid.		
Annual Dividends:		
1. Staffing 360 Solutions Inc common.		
No dividends paid.		
2. Staffing 360 Solutions Inc series A preferred.		
No dividends paid.		
3. Staffing 360 Solutions Inc series E-1 preferred.		
No dividends paid.		
4. Staffing 360 Solutions Inc series E preferred.		
No dividends paid.		
5. Staffing 360 Solutions Inc series C preferred (stated value: \$1.00).		
No dividends paid.		
6. Staffing 360 Solutions Inc series B preferred (stated value: \$10.00).		
No dividends paid.		
7. Staffing 360 Solutions Inc series D preferred (stated value: \$10.00).		
No dividends paid.		
8. Staffing 360 Solutions Inc series A preferred (stated value: \$10.00).		
No dividends paid.		
STAFFING 360 SOLUTIONS INC		
Auditor's Report Auditor's Report		
The following is an excerpt from the Report of the Independent Auditors, Baker Tilly US, LLP, as it appeared in Co.'s 2022 10K: "Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of Staffing 360 Solutions, Inc. (the "Company") as of December 31, 2022, the related consolidated statements of operations and comprehensive loss, stockholders' deficit, and cash flows, for the fiscal year ended December 31, 2022, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the fiscal year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."		
STAFFING 360 SOLUTIONS INC		
Earnings, 6 mos. to (Consol. - \$):		
	07/01/23	07/02/22
Total revenues	125,183,000	108,946,000
Net Sales	125,183,000	...
Cost & expenses	126,717,000	109,287,000
Operating income	(2,960,000)	(1,694,000)
Other income (expense), net	174,000	(988,000)
Net before taxes	(5,687,000)	(4,585,000)
Income taxes	47,000	3,000
Net income	(5,734,000)	(4,588,000)
Balance for common	(5,734,000)	(4,588,000)
Earnings common share		
Primary	\$(1.66)	\$(2.61)
Fully Diluted	\$(1.66)	\$(2.61)

Common Shares:

Full Diluted	3,453,841	1,759,298
Year-end	4,811,020	1,762,158

STAR ALLIANCE INTERNATIONAL CORP

New Accountant On Oct. 30, 2023, Gries & Associates, LLC ("Gries") resigned as Co.'s independent registered public accounting firm. Also on Oct. 30, 2023, Co. engaged GreenGrowth CPAs, as Co.'s independent registered public accountant firm.

STARK FOCUS GROUP INC

New Accountant On Sept. 26, 2023, Co. was informed that Gries & Associates, LLC ("Gries") had sold its business to GreenGrowth CPAs ("GreenGrowth"). On Oct. 18, 2023, Co. engaged and executed an agreement with GreenGrowth, as Co.'s new independent accountant to replace Gries.

SUSTAINABLE PROJECTS GROUP INC

New Accountant On Oct. 24, 2023, Co. dismissed K. R. Margetson Ltd. and engaged Centurion ZD CPA & Co. as its new independent public accounting firm.

T STAMP INC

Official Changes On Jan. 20, 2023, Co. announced the resignation of Mr. David Story as Co.'s Chairman of the Board of Directors and from the Board of Directors. Also, on Jan. 20, 2023, Co. announced the appointment of Mr. William McClintock as Co.'s Chairman of the Board of Directors.

T STAMP INC

Official Changes On Oct. 17, 2023, Co. announced the resignation of Mr. Mark Birschbach from its Board of Directors, effective Nov. 1, 2023. Also, on Oct. 17, 2023, Co. announced the appointment of Mr. Charles E. Potts to its Board of Directors, effective Nov. 1, 2023.

TELESIS BIO INC

Official Changes On Oct. 18, 2023, Co. announced the resignation of Mr. Paul Meister from its Board of Directors. Also, on Oct. 18, 2023, Co.'s Board of Directors appointed Greg Herrema to its Board of Directors.

TEMPEST THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2023	2022
Cost & expenses	21,643	25,706
Operating income	(21,643)	(25,706)
Interest income	712
Interest expense	1,072	1,186
Net before taxes	(22,003)
Net income	(22,003)	(26,606)
Balance for common	(22,003)
Earnings common share		
Primary	\$(1.57)	\$(2.46)
Fully Diluted	\$(1.57)	\$(2.46)
Common Shares:		
Full Diluted	14,059	10,816
Year-end	14,323	10,517

THARIMMUNE INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2023	2022
Cost & expenses	6,924,064	5,115,500
Operating income	(6,924,064)	(5,115,500)
Interest income	94,898
Interest expense	16,151	1,591,244
Net before taxes	(6,845,317)
Net income	(6,845,317)	(6,706,744)
Balance for common	(6,845,317)
Earnings common share		
Primary	\$(0.47)	\$(0.60)
Fully Diluted	\$(0.47)	\$(0.60)
Common Shares:		
Full Diluted	14,607,394	11,248,041
Year-end	17,511,839	11,529,861

THERMOGENESIS HOLDINGS INC

Official Changes On Aug. 23, 2023, Co. announced the resignation of Ms. Vivian Liu from its Board of Directors.

TOKEN COMMUNITIES LTD

New Auditor On Oct. 18, 2023, Co. dismissed Gries & Associates, LLC as its independent registered public accounting firm and engaged GreenGrowth CPAs as its new independent registered public accounting firm.

TOURMALINE BIO INC

New Name On Oct. 20, 2023, Co. changed its name from Talaris Therapeutics Inc. to Tourmaline Bio Inc.

TOURMALINE BIO INC

Stock Trading Symbol Stock symbol, TRML.

UNITED AMERICAN HEALTHCARE CORP.**Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

2022 2021 [□]2020

(revised)

Interest & other income (expense), net	84,000	9,000	26,000
Rental income	3,000
Income (loss) from trading securities	(11,000)	871,000	80,000
Total operating income	76,000	880,000	106,000
Research & development, net of grant proceeds	105,000
Marketing, general & administrative expenses	220,000	213,000
Total operating expenses	105,000	220,000	213,000
Income (loss) from continuing operations, before income tax	(29,000)	660,000	(107,000)
Income tax expense (benefit)	(5,000)	185,000	(21,000)
Income (loss) from continuing operations	(24,000)	475,000	(86,000)
Income (loss) from discontinued subsidiary	(173,000)	(398,000)
Gain from sale of Pulse Systems, net of transaction expenses	585,000	1,266,000	38,913,000
Income tax expense (benefit) from discontinued operations	(164,000)	(306,000)	(2,159,000)
Income (loss) from discontinued operations	421,000	787,000	36,356,000
Net income (loss)	397,000	1,262,000	36,270,000
Weighted average shares outstanding			
- basic	117,061,000	119,999,000	148,749,000
Weighted average shares outstanding			
- diluted	117,061,000	119,999,000	148,749,000
Year end shares outstanding	117,061,040	117,061,040	119,999,344
Income (loss) per common share - continuing operations - basic	\$0.00	\$0.00	\$0.00
Income (loss) per common share - discontinued operations - basic	\$0.00	\$0.01	\$0.24
Net income (loss) per common share - basic	\$0.00	\$0.01	\$0.24
Income (loss) per common share - continuing operations - diluted	\$0.00	\$0.00	\$0.00
Income (loss) per common share - discontinued operations - diluted	\$0.00	\$0.01	\$0.24
Net income (loss) per common share - diluted	\$0.00	\$0.01	\$0.24
Number of common stockholders	91	[□] 617	[□] 81

[□] Restated to reflect the discontinued operations of American Sustainable Rubber Company, LLC; [□] As of March 29, 2022; [□] As of June 18, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2022 2021

Cash & cash equivalents	8,467,000	6,517,000
Other receivables	8,000	41,000
Prepaid expenses & other current assets	21,000	8,000
Available-for-sale debt securities, at fair value	48,000	306,000
Assets of discontinued operations	585,000
Deferred tax benefits from continuing operations	5,000
Deferred tax benefits from discontinued operations	240,000
Total current assets	8,789,000	7,457,000
Property & equipment, net	846,000
Deferred tax benefits from discontinued operations	2,791,000
Total assets	9,635,000	10,248,000
Accounts payables & accrued expenses - related parties	30,000	122,000
Accounts payables & accrued expenses	21,000	17,000
Total current liabilities	51,000	139,000
Total liabilities	51,000	139,000
Common stock	116,000	116,000
Additional paid in capital	29,211,000	29,211,000
Retained earnings (accumulated deficit)	(19,709,000)	(20,027,000)
Accumulated other comprehensive income (loss)	(34,000)	809,000
Total shareholders' equity (deficit)	9,584,000	10,109,000

Recent Dividends:

1. United American Healthcare Corp. common.

No dividends paid.

Annual Dividends:

1. United American Healthcare Corp. common.

No dividends paid.

URGENTLY INC

Merger Completed On Oct. 19, 2023, Co.'s wholly owned subsidiary, U.O Odyssey Merger Sub Ltd. ("Merger Sub"), merged with and into Otonomo Technologies Ltd. ("Otonomo"), with Otonomo continuing as the surviving corporation and became a wholly owned subsidiary of Urgent.ly. As the result of the merger, pursuant to the terms of the Merger Agreement (the "Effective Time"), upon the terms and subject to the conditions set forth in the Merger Agreement, Co. issued an aggregate of 5,427,789 shares of its common stock, par value \$0.001 per share (the "Common Stock"), to former Otonomo shareholders, based on an exchange ratio of 0.51756 shares of Common Stock for each Otonomo ordinary share (excluding shares owned by Otonomo subsidiaries and shares to be canceled pursuant to the Merger Agreement) (the "Exchange Ratio"). In addition, each outstanding restricted share unit award relating to Otonomo ordinary shares (an "Otonomo RSU") granted under Otonomo's 2021 Equity Incentive Plan (the "Otonomo Plan") was assumed by Co. on the same terms and conditions as applied to the Otonomo RSU award immediately prior to the Effective Time and settled into a number of shares of Common Stock equal to the product obtained by multiplying (i) the number of Otonomo ordinary shares subject to the Otonomo RSU award immediately prior to the Effective Time by (ii) the Exchange Ratio. Such assumed Otonomo RSUs continue to be governed by the terms and conditions of the Otonomo Plan. Upon the closing of the Merger, Urgent.ly assumed the Otonomo Plan. Immediately following the Merger, Co.'s existing securityholders owned 60.3% of the combined company on a fully diluted basis and Otonomo's securityholders owned approximately 39.7% of the combined company.

VERICITY INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2023	2022
Total revenues	89,359	82,243
Cost & expenses	81,841	81,297

Operating income	888	(8,205)
Net before taxes	888	(8,205)
Income taxes	790	(194)
Net income	98	(8,011)
Earnings common share		
Primary	\$0.01	\$(0.54)
Fully Diluted	\$0.01	\$(0.54)
Common Shares:		
Full Diluted	14,875	14,875
Year-end	14,875	14,875

*

MERGENT OTC UNLISTED News Reports 0895-3252 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC UNLISTED Manual and provide periodic updates. Send address changes to MERGENT OTC UNLISTED, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2023 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.